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Abstract 
 
Acute Embryotoxicity of Mono-2-Ethylhexyl Phthalate (MEHP) in Mice: Nutrition, 
Epigenomics, and Environment 
 
Mono-2-ethylhexyl phthalate (MEHP) is the primary metabolite of di-2-ethylhexyl 
phthalate (DEHP), a ubiquitous toxicant used in the production of plastics. Studies have associated 
prenatal phthalate exposure with a spectrum of adverse health outcomes including 
neurodevelopmental disorders, although mechanisms are unknown. The importance of adequate 
fetal nutrition for neurodevelopment has been well-studied, but the role of histiotrophic nutrition 
pathways (HNPs) in embryonic development is not well characterized.  This work aimed to 1) 
determine whether chemical inhibition of HNPs may result in epigenetic modifications during 
early organogenesis, 2) elucidate the mechanisms by which the toxicological compounds DEHP 
and MEHP may induce teratogenesis, 3) characterize whether environmental toxicants such as 
MEHP may alter HNP function, C1 metabolism, and epigenetic programming in the conceptus, 
and 4) examine the transcriptomic and epigenomic profiles of conceptal tissues following MEHP 
treatment to identify modes of action and potential contributing factors to teratogenesis. Whole 
embryo culture was used to investigate rodent conceptuses during early organogenesis.  Treatment 
with leupeptin, a protease inhibitor known to decrease HNPs, altered one-carbon (C1) metabolism 
and decreased global DNA methylation in the embryo (EMB) and visceral yolk sac (VYS). MEHP 
treatment reduced embryonic growth, increased the prevalence of open neural tubes (NTD) in 
EMB, and increased susceptibility to oxidation. After 6-h MEHP treatment, decreased EMB and 
VYS expression of genes in pathways involved in the metabolism of amino acids, energy 
xiii 
 
metabolism, and oxidative phosphorylation occurred.  Total HNP function, defined as the 
clearance of extra-conceptal proteins into the conceptal tissues and fluids, was reduced in a dose-
dependent manner after 3-h MEHP treatment. C1 metabolism was increased by 24-h MEHP 
treatment, suggesting time-dependent response in nutrient uptake and metabolism due to 
exposures.  Global embryonic DNA methylation was decreased after 24 h exposure to MEHP and 
in EMB with NTDs. Global histone methylation at the H3K4 and H3K27 loci was increased in 
EMBs with NTDs and treated VYSs.  Parallel transcriptomic and epigenomic analysis examined 
the effects of MEHP treatment and also NTD status. Pathway analysis of expression and DNA 
methylation data revealed disrupted nutrient metabolism, increased xenobiotic metabolism, and 
induction of pathways governing cellular fate such as increased autophagy. This research 
demonstrates that MEHP may induce nutrient starvation and redox control of autophagy 
(NSRCA), and these findings suggest that NSRCA may play a crucial role in teratogenesis.  
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Chapter I 
 
Introduction 
  
I. Overview 
 Prenatal exposures to environmental chemicals have been linked to agent-initiated 
susceptibility to diseases and adverse health outcomes observed later in life. This has prompted 
investigations to identify the precise developmental windows of susceptibility and the mechanisms 
by which these agent-initiated changes may act. The overwhelming majority of these studies have 
focused on chemical insults and dietary manipulations initiated during the fetal stages of 
development. However, the body of research has failed to acknowledge the influence of 
environmental, chemical, and nutritional factors on abnormal programming originating during the 
earlier organogenesis stages where embryonic form and function are first being established. For 
this reason, very little is known about the specific molecular targets, regulatory pathways, or modes 
of action that may be impacted by chemical agents during this critical phase of development, nor 
their consequences on disease later in life. This work seeks to identify the consequences of 
common environmental toxicant exposures, elucidate mechanisms of acute toxicity during early 
organogenesis, and identify mechanisms by which these acute influences may increase 
susceptibility to altered epigenetic gene regulation and developmental defects. 
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II. Phthalates and Development 
 Phthalates are a class of endocrine-disrupting compounds found ubiquitously in the 
environment. They are a common component in plastics, supplying flexibility to the product 
structure, and are often included in cosmetic formulas. Exposures to one of the most common 
phthalates, di-2-ethylhexyl phthalate (DEHP), has been associated with a myriad of adverse health 
outcomes, including increased risk for cancers, reproductive dysfunction, and increased risk for 
obesity [1-3]. DEHP is rapidly hydrolyzed to mono-2-ethylhexyl phthalate (MEHP), its primary 
metabolite (Fig. 1.1). MEHP has been demonstrated in humans and animals to cross the placenta 
and gestational membranes [4,5]. Because developmental plasticity is easily influenced by 
environment, DEHP and MEHP exposures in utero are a major concern. Human and animal studies 
have demonstrated numerous biochemical and cell cycle changes and nervous tissues due to 
phthalate exposures, such as DEHP and MEHP, including impaired neuronal activation, 
proliferation, differentiation, axon guidance, apoptosis, neurotrophin concentrations, and 
increased brain lipid content [6-12]. Likewise, early phthalate exposures have been associated with 
numerous behavioral and cognitive abnormalities, including aggression, attention problems, 
autism spectrum disorders, depression, and various social impairments [13-15]. Structural defects 
have also been observed due to prenatal phthalate exposure, including anterior neural tube defects, 
such as anencephaly and exencephaly [16,17]. Though associations between phthalate exposures 
during development and adverse neurodevelopment have been established, mechanisms 
surrounding phthalate specificity for the developing nervous system have yet to be elucidated. 
 
III. Neurulation and Neural Tube Defects 
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 Mammalian development is a tightly-regulated process during which spatial and temporal 
coordination of signaling, metabolism, proliferation, differentiation, and cell death are crucial for 
tissue patterning, organogenesis, and overall growth. Numerous signal transduction pathways are 
known to coordinate these processes, establishing the blueprints for cellular growth and 
replication. A few of these pathways are particularly critical during early embryogenesis, including 
the Wnt pathways (β-catenin and planar cell polarity), bone morphogenic protein (BMP)/TGF‐β 
receptor pathway, sonic hedgehog (Shh) pathway, and Notch‐Delta pathway [18]. These pathways 
all involve the presence of activating extracellular ligands, and all result in the binding of 
transcription factors to direct gene expression. These signaling ligands are responsible for the 
establishment of cell polarity, and patterning along the dorsal-ventral and anterior-posterior axes. 
Specifically, Shh is secreted from the mesodermal notochord following gastrulation, establishing 
a ventral signal for the neural plate [19]. BMPs, on the other hand, are secreted from the ectoderm, 
establishing the dorsal signal [19]. The coordination of these two signals establishes a dorsal-
ventral axis for the neural plate, providing guidance for the induction of neurulation. Disruption to 
any one of these processes may result in altered structure, function, or potentially spontaneous 
abortion. 
 During early chordate development, the neural plate folds and fuses to form the neural tube, 
called neurulation [20]. This tube is formed by ectodermal cells directly dorsal to the notochord, 
and will give rise to the central nervous system (CNS) [21]. The neural plate is folded, and the 
neural folds fuse using coordinated signaling of cadherin molecules and integrated movement of 
the actin cytoskeleton [22-24]. Because this migration is guided through signaling pathways, 
disruption of pathways involved in dorsal‐ventral patterning and folding during early 
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organogenesis have been correlated with detrimental effects of the CNS, including neural tube 
defects (NTDs) [25-30].  
 Despite intervention efforts, NTDs remain one of the most prevalent birth defects 
worldwide. The most prevalent and well-known NTD is spina bifida, a debilitating disease that 
significantly reduces quality of life or even longevity. The global prevalence of NTDs is 1 per 
every 1000 live births, though rates range from 0.2-2 per 1000 live births based upon geography, 
race, and ethnicity [31,32]. Spontaneous abortion is believed to occur in between 15-31% of 
pregnancies, and it is suggested that NTDs incidence is greater in spontaneous abortions [33-37]. 
Several nations have employed folate fortification of foods and prenatal vitamins, as folate 
supplementation of maternal diet has been associated with nearly a 30% decreased risk for NTDs 
[38-41]. However, the mechanism by which folate is beneficial is unknown [42,43].  
 
IV. Redox Control of Teratogenesis 
 DEHP and MEHP have been repeatedly demonstrated to induce oxidative stress in various 
tissues [44-48]. Oxidative stress is classically defined as the imbalance of cellular environment 
towards a more oxidized, rather than reduced, state, though more recent definitions have included 
disrupted redox signaling and control [49]. Under normal conditions, the cell is in a balanced state, 
where the reducing power of the cell is able to eradicate the damage that would be done by 
oxidizing species. The endogenous antioxidant response, provided by reduced glutathione (GSH) and 
other active compounds, is involved in the metabolism of potentially harmful agents and restoring the 
reducing power of the cell. The biosynthesis of many of these innate antioxidants is governed by the 
nuclear translocation of the transcription factor Nrf2. Nrf2 can bind to a specific sequence of DNA, 
known as the antioxidant response element (ARE), which is found in many chemoprotective gene 
promoters, including those involved in the antioxidant response of Nrf2 [50,51]. The generation of 
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damaging reactive oxygen species (ROS) may be able to overwhelm the innate antioxidant defenses, 
leading to oxidizing cellular conditions. This oxidizing environment may cause lipid peroxidation, 
DNA damage, irregular gene expression, or altered degradation of proteins.  
 Teratogenesis is the production of congential malformations by developmental toxicant 
exposures. A “proposed” mechanism for many teratogens involved cellular dysregulation via 
oxidative stress and altered redox signaling [52]. During development, shifts in embryonic cell 
redox potentials may guide cell fate towards proliferation in a reduced state, or towards 
differentiation, apoptosis or necrosis in increasingly oxidized states [52]. In more severe cases, this 
may decrease growth of tissues, decrease overall size, or induce spontaneous abortion. Differential 
regulation of redox potentials may influence the mode of teratogenesis, as the susceptibility to thiol 
oxidation of redox couples is variable [52]. In this way, developmental exposures to chemicals may 
oxidize different redox couples and their corresponding cellular response pathways, producing 
chemical-specific structural defects. Likewise, exposures to the same chemicals at ranging 
developmental time points may also produce differing structural defects, as susceptibility to oxidative 
damage and ability to activate the endogenous antioxidant response pathways vary throughout 
development [52].  Thus, the timing of exposures and specificity of thiol targets are important factors 
in teratogenesis. During this window of development, environmental agents and conditions that 
result in increased ROS and oxidative stress have been shown to increase the incidence of NTDs 
[27,40,53-55], and supplementation of antioxidants has been shown to reduce risk for NTDs 
[40,41,55,56]. 
 
V. Histiotrophic Nutrition Pathways (HNPs) 
 During the first trimester of gestation, the placenta is not yet formed and the conceptus is 
isolated from direct maternal nutritional input. It has been previously suggested that this 
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environmental isolation was an evolutionary adaptation to provide protection to the developing 
conceptus from ROS [57]. During this time, the conceptus relies primarily on the receptor-
mediated endocytosis (RME) of nutrients via the visceral yolk sac (VYS) brush border and 
subsequent proteolysis and degradation of these proteins, in a process known as HNPs (Fig. 1.2) 
[58-61]. Maternal nutrients and proteins are secreted by the uterine glands into the exocoelomic 
fluids surrounding the implanted embryo [57,62]. HNPs are then responsible for the RME and 
subsequent proteolysis of the nutrient-containing vesicles in order to provide substrates necessary 
for cellular functions [63-66]. The protein clatherin lines pitted regions of the plasma membranes 
of the brush border, which are abundant in receptor proteins, giving rise to a targeted region for 
RME [67-69]. Two cellular membrane proteins, megalin and cubilin, are responsible for the RME 
of numerous ligands, nutrients, and miscellaneous cellular substrates across cellular membranes 
throughout the conceptus, including the initial uptake via the VYS brush border [70]. These 
transporters, collectively known as the multiligand endocytotic receptor complex (MERC), thus 
serve as a biochemical gateway into the conceptus. 
 Following the RME of exogenous proteins and their respective cargoes, these vesicle-
bound nutrients must be further processed before they become available for cellular use. 
Endocytotic vesicles in the VYS fuse with lysosomes initiating removal of vitamin, peptide and 
mineral cargoes and proteolysis of the bulk proteins. Proteins are degraded into the amino acid 
building blocks required for protein and DNA synthesis while other bound nutrients and cargoes 
are used for metabolic processes in the VYS, which may then diffuse into the extraembryonic fluid 
(EEF) or into the vitelline vasculature for transport to the embryo [71]. Studies suggest that the 
developing embryo undergoes several rounds of this process at various epithelial interfaces, 
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including the neuroepithelium where the RME protein, megalin, is more abundantly expressed 
[72,73]. 
  
VI. One-Carbon Metabolism and Epigenetic Gene Regulation 
 Though folate is the best-known protective compound against NTDs, the entire class of 
methyl donor dietary nutrients have been implicated as nutri-preventative for the CNS during 
development [74]. Common dietary methyl donors, including folate, choline, and betaine, are 
metabolized by numerous vitamins and enzymes, including B-vitamins and methyltransferases. 
The MERC is crucial for the uptake of several methyl donors and co-factors in their metabolism, 
including methionine, folate and vitamin B12 [70,75,76]. The process by which these dietary 
methyl donors are metabolized is called one-carbon (C1) metabolism, and it is crucial for 
maintenance of a myriad of cellular functions. C1 metabolism is the process by which S-
adenosylmethionine (SAM), the primary cellular methyl donor, is generated (Fig. 1.3) [77]. In C1 
metabolism, dietary methyl donors are enzymatically metabolized to the amino acid methionine. 
Though methionine is required for protein synthesis, maintenance of a pool of methionine for C1 
metabolism is essential. The enzyme methionine adenosyltransferase 2a (Mat2a) is responsible for 
the conversion of methionine to SAM, which is then utilized in various cellular processes including 
post-translational modifications as well as epigenetic regulation. 
 Cell growth, differentiation, and tissue patterning during organogenesis are controlled in 
part by epigenetic mechanisms, which set the patterns of gene expression responsible for 
determination of cell fate, form, and function. These epigenetic modifications include DNA 
methylation, histone modifications, and non-coding RNA interactions, which may induce or 
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silence gene expression. Thus, epigenetic gene regulation provides environmental, temporal, and 
nutritional variations that DNA sequence, alone, cannot explain.  
 DNA methylation is a widely studied epigenetic mechanism. DNA methylation occurs 
most often in CG dinucleotides (CpGs) throughout the genome in mammals, though epigenetic 
marks are also prevalent across biological classifications [78]. Methylation of CpG sites is initiated 
by the DNA methyltransferase (DNMT) class of enzymes, taking SAM and converting it to S-
adenosylhomocysteine while placing methyl marks on cytosine DNA residues. Canonically, DNA 
methylation in key regulatory regions of gene promoters may disrupt transcription factor binding, 
causing gene silencing.  
 Methylation of histone residues is another common epigenetic regulatory mechanism, 
which has variable effects on gene expression depending upon the locus. Histone 3, a key protein 
in chromatin structure, can become methylated by SAM as well. This methylation may occur at 
numerous loci, but is most common at the lysine-4 (H3K4) and lysine-27 (H3K27) residues. H3K4 
and H3K27 methylation are typically considered activating and repressive marks, respectively 
[79,80]. Methylation at these loci may occur as mono-, di-, or tri-methylation, and the degree of 
methylation may correspond with the function of the epigenetic mark. 
 During development, epigenetic regulation is crucial for differentiation and normal 
development. After fertilization, DNA undergoes widespread demethylation of parental marks 
[81,82]. Several loci retain their methylation marks, known as imprinted genes. At implantation, 
methylation marks are strategically placed and replaced to regulate gene expression and 
differentiation. By the end of embryogenesis and early organogenesis, DNA methylation marks 
are fully programmed throughout the genome. Histone methylation is more dynamic, and marks 
can be applied and removed to influence chromatin structure and function throughout the cell 
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cycle. Again, the placement of these marks is crucial for normal differentiation and development, 
and have been found to correspond with the pluripotent status of embryonic cells [80]. H3K27 
methylation is highest immediately post-fertilization, and then marks are progressively lost 
throughout embryogenesis; H3K4 methylation is low at the time of fertilization and becomes 
progressively more methylated as development progresses [83]. 
 In all, HNPs have numerous downstream consequences, affecting processes involved in 
fundamental gene regulation and differentiation. If disruption of HNPs were to occur, it is possible 
that C1 metabolism and thus SAM would become depleted, and this may decrease the methyl 
groups available for epigenetic gene regulation. In this case, it is likely that dysregulation and 
dysfunction would occur in embryonic tissues, and abnormal development may follow. 
 
VII. Developmental Origins of Health and Disease 
 The developmental origins of health and disease (DOHaD) hypothesis proposes that in 
utero environmental conditions, such as nutrition and toxicant exposures, may predispose 
individuals to disease later in life. During this sensitive period of development, the EMB exhibits 
a great deal of developmental plasticity. Modulation to the embryonic environment may manifest 
as altered epigenetic programming or metabolic dysfunction that alters the gene expression profile 
and overall growth trajectory of the EMB. Because of the dynamic changes to the epigenetic 
landscape during embryogenesis and early organogenesis, exposures or decreased nutrition may 
result in aberrant placement of epigenetic marks. Because these marks are semi-permanent, the 
resultant gene expression changes may present throughout the lifetime [84]. Likewise, decreased 
nutrient availability during this susceptible period may result in a “thrifty phenotype” in the 
offspring, altering the metabolism throughout the lifecourse [85]. In this way, it is possible for 
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malnutrition during development and low birth weight to result in conditions such as obesity or 
diabetes due to embryonic metabolic programming. 
 Though we are primarily concerned with the etiology of NTDs and teratogenesis in this 
study, the outcomes measured in this work may also help to shape health and disease throughout 
the lifecourse. EMB that present with NTDs at this stage in the development may not survive to 
term, or the neural tube may fully close by the end of gestation. However, the delay in neural tube 
closure may still represent physiological, metabolic, and molecular changes to the CNS or even 
the whole organism. 
 
VIII. DEHP and MEHP: Potential Mechanisms of Teratogenesis   
   DEHP and MEHP have been demonstrated to induce oxidative stress in various tissues and 
cell lines, as measured by several antioxidant and inflammatory response pathways [46,48,86-90]. 
Therefore, it is possible that DEHP and MEHP cause developmental toxicity via induction of 
oxidative stress. However, stress in developmental tissues has yet to be characterized, especially 
in the fetal brain and gestational membranes. Previous published and unpublished studies have 
demonstrated the capacity for compounds which induce oxidative stress to limit HNPs, and thus 
there is the potential for DEHP and MEHP to act through a related mechanism [91]. 
Numerous studies have investigated the epigenetic consequences of phthalate exposures. 
Phthalate exposures have been demonstrated to alter histone and DNA methylation in many 
different tissues, though the embryo and fetal brain have not been well-studied [92-95]. Likewise, 
the effects of phthalates on C1 metabolism in the developing conceptus, namely the embryo and 
fetal brain, have not been well-studied. No studies have investigated the ability of phthalates or 
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other endocrine disruptors to inhibit or hinder HNPs, so the upstream consequences for epigenetic 
potential have yet to be characterized during embryogenesis. 
 Teratogenesis may be measured by many different outcomes, including limb growth, 
congenital heart defects, and NTDs. NTDs were selected as the teratogenic outcome of interest for 
this study for several reasons: 1) There is a growing body of literature surrounding prenatal 
exposures to phthalates and neurodevelopmental, cognitive, and neurodegenerative effects, and 2) 
Our preliminary studies demonstrated that NTDs were the most prevalent anatomical defect 
observed, and 3) The mechanisms by which NTDs are produced remain relatively uncharacterized. 
 
IX. Study Overview and Objectives 
  This dissertation seeks to 1) determine whether chemical inhibition of HNPs may result in 
epigenetic modifications during early organogenesis, 2) elucidate the mechanisms by which the 
toxicological compounds DEHP and MEHP may induce teratogenesis, 3) characterize whether 
environmental toxicants such as MEHP may alter HNP function, C1 metabolism, and epigenetic 
programming in the conceptus, and 4) examine the transcriptomic and epigenomic profiles of 
conceptal tissues following MEHP treatment to identify modes of action and potential contributing 
factors to teratogenesis.  
  It is hypothesized that MEHP-induced oxidative stress will disrupt HNPs, C1 metabolism, 
epigenetic programming, and gene expression and induce morphological defects (Figure 1.4). 
 
X. Funding and Institutional Approval 
  The experimental animal protocols utilized in this study were approved by the University 
of Michigan Committee on Use and Care of Animals, and in accordance with the Institute of 
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Animal Laboratory Resources guidelines for humane animal use. This work was supported by the 
Bill and Melinda Gates Foundation (Grand Challenges Exploratons – Rd. 7) and the University of 
Michigan National Institute of Environmental Health Sciences (NIEHS) Core Center “Lifestage 
Exposures and Adult Disease” (P30 ES017885). Support was also provided to K.S. by an NRSA 
institutional training grant (T32 ES007062).  
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Figure 1.1. Chemical structures of DEHP and MEHP. DEHP is rapidly hydrolyzed to MEHP. 
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Figure 1.2. The role of histiotrophic nutrition pathways (HNPs) in the uptake and metabolism of nutrients 
by the conceptus. HNPs are a multi-step nutritional process, involving the receptor-mediated endocytosis 
of proteins and bound cargoes, followed by lysosomal proteolysis of captured proteins within the 
secondary vesicles. 
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Figure 1.3. Involvement of dietary micronutrients in one-carbon metabolism. Substrates obtained via diet 
are highlighted in yellow. (1) Vitamin B6 is a cofactor to serine hydroxymethyltransferase in the conversion 
of tetrahydrofolate (THF) to 5,10-methylene THF. (2) Vitamin B2 is a precursor to FAD, which is a cofactor 
to methylenetetrahydrofolate reductase (MTHFR) in the conversion of 5,10-methylene THF to 5-methyl 
THF. (3) Vitamin B12 is a precursor to methionine synthase, involved in the production of methionine from 
homocysteine and betaine. DHF, Dihydrofolate; FAD, flavin adenine dinucleotide; DMG, dimethyl 
glycine; MTHFR, methylenetetrahydrofolate reductase; SAH, S-adenosylhomocysteine; THF, 
tetrahydrofolate. 
 
 
Figure 1.3 reused and modified from Anderson, O.S., K.E. Sant, and D.C. Dolinoy, Nutrition and 
epigenetics: an interplay of dietary methyl donors, one-carbon metabolism and DNA methylation. 
The Journal of Nutritional Biochemistry, 2012. 23(8): p. 853-859. Permission for reuse approved 
by Rightslink and Copyright Clearance Center, Inc on October 2, 2014. 
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Figure 1.4. Model representing the hypothesized mode of action for teratogenesis due to toxicant exposures 
during early organogenesis. Two modes of action are believed to intersect at dysregulation of gene 
expression, and these mechanistically disrupt crucial developmental processes in the conceptus.  
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Chapter II  
 
Inhibition of proteolysis in histiotrophic nutrition pathways alters DNA 
methylation and one-carbon metabolism in the organogenesis-stage rat conceptus 
Text has been previously published in Sant, K. E., Dolinoy D.C., et al. (2013). "Inhibition of 
proteolysis in histiotrophic nutrition pathways alters DNA methylation and one-carbon 
metabolism in the organogenesis-stage rat conceptus." The Journal of Nutritional Biochemistry 
24(8): 1479-1487. Permission for reuse approved by Rightslink and Copyright Clearance Center, 
Inc on October 2, 2014. 
 
Introduction 
Cell differentiation that gives rise to form and function during embryogenesis is achieved 
through a highly coordinated and integrated program of cell signaling and gene expression. Both 
embryonic and extraembryonic cells within the conceptus contain identical genetic codes from 
which variable gene expression is programmed epigenetically in spatial and temporal patterns. 
DNA methylation is an important process involved in the epigenetic regulation of gene expression 
along with chromatin modification and noncoding RNAs. DNA hypermethylation is generally 
associated with gene silencing, while hypomethylation is associated with transcriptional activation 
[1,2]. Cells within the very early preimplantation embryo (EMB) exist in a globally demethylated 
state and then undergo remethylation in a cell- and gene-selective manner to establish specific 
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differentiation characteristics as embryogenesis progresses [3,4]. In mature cells, a large 
proportion of the genome becomes methylated and is, therefore, not expressed [1].  
Regulatory regions in promoter sequences of actively expressed genes remain 
hypomethylated and enriched in open-chromatin marks to remain transcriptionally poised to 
respond to a wide variety of signals and stimuli [5]. While the roles of several chemicals and 
dietary components have been characterized in the disruption of these processes [6,7], very little 
is known about the mechanisms through which specific nutrients and other environmental or 
developmental stress factors interact to modify the epigenome during differentiation and 
embryonic development. 
Alterations in maternal diet during the preimplantation and fetal phases of development 
have been shown to reduce the conceptual availability of whole protein, amino acids (methionine), 
folate, choline and cobalamin (vitamin B12) and are also known to elicit changes in the epigenome 
through reprogramming of DNA methylation patterns [8]. These dietary nutrients are the source 
of precursors, vitamins and cofactors required for one-carbon (C1) metabolism, the process that 
culminates in S-adenosylmethionine (SAM) biosynthesis. SAM is the universal methyl donor for 
DNA methylation and is generated in its final form from L-methionine and adenosine triphosphate 
(ATP) by the enzymatic activity of methionine adenosyltransferase 2a (Mat2a). C1 precursors must 
be constantly supplied to the conceptus, suggesting that maternal diet and micronutrient 
bioavailability are crucial for proper epigenetic regulation of developmental processes. 
Embryonic and fetal nutrition plays a critical role in growth, differentiation and 
developmental plasticity [9]. During organogenesis, the early postimplantation-stage mammalian 
conceptus is physically isolated from direct access to maternal micronutrients, as the placenta is 
not yet fully functional. Thus, the organogenesis-stage conceptus obtains very few nutrients 
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through transcellular transport and must rely on the receptor-mediated endocytosis (RME) or 
pinocytosis of proteins and nutrients via the visceral yolk sac (VYS) endothelium [10-13]. 
Proteolytic degradation of bulk maternal protein in lysosomes of trophoblast-derived tissues 
provides the conceptus with the majority of amino acids necessary for de novo protein biosynthesis 
[14-17]. In addition to the bulk proteins, RME provides access for other substrates, vitamins and 
cofactors, which enter cells by the same pathways bound to specific carrier proteins. The RME, 
proteolysis and processing of nutrients, termed histiotrophic nutrition pathways (HNPs), comprise 
the primary route of nutrition during organogenesis. HNPs are, therefore, also responsible for the 
maintenance of C1 metabolism during organogenesis (Fig. 2.1). 
Leupeptin, a naturally occurring inhibitor of proteolytic degradation, reduces amino acid 
and micronutrient availability for cellular processes such as protein synthesis, glutathione (GSH) 
biosynthesis and C1 metabolism [18] (Fig. 2.1). Treatment with leupeptin mimics nutritional 
deficiency in the conceptus and has been shown to decrease the activity of HNPs [10]. Because 
substrates obtained via HNPs such as methionine, folate, choline, and vitamin B12 are required for 
SAM biosynthesis, leupeptin treatment during organogenesis may be used as a model to study 
developmental outcomes associated with nutritional deficiencies. While several studies have 
begun to investigate the epigenetic and morphological consequences of these nutritional 
deficiencies during embryonic development, the role of HNPs in these outcomes has yet to be 
characterized [8]. This study examines a unique window of developmental susceptibility where 
alterations in HNP lead to compromised C1 metabolism and a reduction of global DNA 
methylation during organogenesis. Within this context, we propose to test the hypothesis that 
leupeptin, a protease inhibitor, disrupts HNP functions in the organogenesis-stage conceptus, 
25 
 
reducing the availability of methionine required for biosynthesis of SAM by the C1 pathway and, 
thereby, altering patterns of DNA methylation. 
 
Materials & Methods 
Chemicals and reagents 
Leupeptin hemisulfate salt and deuterated isotopic standards (Homocysteine-d8 and N,N-
dimethyl-d6-glycine HCl) for mass spectrometry quantification of C1 components were purchased 
from Sigma (St. Louis, MO, USA). L-Methionine (methyl-d3) and D,L-cysteine (3,3-d2) were 
purchased from Cambridge Isotope Laboratories (Andover, MA, USA). S-Adenosyl-L-
methionine-d3 (S-methyl-d3) tetra (p-toluenesulfonate) salt was from C/D/N Isotopes (Pointe-
Claire, Quebec, Canada). All other reagents and chemicals were purchased from standard vendors 
and were of the appropriate purity for culture and analytical applications. Antibodies for 
immunoblots were purchased from Abcam (Cambridge, MA, USA) [Anti-Mat2a antibody (Rabbit 
polyclonal) — ab77471] and Santa Cruz Biotechnology (Santa Cruz, CA) [Actin antibody (Goat 
polyclonal) — sc-1615; Alkaline phosphatase secondary antibody (donkey anti-goat) — sc-2022; 
Alkaline phosphatase secondary antibody (chicken-anti-rabbit) — sc-2959]. 
 
Whole embryo culture (WEC) 
Female Sprague–Dawley rats were time-mated and obtained from Charles River (Portage, 
MI, USA). Females were checked for positive pregnancy by vaginal smear on the morning 
following copulation. The morning of a sperm-positive result was designated as gestational day 
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(GD) 0. Animals were kept on a 12-h–12-h light/dark cycle and were given food and water ad 
libitum. On the day of each experiment, dams were anesthetized, exsanguinated and sacrificed as 
previously described [19]. Conceptuses were explanted on GD10, prepared for culture and placed 
into 60-ml culture bottles containing 10 ml of control medium. Two different leupeptin exposure 
protocols were used, both starting with conceptuses explanted into culture on GD10. The first 
group, designated as “26 h,” was exposed to 50 μM leupeptin by direct addition to the culture 
medium on the morning of explant and was assessed on GD11 after a total of 26 h in culture. In 
the second group, designated as “6 h,” conceptuses were cultured for 20 h in control medium from 
GD10 and then treated with 100 μM leupeptin on GD11, beginning after the 95% O2/5% CO2 gas 
change, for a total treatment duration of 6 h. Conceptuses from four to six different litters were 
age-matched based on extent of neural tube closure and degree of axial rotation at the time of tissue 
collection and randomized across treatment groups to remove age and litter bias. Control medium 
contained 5 ml heat-inactivated rat serum and 5 ml 1× Hank’s balanced salt solution (HBSS), 
supplemented with 43 μl of penicillin–streptomycin (10,000 U/ml). No more than 10 conceptuses 
were cultured in each bottle. To optimize growth, bottles were gassed on GD10 after explantation 
with 20% O2/5% CO2 and on the morning of GD11 with 95% O2/5% CO2. Culture bottles were 
incubated at 37°C in a roller apparatus throughout the culture period as described previously 
[10,19,20]. 
 
Exposure and sample collection 
Leupeptin was suspended in double-distilled water and added to each culture bottle at the 
time of exposure to yield a 50-μM final concentration in the culture medium for 26-h exposures or 
a 100-μM final concentration for 6-h exposures. These concentrations were optimized for stage of 
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embryonic development and duration of culture based upon morphology, growth parameters, 
viability and the ability to inhibit proteolysis in WEC [10,21]. WEC of rat conceptuses for 26 h in 
concentrations of leupeptin up to 100 μM, beginning on GD10, maintains complete viability but 
reduces total EMB and VYS protein content. The 26-h exposures of 50 μM leupeptin result in 
viable, but much smaller, embryos with few gross anatomical defects but with a high incidence of 
avascular VYS, anophthalmia and some other defects of the optic field. No defects or growth 
restrictions were seen in the 6-h exposures under any condition. At the conclusion of the exposure, 
conceptuses were removed from the culture bottles and washed 2× in HBSS. The VYS and EMB 
were manually separated for each conceptus using watchmaker's forceps. 
VYS and EMB samples for DNA isolation were pooled in duplicate, snap frozen and stored 
at−74°C. Samples to be assayed for Mat2a activity were pooled in triplicate and placed in 250 μl 
of reaction mixture composed of 50mMTris ethanesulfonic acid (TES), 50 mM KCl, 15 mM 
MgCl2 and 0.3 mM EDTA prior to beginning the Mat2a activity protocol [22]. Samples for 
analysis of C1 components were collected in 100 μl of reducing agent, consisting of 200 mM 
dithiothreitol and 100 mM NaOH in water. EMB and VYS tissues collected for immunoblotting 
were placed into 50 μl of radioimmunoprecipitation assay (RIPA) buffer, briefly sonicated and 
stored at −80°C until their use in the immunoblot protocol. 
 
Mat2a specific activity 
Mat2a activity was quantified in EMB and VYS crude homogenates based on the measured 
rates of new SAM biosynthesis from methionine and ATP. EMBs and VYSs were manually 
separated, placed into 250 μl of TES reaction buffer and snap frozen until incubation and 
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processing. Samples were thawed, gently sonicated and allowed to equilibrate by incubation at 
37°C for 10 min. After that time, 20 μML-methionine and 5 mM ATP were added to the incubation 
mixture and allowed to react for 1 h at 37°C. Sodium acetate buffer (0.1 M) and 10% perchloric 
acid were added to the incubation mixture to terminate the reaction. The samples were then 
centrifuged at 10,500g for 2 min, the supernatant was removed to a new tube, and samples were 
processed for SAM determination as described above. Protein pellets were solubilized in 0.25 M 
sodium hydroxide, and total protein was determined using the bicinchoninic acid (BCA) procedure 
(Pierce, Rockford, IL, USA). Activities are expressed as μmol SAM synthesized/min, and data 
were normalized to protein values (mg) for determination of specific activities. 
 
RNA isolation and quantitative polymerase chain reaction (qPCR) 
RNA was isolated from EMB and VYS using the RNeasy Mini Kit (Qiagen, Valencia, CA, 
USA) as performed on a QIAcube (Qiagen). RNA was converted into cDNA using the RT2 First 
Strand Kit (SABiosciences, Valencia, CA, USA). Commercially available qPCR primers for 
Mat2a, Dnmt1, Dnmt3a, Dnmt3b and housekeeping gene ActB (SABiosciences) were used to 
detect changes in gene expression. cDNA, primers, and SYBR Green master mix (Qiagen) were 
added onto a 384-well plate, with each gene being run in triplicate for each sample. PCR was 
performed at the University of Michigan Microarray Core Facility using the 7900HT Fast Real-
Time PCR System (Applied Biosystems, Carlsbad, CA, USA). Controls without template and 
controls without reverse transcriptase were performed for each sample to ensure run quality. 
Results were normalized to actin expression for each respective tissue and treatment. 
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Western/immunoblotting 
Samples were thawed and sonicated in RIPA buffer. Protein concentrations were 
determined by BCA assay. Thirty micrograms of protein per sample was loaded and separated on 
a 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis gel and transferred to a 
polyvinylidene fluoride membrane. The membrane was blocked overnight with tris-buffered saline 
with Tween (TBST)-milk at 4°C prior to a 2-h incubation with anti-Mat2a rabbit polyclonal 
antibody (Abcam, Cambridge, MA, USA) at a concentration of 1 μg/ml. The membrane was then 
washed with TBST prior to 2-h incubation with alkaline phosphatase (AP)-conjugated chicken 
anti-rabbit IgG (Santa Cruz, Santa Cruz, CA, USA) at a concentration of 1 μg/ml. Secondary 
antibody fluorescence was developed following reaction with ECF Substrate (GE Healthcare Life 
Sciences, Piscataway, NJ, USA) and visualized with a Fujifilm FLA-5000 Imager (Valhalla, NY, 
USA). Because Mat2a and actin have similar molecular weights, the membrane was cleared using 
Restore Western Blot Stripping Buffer (Pierce), washed twice with phosphate-buffered saline and 
washed twice with TBST. The membrane was then incubated for 2 h with anti-actin goat 
polyclonal antibody (Santa Cruz) at a concentration of 1 μg/ml. The membrane was washed with 
TBST and incubated for 2 h with AP-conjugated donkey anti-goat IgG (Santa Cruz) at a 
concentration of 1 μg/ml. Signals were visualized as above, and densitometric measurements were 
taken for both the Mat2a and actin images using Image Reader software (Fujifilm). Mat2a/actin 
ratios were calculated from densitometry data for all control and leupeptin-treated samples. 
Relative ratios from the normalized control and treated values were calculated to determine percent 
change between treatment groups. 
 
C1 component quantitation 
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Quantitation of SAM, total cysteine, methionine, homocysteine (Hcy) and dimethylglycine 
(DMG) was performed using a liquid chromatography–tandem mass spectrometry method for a 
TSQ Quantum (Thermo Scientific, Rockford, IL, USA) coupled with a Waters 2695 Separations 
Module outfitted with a Luna C18(2) 5-μm 250× 4.6-mm column and 4-mm C18 guard column 
(Phenomenex, Torrance, CA, USA) and recorded using Xcalibur software (Thermo Scientific). 
Sample preparation was done using a modified version of the protocol outlined by Weaving [23]. 
Briefly, samples were sonicated and incubated in the reducing agent at room temperature for 15 
min. At this time, isotopic standards for each analyte were added at concentrations of 500 ng/ml 
SAM, 200 ng/ml DMG, 500 ng/ml cysteine, 10 ng/ml Hcy and 1000 ng/ml methionine. To suspend 
the C1 components, 500 μl of a mixture containing 0.1% formic acid and 0.05% trifluoroacetic 
acid in water was added to each vial. Vials were centrifuged at 9000g for 2 min, and the supernatant 
was transferred to a high-performance liquid chromatographic vial for analysis. 
Mobile phases were prepared, with buffer A being comprised of water with 0.1% formic 
acid and buffer B comprised of acetonitrile with 0.1% formic acid. An instrument method was 
programmed to start at 100% A, linearly transition to 90% A and 10% B over 10 min, return to 
100% A after 15 s and hold there to equilibrate for a total of 30 min. Flow rate was set to 0.5 
ml/min, and the injection volume was set at 10 μl. m/z transitions were optimized for detection of 
analytes and isotopic standards as follows: 399.1-249.9 (SAM), 402.1-249.9 (S-
adenosylmethionine-d3), 122.0-76.0 (cysteine), 124.0-78.0 (cysteine-d2), 150.0-104.0 
(methionine), 153.0-107.0 (methionine-d3), 136.0-90.0 (Hcy), 140.0-94.0 (homocysteine-d8), 
104.0-58.0 (DMG) and 110.0-64.0 (N, N-dimethyl-d6-glycine HCl). All parameters were 
optimized by direct infusion into the MS and tuning. Analyte concentrations were calculated by 
determining the ratio of analyte peaks to the known isotopic peak concentrations. Because 
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leupeptin may alter cellular protein pools, data were normalized using the control protein 
concentrations. 
 
DNA isolation 
Genomic DNA was isolated from EMB and VYS tissue using a phenol–chloroform 
extraction procedure. Briefly, thawed samples were homogenized in 540 μl of buffer ATL 
(Qiagen) and digested overnight at 50°C after addition of 60 μl proteinase K (Qiagen). 
Approximately 12 μl of 100 mg/μl RNase A (Qiagen) was added to the mixture before repeated 
extractions from phenol–chloroform isoamyl alcohol in phase-lock gel tubes (5 PRIME), followed 
by a chloroform-only wash. Finally, samples were precipitated in ethanol and dried prior to storage 
in Tris-EDTA buffer until use. 
 
LUminometric Methylation Assay (LUMA) assay 
LUMA was used to measure global methylation of EMB and VYS DNA [24-26]. 
Methylation-sensitive and -insensitive enzymatic digestion of 300 ng genomic DNA at CCGG 
sites was completed using HpaII and MspI enzymes (Invitrogen), respectively. Cleavage with 
EcoRI (Invitrogen) was also completed as an internal control. Annealing buffer (Qiagen) was 
added after digestion, and the products were analyzed using the PyroMark Q96 MD system 
(Qiagen). GTGTCACATGTGTG was used as the dispensation order to eliminate background. The 
MspI/HpaII ratios were calculated relative to the EcoRI control, and the percent methylation of 
each sample was calculated using the equation: 1−[(HpaII/EcoRI)/(MspI/EcoRI)]×100. Samples 
were run in triplicate to account for within-sample variation. 
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Mat2a promoter methylation 
Sodium bisulfite conversion of EMB and VYS DNA was completed utilizing the EpiTect 
Bisulfite Kit (Qiagen), and subsequent cleanup was accomplished using the QIAcube platform 
(Qiagen). PCR and pyrosequencing primers were designed using the PyroMark Assay Design 2.0 
Software (Qiagen). The assay was designed against the reverse bisulfite-converted strand, and 
primer sequences and sequence for analysis are listed in Table 1. Within the sequence to analyze, 
the letter ‘R’ represents a site where a purine (either A or G) is interrogated, giving 
complementation to either cytosine or thymine. The primer amplicon falls within a CpG island on 
the Mat2a promoter upstream of the transcriptional start site. Of the eight sites investigated for CG 
methylation using this pyrosequencing assay, site 7 interrogates methylation at the GC box 
required for binding of the transcriptional factor Sp1 (Fig. 2.2). The region of interest was 
amplified using the bisulfite-converted DNA (2 μl), HotStarTaq master mix (Qiagen), reverse 
primer (0.5 pmol) and a biotinylated forward primer (0.5 pmol) in a PCR with an annealing 
temperature of 54°C. Amplified products were verified using gel electrophoresis and analyzed in 
duplicate using the PyroMark Q96 MD System (Qiagen) and a predetermined sequence-to-analyze 
run (Table 2.1). Two samples were excluded from the VYS leupeptin 26-h exposure group due to 
SNPs in the Mat2a locus. 
 
Statistical analyses 
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Values presented are means±S.D. Statistical significance was determined using unpaired 
two-tailed Student's t tests and a confidence level of 95%. Statistical outliers were removed using 
a threshold of 1.5 times the interquartile range outside of the first and third quartile values. 
 
Results 
Mat2a specific activity 
Mat2a enzyme specific activities (μmol SAM/min/mg protein) were determined in EMB 
and VYS based on SAM biosynthesis from methionine and ATP and were normalized to total 
protein concentrations (Fig. 2.3). Mat2a specific activities were almost identical (P=.991) in 
control EMB (3.06±0.42) and VYS (3.07±1.32). Following leupeptin treatment, Mat2a specific 
activities decreased significantly after 6 h in EMB (2.17±0.48) by 29% (P=.022). Similarly, 
leupeptin treatment in the VYS (0.08±0.02) reduced Mat2a specific activity by 97% (P=.007). 
 
Mat2a and DNA methyltransferase (Dnmt) expression 
Mat2a expression in EMB (1.34±0.05) was significantly higher than Mat2a expression in 
VYS (1.20±0.10; P=.020) (Fig. 2.4). No significant changes in Mat2a expression due to leupeptin 
treatment were produced in EMB (1.30±0.11; P=.429) or in VYS (1.24±0.13; P=.580). No changes 
were observed in Dnmt1, Dnmt3a or Dnmt3b expression due to leupeptin treatment, nor did 
expression differ by tissue for any gene (P>.1). 
 
Mat2a and total protein quantification 
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Leupeptin treatment during the 6-h incubation on GD11 produced a 15.7%±0.1% decrease 
in Mat2a protein concentration in the EMB and a 59.2%±0.1% decrease in the VYS based on 
densitometry from the immunoblots (Fig. 2.5A,B). Mat2a densitometry results were normalized 
to the actin values from the same column of the gel. Total protein values, as determined by the 
BCA assay, were increased by 79.3% in the VYS and 18.4% in the EMB following 6-h leupeptin 
treatment (Fig. 2.5C). The total protein effects of leupeptin treatment significantly differed by 
tissue (P=.001), and the increase in the VYS was statistically significant (P<.001). 
 
C1 component concentrations 
C1 component concentrations (μg) were quantified for each sample to determine whether 
leupeptin inhibition of protease activities in the VYS results in depletion of cellular substrates for 
C1 metabolism in the EMB and VYS after a 6-h exposure (Table 2.2). Control EMB SAM 
concentrations (1.22±0.30; n=6) were significantly greater than control VYS concentrations 
(0.21±0.06; n=6; P<.001). Although SAM concentrations were decreased in EMB due to leupeptin 
treatment, variability was high in the leupeptin-treated samples. For this reason, no statistically 
significant difference was observed between control EMB and leupeptin-treated EMB (0.75± 0.81; 
n=6; P=.237). In the VYS, leupeptin-treatment significantly reduced SAM concentrations 
compared to control concentrations (0.10±0.07; P=.012). 
Methionine concentrations in control EMB (1.74±0.58; n=6) were significantly higher than 
control VYS methionine concentrations (0.67±0.34; n=6; P=.003) (Table 2.2). Leupeptin 
treatment significantly reduced methionine concentrations in EMB (0.24±0.10; n=6; P=.001) as 
well as in VYS (0.17±0.01; n=4; P=.015). Cysteine concentrations in control EMB (6.37±2.18; 
35 
 
n=6) and control VYS did not significantly differ (4.81±1.55; n=5; P=.211). Leupeptin treatment 
significantly reduced cysteine concentrations in EMB (2.67±0.81; n=6; P=.003). Leupeptin 
treatment yielded a 56% increase in cysteine concentrations in VYS, though this change was not 
statistically significant (7.52±2.59; n=6; P=.071). 
Control EMB Hcy concentrations (0.46±0.04; n=5) and control VYS concentrations did 
not significantly differ (0.57±0.20; n=6; P=.258). Leupeptin treatment yielded no significant effect 
on Hcy in EMB (0.47±0.90; n=5; P=.998) or in VYS (0.54±0.12; n=6; P=.738). DMG 
concentrations were below the limit of detection in VYS for this method, so no results can be 
reported on this trend. In EMB, leupeptin-treated EMB (0.11±0.03; n=6) had higher DMG 
concentrations than controls, though this change was not statistically significant (0.09±0.03; n=6; 
P=.196). 
 
Global methylation levels 
Global DNA methylation status was quantified in the conceptus using the LUMA assay. 
Embryos and VYSs were assayed separately on GD11 with and without leupeptin treatment as 
described for each of the 26-h and 6-h exposure protocols. Control EMB DNA was found to be 
75.63%±3.30% and 72.42%±3.29% methylated in the 6-h and 26-h protocols, respectively (Fig. 
6). These differences were not significant. Untreated VYS controls were methylated at a 
significantly lower rate than their corresponding embryos at 57.94%±8.20% and 53.44%±6.64%, 
respectively, for the 6-h (P<.001) and 26-h (P<.001) protocols. Leupeptin treatment significantly 
reduced embryo methylation to 71.00%±3.71% after 6-h exposure (P=.009) in the EMB and to 
50.58%±6.55% (P=.05) in the VYS compared to untreated controls (Fig. 2.6A). Leupeptin 
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treatment for 26 h in the VYS reduced the global methylation percentage to 66.00%±5.13% in the 
EMB (P=.007) and to 45.45%±9.45% in the VYS (P=.05) (Fig. 2.6B). 
 
Mat2a promoter methylation 
Because Mat2a contains several CpG sites flanking an Sp1 transcription factor binding site, 
it was important to identify whether changes in histiotrophic nutrition may indirectly affect 
genome-wide epigenetic regulation via hypermethylation of the Mat2a promoter and decreased 
Mat2a expression and activity. After disruption of endocytosis, no significant changes in 
methylation at CpG sites in the Mat2a promoter were observed (Fig. 2.7). Mat2a exhibited low 
methylation levels at this locus across all tissues, exposures and exposure durations (Fig. 2.7A,B). 
The individual CpG site 7 (Fig. 2.7C,D) showed increased methylation levels compared to other 
sites in the Mat2a locus, but did not reveal significant methylation effects by tissue type or 
exposure group. 
 
Discussion 
Genetics play a large role in instructing phenotypic outcomes during development, but 
these regulatory controls are complemented by nutrients, environmental factors, and physical 
insults that inform the epigenetic patterning required for differentiation and the establishment of 
terminal cell fates and functions. Because the placenta is not yet formed or fully functional during 
the early post-implantation phases of development, histiotrophic uptake of maternal proteins and 
their cargos, as facilitated by RME, represents the primary source of nutrient supply during 
organogenesis. While well established in rodent models, the relevant importance of histiotrophic 
37 
 
processes in human embryonic development has been debated. Even though significant anatomical 
differences exist between the maternal–conceptal interface and the duration of gestation of rodents 
and humans, recent evidence also strongly supports a significant role for HNP in mediating nutrient 
uptake in the human conceptus until the time when the placenta becomes fully functional at the 
end of the first trimester [27,28]. Nutrients, in the form of vitamins, precursors and cofactors that 
are important for C1 metabolism and other cellular processes, are believed to be obtained 
exclusively through HNP by uptake across maternal–conceptual interfaces such as the 
syncytiotrophoblast and VYS during the organogenesis stage of embryonic development 
[14,15,28]. Bulk proteins are captured into vesicles, fused with lysosomes in these tissues and 
degraded by cysteine proteases to provide amino acids for embryonic biosynthesis. Leupeptin 
inhibition of lysosomal proteolysis in the VYS during early organogenesis prevents the 
degradation of maternal proteins, thus limiting the availability of methionine and other components 
required for biosynthesis of SAM in the embryonic C1 pathways. Our hypothesis states that 
interruption of HNPs should decrease SAM biosynthesis and its cellular concentrations due to the 
reduced supply of substrates and precursors required for C1 metabolism and, as a result, affect the 
overall extent of DNA methylation required to sustain normal epigenetic programming. 
In the HNP model, leupeptin should cause a decrease in C1 precursors available for 
methylation processes. Table 2.2 shows changes in methionine and total cysteine in both the EMB 
and the VYS, although the magnitude of these changes differs by tissue. Methionine is 
significantly decreased due to leupeptin treatment in both the EMB and VYS, as would be expected 
from disruption of HNPs. Total cysteine, on the other hand, decreased in the EMB and increased 
in the VYS. Decreases in total cysteine in the EMB can be explained by inhibition of source protein 
degradation in the VYS. Increases in total cysteine in the VYS may be related to changes in the 
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dynamic balance of cysteine transport and utilization that occur in biosynthesis pathways, such as 
incorporation into GSH. Hcy and DMG (C1 metabolic products) remain unchanged following 
treatment and exhibit no tissue differences in cellular concentrations. 
The disruption of HNPs and altered methionine and cysteine in the EMB and VYS are 
accompanied by an approximate 52% decrease in SAM in the VYS and a 39% decrease in SAM 
in the EMB. The significant decrease in SAM in the VYS is expected based on the reduction of 
methionine available for synthesis. A change in the EMB was noted, but was not significant, due 
to the high variability of SAM in the EMB after leupeptin treatment. This suggests that leupeptin 
treatment introduces a degree of instability in the EMB, likely resulting in disruption of multiple 
cellular processes. The difference in SAM concentrations between EMB and VYS is also notable. 
SAM concentrations in the EMB are nearly six times those found in the VYS. 
In this study, we have identified several C1 metabolism-related outcomes that are affected 
by the disruption of HNPs and the attenuated provision of nutrients to the developing conceptus. 
SAM is the critical final product of C1 metabolism and is essential for its role in for epigenetic 
programming. Variations in several other C1 substrates and cofactors that contribute to SAM 
biosynthesis (folate, choline, vitamin B12) have also been associated with malformations and 
abnormal developmental outcomes. The conceptal bioavailability of these substrates and cofactors 
as a function of maternal diet and changes in their concentrations due to chemicals and 
environmental factors has yet to be characterized. In future studies, we hope to determine whether 
depletion of these substrates required by the C1 pathway occurs due to exposure in utero and 
whether dietary supplementation of C1 metabolic precursors may be a potential intervention 
against developmental growth deficiencies and embryotoxicity. 
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The enzyme Mat2a is responsible for the final catalytic step in SAM biosynthesis, 
combining adenosine from ATP with methionine. Lack of sufficient precursors could limit SAM 
biosynthesis as proposed, but other direct effects on the enzyme itself cannot be ruled out. Six-
hour GD11 exposure to leupeptin in WEC produced a significant reduction in Mat2a specific 
activity in both the EMB and the VYS, which is consistent with observed decreases in SAM 
concentrations. Mat2a specific activities (Fig. 2.3) were normalized to total sample protein 
according to accepted protocols. Because of leupeptin's inhibition of proteolytic activity in the 
VYS and the continued endocytotic uptake of maternal proteins, total protein in the VYS was 
significantly increased over that normally found in the untreated VYS (Fig. 2.5C). This results in 
a decrease in Mat2a protein to total protein ratio. Because this affects the specific activity 
calculation, Mat2a specific activity was also calculated using control protein values for 
normalization (Fig. 2.8). The reductions in Mat2a specific activity in both the EMB and VYS 
remained statistically significant, again supporting the decreases in SAM concentrations. 
Mat2a expression was unchanged in both the EMB and the VYS after treatment, and DNA 
methylation was extremely low in the CpG island flanking the Sp1 regulatory region of the Mat2a 
promoter. The Mat2a promoter region was found to be virtually unmethylated, indicating that any 
further decreases in methylation due to the leupeptin-induced reductions in SAM availability are, 
therefore, not expected. The lack of significant alterations in Mat2a expression and methylation 
can be expected, as the product of this gene plays a very important functional role in the cell in 
catalyzing the final step of SAM biosynthesis and would, therefore, be expected to be 
constitutively expressed. Regulation is likely to be mediated through cellular sensors that may not 
be easily induced or suppressed. As the universal methyl donor in cells, SAM availability is critical 
for methylation processes in epigenetic programming such as for DNA and histone methylation. 
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Because methylation is a semipermanent modification, methylation would not be a likely 
regulatory mechanism for Mat2a expression. 
Immunoblot data suggest reduced Mat2a protein concentrations in both the EMB and VYS 
due to leupeptin treatment, with a more profound decrease in Mat2a in the VYS. However, these 
changes may not be entirely accurate due to the significant leupeptin-induced differences in 
relative total protein concentrations in the EMB and VYS. Decreased proteolysis due to leupeptin 
treatment increases the total cellular protein content, mostly contained in endocytotic vesicles, and 
reduces the relative proportion of intrinsic proteins and enzymes active in cellular processes. Thus, 
this decrease in Mat2a abundance in the EMB and VYS may be partly artifactual due to these 
altered protein proportions. 
Because both Mat2a specific activity and protein concentration decrease with inhibition of 
HNPs, it is important to consider the regulation of the Mat2a protein. It is possible that redox 
signaling may play a role in Mat2a regulation. Oxidative modifications to the cysteine-150 residue 
of the Mat2a peptide has been shown to lead to a loss of activity and dissociation of the tetrameric 
complex, likely because the residue falls within the Mat2a ATP binding site [29]. Thus, it is 
possible that oxidative stress may be able to decrease the catalytic activity of Mat2a by a directed 
posttranslational modification. Preliminary evidence from our laboratory suggests that attenuation 
of HNP activity leads to decreases in GSH biosynthesis and a shift to more oxidizing conditions 
in the conceptus [30]. Direct regulation of Mat2a may also explain changes in specific activity and 
protein abundance. Degradation of the Mat2a protein by compensatory protease activity may be 
increased due to leupeptin treatment. It is also possible that the Mat2a protein has a high turnover 
rate. If the Mat2a protein has fast rates of both biosynthesis and degradation, disruption of HNPs 
would decrease the amount of amino acids needed for new protein synthesis and shift the balance 
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in favor of lower Mat2a concentrations. Ultimately, these regulatory changes may lead to altered 
Mat2a function and cellular abundance. 
Epigenetic modifications, like DNA methylation, are crucial for normal development. The 
disruption of HNPs and resulting decrease in C1 components such as SAM may lead to a decrease 
in the substrates available for methylation processes and/or changes in methylation and 
demethylation enzymes required for modifications. Expression of Dnmt1, Dnmt3a and Dnmt3b 
was unchanged in both the EMB and VYS. Because these are the enzymes directly involved in the 
placement of methyl groups on the DNA, it is suggested that regulation of DNA methylation in 
this case does not occur at the transcriptional level. It is likely that these enzymes are constitutively 
expressed during this period of development, as epigenetic patterning is being established in 
tissues. 
Using the LUMA assay to measure global DNA methylation at CCGG sites, it was shown 
that EMB and VYS differ significantly with regards to their baseline percentage of global 
methylation. Average methylation values in the EMB approached 72%, while VYS values were 
found to be about 58%. The EMB and VYS tissues differ with respect to their relative states of 
terminal differentiation, cellular homogeneity, imprinting patterns and embryonic germ line of 
origin, all of which have been previously noted as being important factors for differential 
methylation status [31]. It is quite possible that differences of similar magnitude may also exist 
within the EMB proper based on the high degree of cell and tissue heterogeneity present during 
this stage of development, but the details of spatial methylation patterns are not known. 
Along with significant differences in basal levels of global methylation, for each of the 
treatment protocols, leupeptin produced a significant additional reduction in DNA methylation in 
EMBs from 6% to 9% and in VYS from 11% to 15%. The ability of leupeptin to significantly 
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reduce global methylation levels in WEC after only 6 h of treatment is remarkable. Of interest is 
the observation that leupeptin exposure for periods of time much longer than 6 h did not produce 
any additional changes in the percentage decrease in global DNA methylation levels. This suggests 
that the full range of methylation-related events occurs rapidly in the conceptus and that a threshold 
of change exists, beyond which no additional demethylation will occur. Several different factors 
could be responsible for the decrease in global methylation levels, including (a) a reduction in the 
developmentally programmed and ongoing DNA remethylation events aided by insufficient SAM 
availability; (b) the inability of the conceptus to maintain established DNA methylation marks, 
including those that are replicated through successive cell generations via enzymatic DNMT1 
maintenance activity; and (c) the demethylation of existing DNA methylation marks. Further 
investigations into the regulation of DNMT function by environmental and biochemical factors 
will be required to understand this potential mechanism of susceptibility. Because epigenetic 
programming during this stage of development is crucial for differentiation, normal tissue 
patterning and growth, significant modifications of the global epigenome would be expected to 
exert their effects on embryonic viability and the elicitation of morphological defects. Based on 
the significant decreases in global methylation observed, however, it is reasonable to expect that 
methylated regulatory sites throughout the epigenome may be subject to demethylation. Thus, 
epigenome-wide DNA methylation studies will be necessary to fully identify the subset of 
regulatory regions that are sensitive to epigenetic change during this phase of development. 
To summarize, decreased amounts of C1 precursors lead to decreased SAM and global 
DNA methylation. It is likely that Mat2a plays a large role in the regulation of these methylation 
processes, as SAM concentrations mimic Mat2a activity. It is unknown at this time how other 
changes in HNPs, such as disruption of RME, may also alter these processes. Because RME is 
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responsible for the uptake of C1 substrates such as folate, choline, betaine and B vitamins at this 
stage of development, modifications to the endocytotic potential of the VYS may be able to 
produce detrimental epigenetic effects in the developing EMB. Future investigation into the 
relationships between toxicant-induced changes in these processes and the nutrient environment 
of the conceptus is necessary to understand the pathways by which developmental exposures may 
contribute to abnormal epigenetic programming. 
In conclusion, this study identifies a window of susceptibility during which the developing 
epigenome may be affected by nutrients and environmental factors during organogenesis. 
Disruption of HNPs leads to decreased availability of C1 components, reduced Mat2a activity and 
decreased global DNA methylation in the VYS and EMB. All of these changes indicate that 
histiotrophic nutrition is crucial for epigenomic programming in the early organogenesis-stage 
conceptus. Tissue-specific differences between EMB and VYS were evident throughout this study, 
corresponding with divergence in degrees of differentiation and homogeneity. Environmental 
hindrance of HNPs may epigenetically alter gene expression in the conceptus, and these changes 
may be detrimental throughout the life course. Further investigation into the specific pathways and 
products being altered by dietary factors and chemical exposures, namely, HNPs and C1 
metabolism, which lead to developmental abnormalities and predisposition to disease throughout 
the life course, is crucial to understanding the overlaying role of embryonic nutrition during 
development. 
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Figure 2.1. HNPs influence C1 metabolism, SAM biosynthesis and DNA methylation. HNPs are the 
primary mechanism of nutrient supply during early organogenesis. Histiotrophic functions include RME 
and proteolysis of endogenous nutrient proteins taken up through the VYS brush border. After 
proteolysis, resulting amino acids are made available for cellular functions such as protein biosynthesis 
and C1 metabolism. Leupeptin treatment inhibits proteolysis, limits the availability of critical substrates 
through pathways (marked with an X) and results in limited biosynthesis of biomolecules (down arrows). 
This figure summarizes our hypothesis, showing the reduction of precursors to pathways, through which 
SAM, the primary methyl donor for DNA (and other molecule) methylation, is generated. The lack of 
SAM will limit DNA methylation and result in the observed global DNA hypomethylation. 
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Figure 2.2. Sequence of the 5’ flanking region of the rat Mat2a gene. The forward (biotinylated) and 
reverse primers bind to the bisulfite-converted sequence of the italicized region above, producing a 201-
bp pyrosequencing amplicon highlighted in the box. A sequencing primer anneals to the TATA box 
region and extends in the opposite direction to interrogate eight individual CpG sites for methylation 
surrounding the Sp1 transcription factor binding GC box. 
  
46 
 
 
 
Figure 2.3. Mat2a specific activity after 6-h leupeptin exposure. Mat2a specific activities are decreased by 
leupeptin exposure in both EMB and VYS. Mat2a activity is similar in the EMB (n = 4) and VYS (n = 5) 
under control conditions. Specific activity is significantly reduced by leupeptin treatment in the EMB (n = 
5; P = .022) and in the VYS (n = 5; P = .007). **P < .01; *P < .05. 
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Figure 2.4. Mat2a, DNMT1, DNMT3a and DNMT3b gene expression after 6-h leupeptin treatment. Mat2a 
gene expression was significantly higher in the EMB (n = 5) than the VYS (n = 6; P = .02). No statistically 
significant changes were noted between control (n = 5) and leupeptin-treated (n = 6) EMB for any of the 
gene targets tested (P > .1). Likewise, no significant changes occurred in the control (n = 6) or leupeptin-
treated (n = 6) VYS samples (P > .1) for all targets. 
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Figure 2.5. Mat2a protein concentrations and total protein content after 6-h leupeptin treatment. 
Densitometric readings following Western blotting (A) revealed a significant effect difference between 
EMB (n = 3) and VYS (n = 3; P = .001), indicating that leupeptin treatment produced a more significant 
decrease in the Mat2a protein in the VYS (−59%) than the EMB (−16%) (B). However, the accumulation 
of extrinsic proteins due to leupeptin treatment also results in an 18% increase in total protein in the EMB 
and 79% in the VYS (C). *P = .001; **P < .001. 
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Figure 2.6. Global percent methylation for EMB and VYS tissues after 6-h or 26-h exposure determined 
by LUMA. EMB percent methylation is significantly higher than VYS methylation across all tissues (P < 
.001). (A) Control EMB (n = 10) was significantly higher than leupeptin EMB (n = 10) after 6-h exposure 
(P = .009). Control VYS (n = 11) methylation was significantly higher than leupeptin VYS (n = 8; P = .05). 
(B) Control EMB (n = 9) was significantly higher than leupeptin EMB (n = 8) after 26-h exposure (P = 
.007). Control VYS (n = 10) was higher than leupeptin VYS (n = 8; P = .05). (A and B) Control EMB and 
leupeptin EMB both showed significant decreases in percent methylation between 6- and 26-h exposure (P 
= .05 and .03, respectively). VYS showed no significant change over time. **P < .01; *P < .05. 
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Figure 2.7. Mat2a promoter methylation levels determined by pyrosequencing. The Mat2a promoter 
exhibits low methylation levels surrounding the Sp1 binding site in both the EMB and VYS after 6-h or 26-
h leupeptin exposure. (A) No significant difference was detected between control EMB (n = 10) and 
leupeptin EMB (n = 10) after 6-h exposure, or between control VYS (n = 10) and leupeptin VYS (n = 9). 
(B) Likewise, there was no significant difference between control EMB (n = 8) and leupeptin EMB (n = 8) 
after 26-h exposure, or between control VYS (n = 8) and leupeptin VYS (n = 6). (C) Although individual 
CpG site 7 methylation is above average for the Mat2a locus assayed, no significant changes in methylation 
were apparent for tissues after 6-h leupeptin exposure. (D) No statistically significant changes in CpG site 
7 methylation were detected after 26-h leupeptin exposure. 
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Figure 2.8. Control-normalized Mat2a specific activity after 6-h leupeptin exposure. Because leupeptin 
inhibits protein degradation in the VYS without diminishing the continuous uptake of extraconceptal 
proteins from the media via RME, treated VYSs accumulate more total protein than the corresponding 
controls. This results in the protein of interest representing a significantly lower proportion of the total 
measured protein content in the VYS. In order to account for the exogenously increased protein in the VYS, 
Mat2a specific activities were also calculated using the concurrent control protein concentrations to 
normalize the data. Using this approach, leupeptin treatment on GD11 produced a significant 36% decrease 
in Mat2a specific activity in the EMB (1.95 ± 0.19; P = .003). In the VYS, leupeptin treatment yielded a 
significant 76% decrease in Mat2a specific activity (0.74 ± 0.07; P = .017). These results corresponded with 
the specific activity data shown in Fig. 3, strengthening the relationship between leupeptin treatment and 
the reduction in Mat2a specific activity. 
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Table 2.1. PCR and pyrosequencing primers (5' to 3') and analyzed sequence for the Mat2a promoter. 
 
  
Primer type Primer sequence Melting temp (°C) 
Forward-
biotinylated GTTATTAGGATGATTAATTATTGTTAGG 54.5 
Reverse ACCCAATATTTATAAAACAACTCC 56.3 
Sequencing CAATATTTATAAAACAACTCC 40.8 
Sequence to 
analyze 
CRCRCRCRCCCRACTCRAACCCCRCCCCTCRACRTCRCRCRCCAATACRCCACRA
ACAAACRAAT 
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Table 2.2. Leupeptin-induced effects on bioavailability (µg) of C1 metabolism components 
concentrations in EMB and VYS. 
 
Component Control Leupeptin-treated 
SAM   
        EMB 1.22 ± 0.30 0.75 ± 0.81 
        VYS 0.21 ± 0.06a 0.10 ± 0.07c 
Methionine   
        EMB 1.74 ± 0.58 0.24 ± 0.10b 
        VYS 0.67 ± 0.34a 0.17 ± 0.01c 
Cysteine (total)   
        EMB 6.37 ± 2.18 2.67 ± 0.81b 
        VYS 4.81 ± 1.55 7.52 ± 2.59 
Hcy   
        EMB 0.46 ± 0.04 0.47 ± 0.90 
        VYS 0.57 ± 0.20 0.54 ± 0.12 
DMG   
        EMB 0.09 ± 0.03 0.11 ± 0.03 
        VYS ND ND 
 
‘ND’ signifies that no data were collected due to results falling below the limit of detection. 
a Indicates a significant difference between control EMB and control VYS (P<.05). 
b indicates a significant difference between control EMB and leupeptin-treated EMB (P<.05). 
c indicates a significant difference between control VYS and leupeptin-treated VYS (P<.05). 
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Chapter III 
Mono-2-ethylhexyl phthalate disrupts neurulation and modifies the embryonic 
redox environment 
 
 
Introduction 
Development is a highly regulated process that relies on tightly controlled intra- and 
intercellular signaling for normal growth. Dysregulation of embryogenesis can be caused by a 
myriad of genetic, physiological, and environmental factors, and can alter specific signaling 
pathways to manipulate cell polarity and migration, membrane transport, and protein structure and 
function [1-4]. Ultimately, these changes may potentially manifest as spontaneous abortion, birth 
defects, or predispose individuals to diseases that arise during childhood and into adulthood. One 
such factor that may lead to this dysregulation is altered redox signaling and control, or 
perturbations of soluble thiol status from the steady state [5]. Classically, many teratogens, or 
compounds that produce congential malformations, were thought to act via classical oxidative 
stress: a change from a balanced and reducing intracellular redox environment to predominantly 
oxidizing conditions, concurrent with the generation of reactive oxygen species (ROS) [6]. An 
oxidizing environment during development has been associated with increased risk of diseases 
including neurodegeneration, hypertension, cancer, and Type II Diabetes [7-9]. However, ROS are 
now known to have a critical role in normal cell function, and redox potential may be a crucial 
indication of the steady state redox conditions that permit differentiation and tissue patterning 
during embryogenesis and organogenesis [5,10].  
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Altered redox potentials during embryonic development can range from mild to severe, 
leading to manifestations ranging from altered signal transduction to apoptosis and necrosis, 
respectively. Because these consequences are likely harmful, the body has an endogenous 
antioxidant system to prevent and protect against the more damaging consequences of oxidation. 
The reducing agent glutathione (GSH) and related enzymes glutathione reductase, glutathione 
peroxidase, and glutamate-cysteine ligase are primarily responsible for the maintenance of a 
balanced cellular redox potential. Production and recycling of these endogenous antioxidants is 
initiated through the induction of the Nrf2 antioxidant pathway. When this is insufficient to 
maintain a balanced environment during development, teratogenesis may occur [5]. 
 
It has been demonstrated that several chemical compounds have the ability to modify the 
embryonic redox environment, and that these changes may result in teratogenic outcomes [5,11-
15]. Compounds such as ethanol, diamide, methylmercury, phenytoin, and L-buthionine-S,R-
sulfoximine have been associated with oxidation of the various tissue and fluid compartments of 
the conceptus, including the visceral yolk sac (VYS), the yolk sac fluid, the amnion and amniotic 
fluid, and the embryo proper (EMB) (unpublished data) [14,16,17]. These compounds are able to 
decrease embryonic and fetal tissue glutathione concentrations, and co-treatment with antioxidants 
such as N-acetylcysteine and dithiole-3-thione (D3T) could prevent toxicant-induced injury 
[11,14,16,18-25].  The body of evidence for other toxicants altering redox signaling in the 
organogenesis-stage conceptus is growing, and many of these exposures are associated with 
adverse health outcomes and structural defects.  
Mono-2-ethylhexyl phthalate (MEHP) is the primary metabolite of the common 
plasticizing agent, Di-2-ethylhexyl phthalate (DEHP). DEHP has been widely incorporated to 
products all over the world, especially including vinyl piping and medical tubing. Evidence of 
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phthalate transfer to the embryo and fetus has been evident through detection of MEHP in 
meconium, amniotic fluid, cord blood, rodent fetal tissues, and placental perfusate [26-34]. It has 
been previously demonstrated that MEHP can induce oxidative and inflammatory conditions in 
various reproductive tissues and developmental tissues, though these studies focus on other model 
organisms and different stages of development [35-38]. Thus, it is crucial to construct an ontogeny 
of redox potentials across the susceptible window of early organogenesis. 
The goal of this study was to characterize MEHP-induced morphological changes in mouse 
whole embryo culture (mWEC), determine whether MEHP changes tissue and fluid antioxidant 
levels and alters redox potentials in embryonic tissues, and utilize gene expression profiles to 
identify pathways altered by MEHP treatment that may play a role in dysmorphogenesis. 
 
Materials & Methods 
Chemicals and reagents 
Dioctyl phthalate (DEHP), dimethyl sulfoxide (DMSO), glutathione, glutathione disulfide, 
cysteine, cystine, γ-glutamyl-glutamate, iodoacetic acid, iodoacetamide, bicinchoninic acid, 
RNAlater®, Tyrode’s balanced salt solution, and penicillin/streptomycin (10,000 units/ml 
penicillin, 10,000 μg/ml streptomycin sulfate) were obtained from Sigma/Aldrich (St. Louis, MO). 
Hanks balanced salt solution (HBSS) was purchased from GIBCO/Life Technologies (Grand 
Island, NY). Dansyl chloride was purchased from Fluka Chemie/Sigma-Aldrich (St. Louis, MO). 
Glacial acetic acid was obtained from Fisher Scientific (Waltham, MA). Mono-2-ethylhexyl 
phthalate was obtained from AccuStandard (New Haven, CT). 
 
Mouse whole embryo culture 
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Mouse embryo culture was performed according to the procedures outlined in [39]. Briefly, 
female CD-1 mice were time-mated and obtained from Charles River (Portage, MI). The morning 
of discovery of a vaginal plug was designated as gestational day (GD) 0. Animals were maintained 
on a 12 h light-12h dark cycle and were supplied food and water ad libitum. On GD 8, female mice 
were euthanized with CO2 and the uterus was removed. Culture-ready conceptuses were explanted 
from the uterus, removed from the decidual mass and freed from the Reichert’s membrane, 
randomized, and placed into 10 ml culture bottles containing 5 ml of 75% heat-inactivated rat 
serum/25% Tyrode’s balanced salt solution (TBSS) and 21.5 μl penicillin/streptomycin. Bottles 
were placed on a continuous-gassing carousel in an incubator held at 37°C and supplied with 5% 
O2/5% CO2/90% N2. After 6 h in culture, the gas input was changed to 20% O2/5% CO2/75% N2 
to mimic the increased oxygenation of the in utero environment due to onset of embryonic 
heartbeat and active conceptal circulation. 
 
Exposure and sample collection 
DEHP and MEHP were suspended in DMSO to increase solubility in culture. DEHP and 
MEHP were added to the culture medium to bring the final concentration in culture to 100, 250, 
500, or 1000 μg/ml. These concentrations were selected based upon concentrations utilized in other 
phthalate whole embryo culture studies [40,41]. DMSO was added to control bottles, and all 
DMSO concentrations were less than 1 μl/ml in culture. For morphology experiments, conceptuses 
were grown in culture for a total of 24 h before removal. For redox analysis, conceptuses were 
collected at 0 h before explant into culture, and following 1, 3, 6, 12, and 24 h in culture. Samples 
designated for RNA isolation were collected following 6 h in culture. At the time of removal from 
culture, all conceptuses were washed in Hank’s balanced salt solution (2x) and ectoplacental cones 
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were removed. The EMB and VYS were manually separated using watchmaker’s forceps. At this 
time, samples were either designated for morphology assessment or for redox analysis. Samples 
for redox analysis were placed into thiol preservation buffer (containing 5% perchloric acid, 0.2 
M boric acid, and 10 μM γ-glutamylglutamate) snap frozen in liquid N2, and stored at -76⁰ C, as 
specified in [10]. Tissues collected for RNA isolation were placed into RNA later and stored at -
76⁰ C. 
 
Morphology Assessment. 
At the conclusion of the culture period, conceptuses for morphology assessement were 
removed from culture and washed thoroughly in HBSS without disruption. Once rinsed, 
conceptuses were placed into clean HBSS under a microscope for analysis and imaging. Images 
were taken before and after removal of the VYS. Morphological parameters were evaluated as 
specified in [39]. In short, we evaluated quality and developmental progress of the VYS, allantois, 
heart, flexion, caudal neural tube, forebrain, midbrain, hindbrain, otic vesicle, optic cups, 
forelimbs, mandible, maxillary process, and counted the number of somites. Additionally, crown-
rump length, VYS diameter, and head length were measured [39]. Inviable conceptuses, 
characterized by a lack of heart beat, were excluded from the data set though the number of inviable 
embryos increased as the dose of MEHP increased. Protein quantification of tissue was done using 
bicinchoninic acid (BCA) assay on a microplate reader [42]. 
 
HPLC quantification of thiols and redox potentials. 
Samples were thawed on ice and prepared for HPLC analysis of soluble thiols as previously 
described in [16,43]. Briefly, a Waters 2695 Alliance Separations module equipped with a 
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Supelcosil LC-NH2 column (Sigma, St. Louis, MO) was coupled with a Waters 2475 Fluorescence 
Detector. Reverse-phase chromatography was used to measure reduced glutathione (GSH), 
oxidized glutathione disulfide (GSSG), reduced cysteine (cys), and oxidized cystine (cySS). Flow 
was set to 1 mL/min using a mobile phase gradient consisting of two mobile phases. Mobile phase 
A contained 80% methanol and mobile phase B consisted of 62.5% methanol, 12.5% glacial acetic 
acid, and 214 mg/ml CH3COONa-3 H2O. Peaks were evaluated (excitation 335 nm, emission 518 
nm) using the Waters Empower software (Milford, MA). The Nernst equation (pH 7.4) was used 
for the calculation of redox potential (Eh) for both the cys/cySS and GSH/GSSG redox pairs: 
Eh=−264+30 log ([GSSG]/[GSH]2), Cys/CySS, Eh=−250+30 log ([CySS]/[Cys]2) . Absolute 
concentrations of GSH, GSSG, cys, and cySS were calculated and normalized to tissue protein 
concentrations following BCA assay. 
 
RNA isolation and Affymetrix microarray analysis of expression 
Samples stored in RNAlater were thawed on ice and RNA was isolated following the 
instructions of the RNeasy Mini Kit (Qiagen). RNA was submitted for Affymetrix microarray 
processing at the University of Michigan Microarray Core Facility. Mouse MG-430 PM strip 
arrays were processed using the IVT Express Kit (Affymetrix). RNA purity and integrity were 
confirmed using the RNA 6000 Nano Kit for the Agilent 2100 Bioanalyzer. Raw data obtained for 
the array was further examined for quality and supported by satisfactory scores for PM chip 
density, RNA degradation, and standard errors. Robust multi-array average (RMA) was used for 
background correction, normalization, and quantification of log2 expression. Principle component 
analysis revealed distinctions between samples, confirming EMB and VYS tissue differences (Fig. 
3.1).  
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Overall differences in expression between control and MEHP-treated EMB and VYS were 
examined using the Limma package in R 2.4.1. The lmFit function was used to downweight 
potential outliers. Raw p-values were obtained by t-test, and adjusted and ranked using an 
empirical Bayesian method (eBayes function in Limma). Enrichment was analyzed using LRpath, 
and biologically and statistically altered pathways were identified using the KEGG database [44]. 
Pathways containing genes were many statistical differences were considered “enriched”. Highly 
conserved pathways containing fewer statistically altered genes than would be expected by random 
chance were considered “depleted”. 
 
Statistical Analysis 
 Values presented in this paper are means ± standard error of the mean. Statistical outliers 
were removed, identified as values 1.5 times the interquartile range outside of the first and third 
quartiles of the data. One-way ANOVA with Tukey posthoc tests and independent t-tests were 
used to assess statistical significance of differences between groups of data. A confidence level of 
95% was used, and p-values <0.05 were deemed as statistically significant changes. 
 
Results 
Morphology Assessment 
Following the culture period, dose-response examination of the morphological outcomes 
from both the parent compound and metabolite treatments was conducted, examining morphology 
in response to MEHP at concentrations of 100 μg/ml (M100), 250 μg/ml (M250), 500 μg/ml 
(M500), or 1000 μg/ml (M1000), or DEHP at concentrations of 100 μg/ml (D100), 500 μg/ml 
(D500), or 1000 μg/ml (D1000). Concentrations were selected based upon benchmark 
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concentrations obtained in another study [40], and confirmed following the initiation of this study 
[41]. In all, conceptuses treated with MEHP exhibited morphological changes, while conceptuses 
treated with DEHP remained similar morphologically to controls (Fig. 3.2). This is consistent with 
the likelihood that DEHP is metabolized maternally prior to conceptual exposure, and that MEHP 
is the active compound for teratogenesis. Conceptuses treated with MEHP were noticeably smaller 
than controls, and overall size decreased in a dose-dependent fashion (Fig. 3.3). Table 3.1 displays 
the average scores for all morphological parameters after MEHP treatment. Control conceptuses 
(n=17) had an average total morphology score of 86.6 ± 6.1. None had any notable defects, and 
they were fairly robust in size. Treatment significantly reduced many of the scores, though it 
seemed to have had little effect on the mandibular or forelimb scores. Of the affected 
developmental outcomes, the closure of the neural tube was particularly affected. Neural tube 
closure was significantly halted or delayed by MEHP treatment in the cephalic fore-, mid-, and 
hindbrain segments as well as in the caudal neuropore (Fig. 3.4). 
 
MEHP morphology 
The M100 group (n=7) had an average total morphology score of 73.8 ± 10.0, indicating a 
fair amount of morphological variability in these samples. Several of these M100 embryos were 
hypoplastic in the forebrain region, and 43% of the embryos had open neural tubes at least at one 
of the four neural tube regions examined (forebrain, midbrain, hindbrain, caudal neural tube). This 
is consistent with other concurrent studies being conducted in the laboratory, with open neural 
tubes occurring with an incidence of 33-45% in M100-treated conceptuses. One of the embryos 
developed a clear blister on the prosencephalon.  
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The M250 group (n=6) followed a similar pattern, with an average total morphology score 
of 72.9 ± 2.9. All but one of the embryos had an open neural tube at one or more of the neural tube 
regions scored. Though all of the caudal neural tubes were closed in the M250 group, all were 
highly hypoplastic at this locus.  
The M500 group (n=16) had an average morphology score of 56.6 ± 3.3, and also showed 
hypoplasia of the caudal neural tube. About a third of the embryos possessed caudal neural tubes 
that were so necrotic that they could not be fully assessed due to the status of the caudal neuropore. 
In all of the embryos, the caudal region was truncated and hypoplastic. Allthe spinal columns of 
the M500 embryos had a ‘zig-zag’ pattern running dorsally along the neural tube. One of the 
embryos had complete dissociation of the neural epithelium, with large blisters and severe 
hypoplasia in the forebrain region. In approximately a third of the embryos, the pericardium was 
enlarged and fluid-filled, and these same embryos had blood pooling in the antimesometrial end 
of the VYS. One of the M500 embryos also had a very thin second branchial arch.  
The M1000 group (n=5) was the first exposure that resulted in loss of viability in some of 
the conceptuses, with merely a 28.4 ± 0.8 morphology score. Nearly 30% of embryos lacked a 
heartbeat entirely, and those that survived had very weak heartbeats in terms of rate and apparent 
contractile force. All of the M1000 embryos were very hypoplastic at the caudal end, and had the 
‘zig-zag’ pattern running along the dorsal side. All lacked a posterior neuropore, and had signs of 
necrosis. In one of the embryos, necrotic debris was visible within the hindbrain region. All of 
these M1000 embryos had blood pooling in the antimesometrial end of the VYS, and all had very 
thin second branchial arches.  
 
DEHP morphology 
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Compared to the MEHP-treated conceptuses, the DEHP-treated conceptuses were normal 
morphologically. The D100 group (n=3) showed almost no signs of change relative to the 
morphology of the controls. The D500 (n=5) and D1000 (n=5) groups also showed little change, 
though the caudal neural tube and the forebrain regions were slightly hypoplastic. 
 
 Control EMB and VYS glutathione concentrations 
Reduced glutathione, GSH, concentrations were measured in EMB and VYS tissues. 
Embryonic GSH rapidly increases after conceptal transfer into culture. At the time of placement 
into culture (t=0), control GSH concentrations are approximately 1188.1 ± 286.4 µM (n=5). After 
1 h, control GSH concentrations rose to 1533.4 ±164.9  μM (n=4). After this time, GSH initially 
declines and then remains steady over the next 24 hours in controls (Fig. 3.5). After 3, 6, and 12 
h, the concentrations decline to 777.3 ± 94.3 (n=4), 754.4 ± 174.9 (n=8), and 705.4 ± 16.4 (n=4) 
μM, respectively. After 24 h in culture, control EMB GSH concentrations decrease slightly to 
620.1 ± 51.2 μM (n=6). GSH concentrations in the VYS follow a different pattern (Fig. 3.5). At 
the start of the culture period, control VYS GSH concentrations are 1272.1 ± 142.0 μM (n=4), 
which is similar to embryonic concentrations. Unlike in the EMB, GSH concentrations are reduced 
after 1 h to 1119.8 ± 31.0 (n=4). Concentrations steeply decrease after 3 h to 225.2 ± 43.3 μM 
(n=5), and then rise again at 6 h to 577.6 ± 46.3 (n=7). GSH remains fairly constant after 12 h 
(535.3 ± 6.4; n=4), but then increases by 50% to 804.8 ± 49.5 μM after 24 h (n=6). 
 
Embryonic glutathione concentrations 
MEHP treatment reduces GSH concentrations in the EMB after 1 h exposure in a dose-
dependent manner, measuring 1014.3 ± 75.3 (p=0.034; n=3) and 539.3 ± 67.6 (p<0.001; n=5) μM 
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for the M100 and M250 groups, respectively. While the M250 group GSH concentrations continue 
to decline after 3 h exposures (634.2 ± 85.6; p>0.1; n=4), GSH concentrations increased in the 
M100 group to 1172.1 ± 139.3 μM (p=0.07; n=4). Though there was no statistically significant 
difference between controls and treated groups, GSH concentrations of the M100 group were 
significantly elevated compared to those of the M250 group (p=0.017). After 6 h in culture, the 
GSH concentrations of all exposure groups becomes fairly regular. The M100 concentrations are 
very similar to those of controls (754.2 ± 109.2; p>0.99; n=8). The M250 group appears to recover, 
and is slightly elevated (913.6 ± 125.5; p>0.5, n=8). After 6h in culture, gas concentrations are 
changed to mimic the in utero increased oxygen environment. While the control group was able 
to maintain a steady GSH concentration, the M100 and M250 groups were found to have decreased 
GSH concentrations in a dose-dependent manner. GSH concentrations were reduced in the M100 
group to 337.7 ± 25.4 (p<0.001; n=3), and even more so by the 250 μg/ml exposure (153.0 ± 22.2; 
p<0.001; n=4). By 24h, all treatment groups had approximately the same GSH concentrations. 
GSH concentrations rose slightly to 612.9 ± 20.0 μM in the M100 exposure group (p=0.983; n=10) 
and to 651.1 ± 13.1 μM in the M250 exposure group (p=0.758, n=7). 
 
Visceral yolk sac GSH concentrations 
 After 1 h in culture, VYS GSH concentrations in the M100 and M250 groups are both 
significantly lower than controls, with 477.6 ± 126.8 (p=0.010; n=5) and 637.2 ± 148.2 μM 
(p=0.017; n=5), respectively. Concentrations remain fairly stable at 490.3 ± 97.2 in the M100 
group, but elevated compared to controls (p=0.09; n=3). The M250 group GSH concentrations 
decreased to 339.7 ± 95.7 μM after 3 h (p=0.519; n=4), remaining elevated compared to controls 
but depressed compared to the M100 exposure group. This relationship is still evident after 6 h of 
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exposure. The M250 VYS group had GSH concentrations lower than controls (p=0.515), but 
greater than the M100 VYSs (p=0.112). All of these concentrations were increased compared after 
3 h exposures, with concentrations of 685.0 ±70.4 (n=7) and 458.4 ± 99.4 (n=7) μM for the M100 
and M250 groups, respectively. Following the increased oxygenation of the environment and rapid 
morphological changes, all GSH concentrations decreased at the 12 h time point. Concentrations 
dropped to 350.7 ± 87.6 μM in the M100 group (n=4) and 524.9 ± 90.2 μM in the M250 group 
(n=6), and were similar to controls (p=0.291; p=0.897). All GSH concentrations were increased 
after 24 h, with concentrations of 816.3 ± 20.3 (n=10) and 906.8 ± 28.5 (n=8) μM for the M100 
and M250 groups, respectively. There was a dose-dependent, slight increase in GSH 
concentrations compared to controls, though these differences were not statistically significant 
(M100: p=0.964; M250: p=0.096). 
 Overall, MEHP exposure decreases EMB GSH concentrations in a dose-dependent manner 
at crucial windows of EMB development, but the EMB and VYS are capable of restoring GSH 
concentrations after 24 h. 
 
Control EMB and VYS cysteine concentrations 
 Reduced cysteine, cys, was measured in EMB and VYS tissues. Cysteine concentrations 
progressively decrease over the first 6 hours in control EMB and VYS. In the EMB, cys 
concentrations start at 234.2 ± 96.1 μM prior to the culture period (n=5). After 1, 3, and 6 h, cys 
decreases to 211.3 ± 53.6 (n=4), 159.1 ± 26.6 (n=4), and 46.7 ± 10.5 (n=7) μM, respectively.  After 
introduction of the higher oxygen environment and entrance into a stage of rapid embryogenesis, 
embryonic cysteine concentrations climb to 224.6 ± 29.4 μM by 12 h (n=5), and then drops again 
by 24 h to 86.2 ± 6.6 μM (n=6). Concentrations of cys in the VYS are slightly elevated compared 
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to the EMB at t=0, measuring at 374.2 ± 152.3 μM (n=5). Unlike the EMB, cys is increased in the 
control VYSs to 1990.0 ± 804.5 after 1 h in culture (n=4).  Concentrations rapidly drop to 136.4 ± 
25.5 μM after 3 h (n=4), and then to 52.8 ± 9.1 after 6 h (n=6). Like in the EMB, the numerous 
changes that occur between 6 and 12 h are pronounced at the 12 h time point by a rapid increase 
in cys to 467.4 ± 111.2 μM (n=4), and this is succeeded by a 75% decrease in cys to 118.5 ± 13.5 
μM at 24 h (n=6). 
 
Embryonic cysteine concentrations 
 After 1 h of exposure, embryonic cysteine concentrations are slightly elevated in the M100 
group to 221.0 ± 28.1 μM (n=5) and decreased in the M250 group to 144.4 ± 9.4 μM (n=3), but 
neither change was statistically significant (p>0.05 for all relationships; Fig. 3.6). After 3 h 
exposure, a dose-dependent decrease in cysteine concentrations is evident, dropping to 87.2 ± 31.3 
μM for the 100 μg/ml exposure group (n=4) and 32.1 ± 2.8 μM for the 250 μg/ml group (n=3). 
Though this decrease compared to controls is not statistically significant in the M100 group 
(p=0.169), it is significant for the M250 group (p=0.03). Low- and high-dose exposures to MEHP 
are fairly similar to controls following 6 h in culture (p=0.651 and p=0.653, respectively). The 
M100 group cysteine concentrations dropped further to 37.7 ± 4.3 μM (n=7), and the M250 group 
to 37.7 ± 4.8 μM (n=7). Following the morphological and environmental oxygen changes in 
culture, the 12 h time point results in decreased cysteine concentrations in both the M100 and 
M250 groups though neither is statistically significant (p=0.338 and p=0.960, respectively). The 
low-dose exposure results in an average cysteine concentration of 177.4 ± 9.0 μM (n=4), while the 
M250 group cysteine concentrations were 216.0 ± 18.6 μM (n=4) after 12 h. All cysteine 
concentrations decrease leading up to the 24 h time point, though all concentrations are fairly 
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similar (p>0.4 for all relationships). The M100 group concentration was 73.3 ± 6.1 μM (n=10), 
and the M250 group concentration was found to be 73.6 ± 7.6 μM (n=8). 
 
Yolk sac cysteine concentrations 
 Following 1 h exposure, control and exposed VYSs all had similar cys concentrations 
(p>0.99 for all relationships). Yolk sac cys concentrations for the M100 group were highly 
variable, averaging 1978.7 ± 986.8 μM (n=5), while the M250 group had average cys 
concentrations of 1902.4 ± 34.5 μM (n=3). After 3 h exposure, the M100 group has significantly 
greater cysteine than the control or high-dose group, though these relationships are not statistically 
significant (p>0.07). Cysteine concentrations from the M100 group were highly variable and 
average at 329.4 ± 138.1 μM (n=3), while M250 concentrations drop to 82.5 ± 15.0 μM (n=4). 
Concentrations all remain low at the 6 h time point, with M100 VYSs dropping cysteine 
concentrations further to 55.9 ± 18.6 μM (n=6) and M250 concentrations rising slightly to 103.5 
± 26.2 μM (n=7), though no statistically significant relationships were observed at the 6 h time 
point (p>0.2). After 12 h in culture, MEHP-exposed VYSs had significantly lower cys 
concentrations than controls (p=0.003 for both relationships). M100 (n=3) and M250 group (n=6) 
cys concentrations rose to 196.3 ± 12.5 and 275.5 ± 29.2 μM, respectively. Cysteine concentrations 
all drop at the 24 h time point, though this is exacerbated in the M100 group. The M100 group cys 
concentrations in the VYS drop to a mere 11.5 ± 1.3 μM (n=8), significantly lower than control 
(p<0.001) and M250 cys concentrations (92.2 ± 16.2 μM; p<0.001; n=8). 
 
Total glutathione and cysteine concentrations 
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 Total glutathione concentrations are shown for the EMB (Fig. 3.7A) and VYS (Fig. 3.7B), 
as well as total cysteine concentrations in the EMB (Fig. 3.7C) and VYS (Fig. 3.7D). Total 
glutathione is defined as the sum of the reduced fraction concentration and two times the disulfide 
concentration. No obvious trends were observed in the VYS for either total cys or total GSH. Total 
GSH in the EMB follows two interesting profiles: one occurring between t=0-6, and another 
between t=12-24. Between 0-6 hours, each treatment group has peak total GSH concentrations at 
different time points, suggesting that biosynthesis may play a role in this measure. Control total 
GSH concentration peaks at 1 h in culture, and is significantly greater than the treated EMBs 
(p=0.002). Total GSH then decreases progressively until the t=6 point. The M100 total GSH 
concentration peaks at 3 hours, and is elevated compared to the dwindling control (p=0.073) and 
M250 (p<0.001) total GSH measures. After 6 h, total GSH peaks for the M250 group, though it is 
not statistically different (p>0.6). Because the amount of bioactive GSH is dependent on both the 
utilization and biosynthesis of GSH, it is likely that this may be time- and dose-dependent 
oxidation of the EMB due to MEHP as well as decreased capacity to reduce and synthesize new 
GSH. At 12 h, total GSH in the EMB significantly decreases in a dose-dependent manner 
compared to controls (M100: p=0.035; M250: p<0.001). However, all embryonic total GSH 
concentrations are almost identical after 24 h exposures (p>0.28). This suggests that MEHP may 
reduce the embryonic antioxidant capabilities during significant windows of development 
including the peak of morphological and in utero environmental change. Embryonic total cys 
measures also follow a dose-dependent pattern over the first 6 h of exposure on GD8. However, a 
great deal of variability was observed in these samples. Because GSH is synthesized from cys, it 
is possible that in addition to the influence of MEHP on uptake and utilization of cys itself, the 
increased GSH demand of the EMB requires increased utilization of cys for GSH. 
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Redox Profiles 
Control redox profiles at the 24h time point match control redox profiles from the same 
stage of development (GD9) in prior in vivo and WEC studies (unpublished data). After 6 h in 
culture, EMB GSH/GSSG redox potentials are reduced in a dose-dependent manner, though these 
observations are not statistically significant (Fig. 3.8). After 6 h in culture, control EMB redox 
potentials were -193.4 ± 11.7 mV (n=8), and was reduced to -198.8 ± 9.3 (n=8) and -208.8 ± 9.1 
(n=8) mV by MEHP concentrations of 100 and 250 μg/ml, respectively. It is likely that GSH 
biosynthesis has been increased in MEHP-exposed conceptuses, as MEHP itself would not be 
expected to reduce cellular redox environment. After 12 h, control samples are significantly more 
reduced than M100 (p=0.009) and M250 (p<0.001) EMB, and increasing dose significantly 
oxidizes the EMB. Control EMB GSH/GSSG redox potentials were -176.9 ± 1.6 mV (n=4), and 
the M100 and M250 groups were -158.3 ± 1.4 (n=3) and -138.2 ± 4.5 mV (n=4), respectively. 
After 24 h, all samples are much more reduced than at previous time points, but this dose-
dependent oxidation in the EMB is still apparent. This also supports that MEHP induces embryonic 
oxidation during the most active window of embryogenesis. The EMB cys/cySS redox potential 
follows a similar trend. After 1 h, MEHP treatments reduced the environment, though only the 100 
μg/ml induces a significant change (p=0.014). After 1 h, control EMB cys/cySS redox potentials 
were -158.6 ± 1.0 mV (n=3), and were reduced in M100 and M250 EMB to -177.6 ± 4.5 (n=5) 
and -165.8 ± 2.6 mV (n=5), respectively. After 3 h, EMB are oxidized by MEHP in a dose-
dependent fashion though only the 250 μg/ml dose was statistically significant (p=0.009). Control 
potentials were -165.3 ± 7.1 mV (n=5) and reduced to -145.7 ± 4.4 (n=3) and -132.4 ± 9.8 mV 
(n=4), respectively. This dose-dependent decrease is continued to the 6 h time point, with cys/cySS 
72 
 
potentials of -138.8 ± 5.3 (n=6), -131.7 ± 5.8 (n=8), and -130.1 ± 2.7 (n=7) for control, M100, and 
M250 groups, respectively. EMB cys redox potentials are similar for all groups at 12 h, and only 
the 250 μg/ml EMB are significantly oxidized at 24 h compared to controls (p=0.04). 
In the VYS, GSH/GSSG redox potentials were oxidized by MEHP treatment at the 1 h and 
12 h time points (p>0.05). At 12 h, this oxidation results in a near 15 mV change in redox potential. 
At 3 h, redox potentials are more reduced with increasing doses of 100 and 250 μg/ml MEHP 
(p=0.06 and p=0.04, respectively). These 3 h redox potentials were -145.4 ± 4.9 (n=3), -162.2 ± 
5.2 (n=3), -164.5 ± 1.1 mV (n=3) for control, M100 and M250 groups, respectively. After 24 h, 
GSH/GSSG redox potentials are fairly similar across treatment groups, though EMB are slightly 
reduced in the MEHP-treated groups (p>0.05). The cys/cySS redox potentials are also reduced at 
the 3 h time point, though the 100 μg/ml MEHP-treated VYS are most significantly reduced 
(p=0.014). At 12 h, increasing dose of MEHP increases oxidization of the VYS (p>0.05). At the 
24 h time point, the controls and 250 μg/ml MEHP-treated VYS have similar redox potentials, but 
the 100 μg/ml MEHP-treated VYS are significantly oxidized after 24 h (p<0.001). 
 
Pathways enriched by MEHP treatment 
Pathways significantly enriched or depleted by 6 h MEHP treatment are shown in Table 
3.2. “Enriched” pathways are those that contain many significantly changed genes. “Depleted” 
pathways have fewer changed genes than would be expected by chance, indicating conservation 
of these pathways. Several similarities were noted in EMB and VYS in response to MEHP. The 
most significantly enriched pathway in both EMB and VYS was oxidative phosphorylation 
(p≤0.001). Expression of several NADH dehydrogenase genes was significantly decreased, 
including Ndufa3, Ndufs5, Ndufa6, and especially Ndufa7 in both EMB and VYS. In EMB, 
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expression of several ATPases and ATP synthases was also significantly altered by MEHP 
treatment—primarily those of lysosomal and mitochondrial origin. ATPases were primarily 
upregulated, while ATP synthases were primarily downregulated. Expression of Uqcr11, part of 
the ubiquinol-cytochrome c reductase complex crucial for cellular respiration, was increased in the 
VYS but decreased in the EMB.  
The majority of enriched pathways in both tissues were, in general, metabolic pathways, 
namely xenobiotic response and amino acid metabolic pathways. The drug metabolism - 
cytochrome P450 (CYP450) and the glutathione metabolism pathways were significantly enriched 
in the VYS. The constituents of these pathways, consisting mostly of CYP450 isozymes, 
glutathione-S-transferases, and glutathione peroxidases were significantly increased in expression. 
The occurrence of these changes in the VYS and not the EMB confirm that the VYS is a metabolic 
barrier that serves to protect the developing EMB from chemical and environmental insults. 
Amino acid metabolic pathways including histidine metabolism, arginine and proline 
metabolism, and alanine, aspartate and glutamate metabolism were all enriched in both EMB and 
VYS. Starch and sucrose metabolism was also enriched in the EMB. Synergistically, these 
alterations are likely indicative of decreased nutrient availability to the EMB, and have numerous 
downstream consequences affecting signal transduction and energy biosynthesis. 
Retinol metabolism was enriched in the EMB, namely with regards to non-optic pathways. 
Though involved in the metabolism of Vitamin A, the genes most affected by MEHP treatment 
were mostly involved in the xenobiotic response and direct signal transduction during 
embryogenesis. Retinol dehydrogenase 1 (Rdh1), the enzyme responsible for the rate-limiting step 
of retinaldehyde biosynthesis, was significantly decreased in the EMB following MEHP treatment. 
As previously mentioned, several CYP450 genes were upregulated by treatment—including 
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CYP26 family variants. The function of the CYP26 family is to convert retinaldehyde into retinoic 
acid, and is essential for guiding posterior tissue patterning by directing Hox genes for hindbrain 
formation. Interestingly, Hox gene expression was significantly reduced in several Hoxb, Hoxc, 
and Hoxd variants. 
1.2% of significantly affected genes were members of the solute carrier (SLC) gene 
families, which are evolutionarily well-conserved across the animal kingdom [45] (Table 3.3). 
Although no single family was specifically altered in the pathway analysis, the collective volume 
of significantly altered SLC genes was notable. Though SLCs have a diverse array of functions, 
all are involved in the transport of important cellular substrates across cellular membranes [46]. 
The largest group of transporters significantly impacted by MEHP treatment were involved in the 
mitochondrial transport of solutes. These mitochondrial transporters are important for metabolism, 
namely in oxidative processes [47]. Expression of SLC7A9, involved in cySS absorption, was 
significantly decreased in EMB [48]. In addition to regulating cys/cySS redox balance, SLC7A9 
is crucial for proper kidney development and defects in the gene have been associated with 
increased risk for chronic cystinuria later in life [49,50].  Significant expression changes to 
members of the SLC6 family, involved in neurotransmission, appear only in the EMB tissue. 
Decreased expression was observed in several of these genes, crucial for glycine, noradrenaline, 
and methionine homeostasis. Several patterns were observed in the overall expression of these 
genes. Though there was a mixture or upregulated and downregulated SLC family expression in 
the EMB, there was a strong pattern of downregulation in the VYS.  
 
Pathways depleted due to MEHP treatment 
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 Though depleted pathways are not significantly altered, they are of interest because they 
are more heavily conserved. Pathways depleted in EMB and VYS by MEHP treatment are also 
listed in Table 3.2. Many signal transduction pathways essential for tissue patterning are 
conserved, including Wnt, Jak-STAT, ErbB, calcium, and VEGF signaling pathways. Neuronal 
function pathways including neuroactive ligand-receptor interaction and axon guidance pathways 
are also conserved, which is surprising due to the morphological findings of this work. Though 
these pathways were conserved, specific genes in these pathways may still be significantly altered. 
Several genes involved in these pathways are significantly upregulated, including EphB4 in the 
VYS and Ngef in the EMB. Additionally, conservation of expression in these pathways does not 
necessarily mean that there are no changes to the functional product. It is possible that regulation 
of these pathways is occurring at the translational or post-translational level.  
 
Discussion 
 Development is a tightly regulated process, governed by combinations of genetic and 
environmental cues. These environmental cues come from a myriad of sources, including nutrient 
availability, maternal hormones, extracellular ligands, and redox environment. Redox environment 
in particular is crucial in the determination of cell fates. Oxidation of protein thiol residues, 
including those of the early EMB, can serve as a sensitive switch, indicative of disruption of redox 
steady state. The consequences that accompany altered redox potentials may guide cell fate 
towards proliferation, differentiation, apoptosis, or necrosis [51,52]. Typically, more reducing 
environments are correlated with cells undergoing proliferation, while more oxidative 
environments are associated with differentiation or ultimately cell death. For these reasons, protein 
thiol oxidation and ROS have been implicated in the pluripotency of stem cells and in the formation 
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of cancers [53-56]. The coordination of redox signals is crucial for normal growth and 
development, and dysregulation of redox environment may largely contribute to teratogenesis 
[5,51,57]. 
 The EMB is sensitive to changes in redox potential. An Eh shift of merely 20 mV as 
measured for the GSH/GSSG redox couple may alter cell fate from proliferation to differentiation, 
while a 50 mV increase may permit conditions favorable toward death [58]. In this study, changes 
in redox environment were measured following MEHP treatment with 100 or 250 μg/ml in culture. 
After 12 h in culture, the 100 and 250 μg/ml MEHP treatments resulted in nearly 20 and 40 mV 
potential increases, respectively, in the EMB for the GSH/GSSG redox couple. Thus, it is possible 
that exposure to MEHP is inducing changes in cell fate and has the potential to alter tissue 
patterning via abnormal differentiation and even cell death. However, we have yet to characterize 
the individual proteins, pathways and signaling nodes involved. 
 The EMB undergoes many phenotypic and physiological changes at this time point in 
development. The 12-h time point in culture coincides with GD 8.5 in development, a very 
dynamic window of embryonic change. At this time, the EMB heart begins to beat, and conceptal 
circulation via the vitelline vasculature commences. Also at this time, the EMB flexion rotates, 
and the neural tube begins to close [59]. By 24 h, on GD 9, the anterior neural tube is expected to 
be fully closed. After 24 h in culture, the number of defectively open neural tubes was significantly 
increased with increasing dose of MEHP in culture. It is possible that the increased Eh and probable 
increased generation of ROS altered the migration and proliferation of the ectodermal germ layer. 
Future work should investigate whether oxidation of specific protein thiols and the consequences 
related to altered redox potentials may contribute to the teratogenic potential of MEHP in the EMB, 
especially focused on the tissues of the developing CNS. 
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The balance of the GSH/GSSG redox couple is built upon coordinated cellular efforts to 
reduce and recycle existing GSH, as well as to synthesize additional GSH. Both GSH biosynthesis 
and enzymatic reduction processes are mediated by the induction of the Nrf2 antioxidant response 
pathway. Nrf2 serves as a transcription factor that binds to the antioxidant response element (ARE) 
of promoters for genes involved in cellular redox balance [60,61]. As a result, enzymes and 
cofactors involved in reducing oxidized glutathione species are increased, and GSH can be 
recycled. GSH biosynthesis is also crucial to the GSH/GSSG balance. GSH is a tripeptide, created 
from cysteine, glutamate, and glycine building blocks. Decreased nutritional supply of amino 
acids, namely cysteine, have been associated with decreased GSH concentrations and increased 
oxidative stress [62-64]. It is additionally possible that glutamate may also be rate limiting under 
conditions of nutrient starvation. 
Histiotrophic nutrition pathways (HNPs) are the processes by which nutrients and other 
substrates are transported from the maternal uterine environment to the conceptus, via the receptor-
mediated endocytosis (RME) and subsequent proteolysis of the substrate-containing vesicles [65-
67]. During this time, the placenta is not functional and the conceptus replies solely on HNPs for 
nutrient uptake. Thus, the VYS serves an important role in providing critical nutrients to the 
developing EMB. Because of the expected depletion of amino acids and observed general decrease 
in expression of SLCs in the VYS induced by MEHP treatment, it is possible that MEHP may be 
disrupting HNPs. Therefore, it is probable that decreased expression of SLCs in the VYS may have 
numerous downstream consequences affecting signaling and overall growth and differentiation. 
The decreased size of embryos exposed to MEHP raises questions regarding the implications of 
phthalates in both growth and also potentially metabolic disease later in life. 
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HNPs are believed to be evolutionarily adaptive, as they limit the oxygenation and resultant 
generation of teratogenic ROS during the first, and most sensitive, trimester [68]. At the end of the 
first human trimester of gestation, implementation of conceptal and then maternal circulation 
steeply increases the oxygenation of the embryonic environment [69,70]. At the 12-h time point, 
the oxygenation of the culture environment was increased to mimic the implementation of 
circulation in the conceptuses, and then from maternal circulation [39]. At this point in the culture 
period, MEHP caused oxidation and depleted GSH concentrations in the EMB. The end of the first 
trimester marks a sensitive period of development. Even though teratogenesis typically originates 
earlier during embryogenesis, chemically-induced susceptibility during this time may lead to 
functional rather than structural deficits [68]. 
Because HNPs are responsible for the uptake of amino acids and other micro- and 
macronutrients crucial for growth and development, decreased HNP function may result 
conditions akin to in amino acid starvation. In this study, numerous pathways involved in amino 
acid metabolism were disrupted, such as the metabolism of alanine, aspartate, glutamate, arginine, 
proline, and histidine. Additional indirect amino acid metabolic pathways, such as GSH 
metabolism and TCA cycle were also affected. Because all of these pathways rely on the supply 
of amino acids, it is possible that MEHP treatment is inducing amino acid starvation via decreased 
HNP activity. Amino acid starvation has been discovered to have numerous physiological and 
metabolic consequences, namely effects on energy metabolism including oxidative 
phosphorylation (unpublished data) [71]. 
Oxidative phosphorylation was the most significant pathway for both EMB and VYS due 
to phthalate treatment. The changes in oxidative phosphorylation processes observed are indicative 
of MEHP-induced dysregulation of energy metabolic processes. Increases in the expression of 
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ATPases, some of the most redox-sensitive proteins in the cell, suggest the necessity to maintain 
cellular homeostasis and potentially mitochondrial ion gradients during toxicant-induced 
physiological changes in the cell [72-77]. Likewise, decreases in the expression of ATP synthases 
may be indicative of decreased substrates available for energy production (ATP-form) in the cell. 
This suggests that the ability to produce ATP is compromised, and yet the energy demands are 
growing.  
Oxidative phosphorylation, generation of mitochondrial ROS, and resultant changes to 
redox potentials have been associated with the induction of autophagy [78]. Autophagy is the 
process by which cellular proteins and even organelles are vesicle-bound and tagged for lysosomal 
proteolysis, in order to recycle cellular substrates to maintain viability under starvation conditions 
[78]. In autophagy, other processes are halted in order to conserve energy and resources and to 
preserve those of utmost importance. Proteins from these non-essential processes are often 
degraded to preserve a reservoir of amino acids for synthesis of proteins and enzymes for essential 
processes. Often, processes governing mitochondrial function are stimulated or supported at the 
expense of cytosolic processes [79]. Expression changes to enzymes involved with amino acid 
metabolism, GSH metabolism, TCA cycle, and oxidative phosphorylation, coupled to the 
expression changes observed in the SLC25 mitochondrial transporters class suggest that this 
shunting and prioritization of the maintenance of mitochondrial functions is beginning to occur at 
this 6 h time point.  
The brain has very high energy demands, and relies heavily on oxidative phosphorylation 
and mitochondrial function [80]. It is not surprising that this time in development would be very 
susceptible to changes in oxidative phosphorylation, since large increases in mitochondrial density 
and mitochondrial proteins are initiated at the beginning of neurogenesis [81]. Changes to the 
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oxidative phosphorylation pathway have been previously demonstrated to be altered by exposures 
in the brain and NTDs [82,83]. Because oxidative phosphorylation requires the coordination of 
numerous enzymes and energy substrates, as well as maintenance of a high-energy proton gradient, 
these processes are often decreased in starved cells. These cells then rely on the more efficient but 
lower energy payout process of glycolysis. While autophagy may be able to prolong cell growth 
and function in times of distress, this would likely be unsustainable over longer periods of time. 
Studies have associated decreased autophagic capacity with increased apoptosis and increased risk 
for NTDs [84-87]. More work is necessary to determine whether MEHP treatment is resulting in 
amino acid starvation, and whether or not these conditions may induce autophagy if prolonged. It 
is possible that these factors may play a role in the etiology of NTDs. 
In summary, this work suggests a novel mechanism by which MEHP treatment elicits 
developmental malformations in mWEC and that NTD incidence increases with increasing doses 
of MEHP. Dose-dependent oxidation of the GSH and cys redox couples and resultant disruption 
of steady state redox potentials were present at the 12-h time point—a period of rapid growth and 
metabolic change during early organogenesis. This suggests that MEHP may increase 
susceptibility to damage and dysfunction during sensitive windows of development. Altered 
metabolic capabilities suggest the MEHP induces conditions akin to amino acid starvation, yet 
more work is needed to characterize the role of amino acid supply, HNPs, and nutrition in these 
metabolic changes. Dysregulation of oxidative phosphorylation and energy metabolism in this 
study suggests the possible initiation of cell survival and potentially autophagy activities at the 6-
h time point due to MEHP treatment in culture. Future work should characterize expression 
changes in oxidative phosphorylation, autophagy, and apoptosis pathways in order to discern 
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whether MEHP-induced alterations in amino acid availability and metabolism may be contributing 
the NTD phenotypes.  
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Figure 3.1. Principle components analysis (PCA) of Affymetrix data. The PCA plot reveals distinct 
differences in expression patterns between the EMB and VYS tissues. There is greater variability in the 
VYS samples. There is some distinction between control and MEHP-treated samples as well. 
 
  
83 
 
 
Figure 3.2. MEHP treatment reduces overall morphological score. Unlike the parent compound DEHP, 
metabolite MEHP is able to reduce overall morphological scores in a dose-dependent manner after 24 h 
treatment in WEC. * indicates a significant change (p<0.05) in the MEHP group from the control at this 
dose. *** indicates a very significant change (p<0.001) in the MEHP group from the control at this dose. 
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Figure 3.3. MEHP decreases embryonic size and induces malformations. Images taken of the exposed 
conceptuses reveals a gradual decrease in overall size and an increase in malformations as media MEHP 
concentrations were increased. Image key: control (A&B), MEHP 100μg/ml (C&D), MEHP 500μg/ml 
(E&F), MEHP 1mg/ml (G&H). 
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Figure 3.4. MEHP treatment impairs neural tube closure in WEC. An unusually high number of open neural 
tubes were observed in the MEHP-treated groups after 24 h treatment. Some of those malformations are 
shown above. Overall, with increased concentration of MEHP in the culture media, there is a reduction of 
neural tube scores. The highest possible total neural tube score attainable is 20, and scores are reduced by 
characteristics such as an open neural tube, necrotic debris present in the neural tube, and hypoplastic tissues 
around the brain regions. *** indicates a very significant change (p<0.001) in the MEHP group from the 
control at this dose. 
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Figure 3.5. Ontogeny of reduced and oxidized glutathione measurements in EMB and VYS following 
MEHP treatment. Black fractions represent the concentrations (μM) of reduced glutathione (GSH), and 
gray fractions represent the concentrations (μM) of oxidized glutathione (GSSG). 
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Figure 3.6. Ontogeny of reduced and oxidized cysteine measurements in EMB and VYS following 
MEHP treatment. Black fractions represent the concentrations (μM) of reduced cysteine (cys), and gray 
fractions represent the concentrations (μM) of oxidized cystine (cySS). 
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Figure 3.7. Ontogeny of total thiol measurements in EMB and VYS following MEHP treatment. Total 
concentrations are equal to the sum of the reduced and 2x the oxidized fractions of the thiol, since disulfides 
were measured. Image key: (A) total glutathione concentrations measured in EMB, (B) total glutathione 
concentrations measured in VYS, (C) total cysteine concentrations measured in EMB, and (D) total cysteine 
concentrations measured in VYS. 
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Figure 3.8. Ontogenies of redox profiles in conceptal tissues following treatment MEHP treatment. 
Embryonic redox profiles for glutathione (A) and cysteine (B) redox couples are shown left. VYS redox 
profiles for glutathione (C) and cysteine (D) redox couples are shown right. 
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Table 3.1. MEHP treatment significantly alters developmental progress in WEC. Though DEHP treatment 
produced little change in most measurable developmental parameters, the metabolite MEHP significantly 
altered many defect scores. Values presented are the means ± standard error of the mean. *p<0.05, 
**p<0.01, ***p<0.001, --- indicates that the specimen were too necrotic to accurately assess this parameter. 
  
Control 
(n=17) 
MEHP (100 
μg/ml) 
(n=7) 
MEHP 
(250 μg/ml) 
(n=6) 
MEHP  
(500 μg/ml) 
(n=16) 
MEHP  
(1 mg/ml) 
(n=5) 
Yolk Sac 5.0 ± 0 4.6 ± 0.3 5.0 ± 0 2.1 ± 0.3 0.4 ± 0.2 
Allantois 3.0 ± 0 2.6 ± 0.2 3.0 ± 0 1.8 ± 0.2 1.2 ± 0.4 
Flexion 4.7 ± 0.1 3.9 ± 0.4 4.3 ± 0.2 4.0 ± 0.1 4.0 ± 0 
Heart 3.8 ± 0.1 3.7 ± 0.2 3.5 ± 0.2 3.3 ± 0.1 2.6 ± 0.2 
CaudalNT 4.2 ± 0.1 3.7 ± 0.2 4.0 ± 0 1.3 ± 0.5 -- 
HindB 4.9 ± 0.1 3.6 ± 0.4 2.8 ± 0.3 3.0 ± 0.3 2.0 ± 0 
MidB 4.9 ± 0.1 3.6 ± 0.5 2.8 ± 0.4 2.6 ± 0.3 2.0 ± 0 
ForeB 4.6 ± 0.2 3.3 ± 0.5 2.8 ± 0.5 2.9 ± 0.2 2.2 ± 0.2 
Otic Ves. 4.5 ± 0.2 3.3 ± 0.3 2.5 ± 0.2 2.7 ± 0.3 2.4 ± 0.2 
Optics 4.6 ± 0.2 3.7 ± 0.4 2.8 ± 0.5 1.9 ± 0.3 1.0 ± 0 
Branchial 2.7 ± 0.1 2.6 ± 0.2 2.7 ± 0.2 2.0 ± 0.1 2.0 ± 0 
Maxillary 3.0 ± 0 1.9 ± 0.1 2.0 ± 0 1.7 ± 0.1 1.0 ± 0 
Mandible 2.0 ± 0 2.0 ± 0.2 2.0 ± 0 1.9 ± 0.1 2.0 ± 0 
Forelimbs 2.1 ± 0.2 1.9 ± 0.3 2.2 ± 0.2 2.0 ± 0.2 1.6 ± 0.2 
Somites 24.6 ± 0.4 21.0 ± 0.8 23.7 ± 0.8 18.8 ± 1.5 -- 
VYS volume 17.9 ± 1.4 13.8 ± 1.4 17.1 ± 0.8 13.8 ± 1.1 10.2 ± 0.9 
Crown Rump 2.9 ± 0.1 2.7 ± 0.1 2.9 ± 0.1 2.5 ± 0.1 1.7 ± 0.2 
Head Length 1.5 ± 0 1.2 ± 0.1 1.4 ± 0.1 1.2 ± 0 1.0 ± 0.1 
TOTAL SCORE 86.6 ± 1.5 73.8 ± 3.8 72.9 ± 2.9 56.6 ± 3.3 28.4 ± 0.8 
 
P>0.05   
P<0.05   
P<0.01   
P<0.001   
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Table 3.2.  EMB pathways significantly altered by 6h MEHP treatment in WEC.  Significantly enriched 
KEGG pathways (shown left) include many metabolic pathways and those dependent upon the redox 
environment. Significantly depleted pathways (shown right) include pathways involved in signal 
transduction, including several crucial for neurodevelopment. 
Pathways significantly enriched in EMB tissue   Odds Ratio P-value   Pathways significantly depleted in EMB tissue   Odds Ratio P-value 
Oxidative phosphorylation  4.136 0.001  Fc gamma R-mediated phagocytosis  0.032 0.001 
Alanine, aspartate and glutamate metabolism  8.517 0.002  Ribosome  0.022 0.003 
Retinol metabolism  5.637 0.005  Pathways in cancer  0.322 0.005 
Phagosome  3.060 0.008  Intestinal immune network for IgA production  0.008 0.007 
Proteasome  5.231 0.010  Calcium signaling pathway  0.217 0.009 
Rheumatoid arthritis  3.816 0.011  Wnt signaling pathway  0.215 0.013 
Collecting duct acid secretion  6.880 0.012  Axon guidance  0.203 0.017 
Purine metabolism  2.679 0.014  Prostate cancer  0.140 0.021 
Arginine and proline metabolism  4.135 0.023  Amoebiasis  0.173 0.024 
Vasopressin-regulated water reabsorption  4.610 0.024  Pancreatic cancer  0.118 0.028 
Starch and sucrose metabolism  4.713 0.028  Pyruvate metabolism  0.042 0.032 
Histidine metabolism  5.117 0.040  ABC transporters  0.045 0.032 
Parkinson's disease  2.633 0.047  Adherens junction  0.155 0.042 
     
Arrhythmogenic right ventricular cardiomyopathy 
(ARVC)  0.158 0.043 
     T cell receptor signaling pathway  0.245 0.047 
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Table 3.3.  VYS pathways significantly altered by 6h MEHP treatment in WEC.  Significantly enriched 
KEGG pathways (shown left) are similar to EMB, including pathways central to metabolism, and 
adaptation of redox environment. Significantly depleted pathways (shown right) are also similar for both 
tissues, including pathways involved in signal transduction, including several crucial for 
neurodevelopment. 
Pathways significantly enriched in VYS 
tissue   
Odds 
Ratio P-value   
Pathways significantly depleted in VYS 
tissue   
Odds 
Ratio 
P-
value 
Oxidative phosphorylation  8.109 0.000  Neuroactive ligand-receptor interaction  0.127 0.000 
Parkinson's disease  7.795 0.000  Tight junction  0.059 0.001 
Glutathione metabolism  13.522 0.000  Axon guidance  0.108 0.005 
Alzheimer's disease  5.166 0.000  Fc gamma R-mediated phagocytosis  0.068 0.007 
Aminoacyl-tRNA biosynthesis  11.307 0.000  Leukocyte transendothelial migration  0.093 0.007 
Histidine metabolism  11.235 0.002  Cell adhesion molecules (CAMs)  0.105 0.007 
N-Glycan biosynthesis  8.051 0.002  Long-term depression  0.037 0.007 
Antigen processing and presentation  7.024 0.003  Hypertrophic cardiomyopathy (HCM)  0.057 0.008 
Drug metabolism - cytochrome P450  6.644 0.004  
Arrhythmogenic right ventricular 
cardiomyopathy (ARVC)  0.049 0.008 
Selenocompound metabolism  14.129 0.006  Wnt signaling pathway  0.158 0.009 
Huntington's disease  3.321 0.007  Jak-STAT signaling pathway  0.160 0.014 
Alanine, aspartate and glutamate metabolism  8.852 0.007  Dilated cardiomyopathy  0.089 0.015 
Arginine and proline metabolism  5.335 0.015  Pathways in cancer  0.345 0.016 
Ribosome biogenesis in eukaryotes  4.276 0.022  Osteoclast differentiation  0.145 0.017 
Complement and coagulation cascades  3.972 0.039  ECM-receptor interaction  0.095 0.019 
     ErbB signaling pathway  0.105 0.020 
     Hepatitis C  0.176 0.022 
     T cell receptor signaling pathway  0.151 0.023 
     Regulation of actin cytoskeleton  0.293 0.028 
     Amoebiasis  0.153 0.030 
     Fc epsilon RI signaling pathway  0.117 0.034 
     Glioma  0.088 0.038 
          VEGF signaling pathway   0.119 0.039 
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Table 3.4. Solute carrier (SLC) family genes are significantly impacted by 6h MEHP treatment in WEC. 
The mitochondrial transport family (SLC25) represents the most significantly altered family of 
transporters, crucial for the catabolic processes of the cell. 
  # genes sig. changed 
SLC family Function EMB VYS TOTAL 
1 glial high affinity glutamate/neutral amino acid transporter 1 2 3 
4 bicarbonate transporters 6 2 8 
5 inositol/sodium-dependent glucose transporters 2 1 3 
6 neurotransmitter transporters 3 0 3 
7 cationic/L-type amino acid transporters 3 2 5 
8 sodium/calcium exchangers 1 1 2 
9 sodium/hydrogen exchangers 3 3 6 
10 sodium/bile salt exchangers 0 1 1 
11 proton-coupled divalent metal ion transporters 1 0 1 
12 electroneutral cation-coupled chloride cotransporters 2 1 3 
13 sodium sulphate/carboxylate exchangers 0 1 1 
16 monocarboxylic acid transporters 6 2 8 
17 phosphate/organic anion transporters 2 1 3 
19 folate/thiamine transporters 1 1 2 
21 organic anion transporters 4 3 7 
22 organic cation/anion transporters 4 0 4 
23 ascorbate/nucleobase transporters 1 1 2 
24 sodium/potassium/calcium exchangers 1 0 1 
25 mitochondrial transporters 9 6 15 
26 sulfate/anion transporters 2 2 4 
29 nucleoside transporters 1 0 1 
30 zinc transporters 2 2 4 
31 copper transporters 1 0 1 
33 acetyl-CoA transporters 0 1 1 
35 nucleotide sugar transporters 8 1 9 
36 proton-coupled amino acid transporters 0 1 1 
37 sugar phosphate exchangers 1 0 1 
38 sodium-amino acid cotransporters 1 0 1 
39 zinc/metal ion transporters 1 3 4 
44 choline transporter-like family 1 2 3 
45 putative sugar transporters 2 1 3 
46 folate transporters 1 1 2 
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Chapter IV 
Mono-2-ethylhexyl phthalate (MEHP) alters histiotrophic nutrition pathways and 
epigenetic processes in the developing conceptus 
 
Introduction 
The processes by which mammalian embryos obtain nutrients and substrates for growth 
and development during embryogenesis and early organogenesis are known as histiotrophic 
nutrition pathways (HNPs). Because the placenta has not yet become fully functional, active 
maternal-embryonic supply of substrates and metabolic cofactors from maternal circulation is not 
yet available. HNPs involve the receptor-mediated endocytosis (RME) of proteins and their bound 
nutrient and cofactor cargoes through the visceral yolk sac (VYS) brush border, and subsequent 
proteolysis of the proteins in the vesicles to release nutrients for cellular processes in the VYS and 
the embryo proper (EMB). During HNPs, RME of whole, bulk proteins and their cargos followed 
by their subsequent proteolysis maintains an amino acid and nutrient pool to provide substrates for 
protein biosynthesis and enzymatic function. 
 HNPs are responsible for providing and  transporting many substrates to the EMB, 
including methyl donors for one-carbon (C1) metabolism such as methionine and folate. C1 
metabolism is the process by which dietary methyl donors are utilized to synthesize S-
adenosylmethionine (SAM), the primary molecular methyl donor for cells. Through C1 
metabolism, SAM is made available for numerous processes, including post-translational 
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modifications and epigenetic regulation. Thus, the nutritional state of the conceptus may govern 
epigenetic regulation of genetic processes [1].  
 During the first trimester of pregnancy, cells are rapidly dividing to facilitate overall 
growth and anatomical form in order to complete embryogenesis. During this time, DNA 
undergoes substantial epigenetic remodeling, from near-complete loss of methylation marks after 
fertilization to reprogramming of methylation marks during embryogenesis and early 
organogenesis [2,3]. Histone methylation, on the other hand, is variable; methylation increases 
over developmental time at the H3K4 locus and decreases at the H3K27 locus [4]. Because these 
processes occur during the phase of HNP-supplied nutrition and this process provides the 
necessary methyl donors for epigenetic marks, it is possible that perturbation of HNPs may result 
in abnormal epigenetic programming. Previous work has demonstrated that inhibition of HNP 
lysosomal function with leupeptin resulted in decreased DNA methylation in the EMB and VYS 
during early organogenesis [5]. 
Common dietary methyl donors and cofactors for C1 metabolism, including folate, betaine, 
choline, and vitamin B12, are required for normal growth and development. Maternal deficiencies 
in folate and choline during pregnancy have been associated with increased risk for neural tube 
defects (NTDs) [6-8]. Previous studies have demonstrated that exposure to mono-2-ethylhexyl 
phthalate (MEHP), the primary metabolite of the ubiquitous plasticizing agent di-2-ethylhexyl 
phthalate, increased the number of embryos with NTDs (Chapter 3). Thus, the purpose of this work 
is to identify whether this increased number of NTDs is concordant with decreased nutrient 
bioavailability to the EMB, and whether this may have epigenetic consequences. It is hypothesized 
that MEHP exposure will reduce the efficacy of HNPs, reducing availability of methyl donors and 
C1 metabolism, and that these changes will result in decreased DNA and histone methylation. 
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Materials & Methods 
Chemicals and Reagents 
Bicinchoninic acid, dimethyl sulfoxide (HPLC grade), Tyrode’s balanced salt solution 
(TBSS), penicillin/streptomycin (10,000 units/ml penicillin, 10,000 μg/ml streptomycin sulfate), 
N,N,N-Trimethyl-d9-Glycine HCl (Betaine-d9), Homocysteine-d8 were obtained from 
Sigma/Aldrich (St. Louis, MO). Hanks balanced salt solution (HBSS) was purchased from 
GIBCO/Life Technologies (Grand Island, NY). Mono-2-ethylhexyl phthalate was obtained from 
AccuStandard (New Haven, CT). L-Methionine (methyl-d3) and D,L-cysteine (3,3-d2) were 
purchased from Cambridge Isotope Laboratories (Andover, MA, USA), and S-Adenosyl-L-
methionine-d3 (S-methyl-d3) tetra (p-toluenesulfonate) salt was from C/D/N Isotopes (Pointe-
Claire, Quebec, Canada). 
 
Mouse whole embryo culture 
Mouse embryo culture (mWEC) was performed following the conditions outlined in [9], 
and described in Chapter 3. Briefly, female CD-1 mice were time-mated and obtained from Charles 
River (Portage, MI). The morning of discovery of a vaginal plug was designated as gestational day 
(GD) 0. Animals were maintained on a 12 h light-12h dark cycle and were supplied food and water 
ad libitum. Pregnant mice were euthanized with CO2 on GD 8 and the uterus was removed. 
Conceptuses were explanted from the uterus, randomized, and placed into 10 ml culture bottles. 
Each culture bottle contained 5 ml of 75% heat-inactivated rat serum/25% Tyrode’s balanced salt 
solution (TBSS), and 21.5 ul penicillin/streptomycin. Bottles were placed on a continuous-gassing 
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carousel supplied with 5% O2/5% CO2/90% N2, and the gas mixture was changed after 6 hours to 
20% O2/5% CO2/75% N2 to mimic in utero circulatory changes. 
 
Exposures and Sample Collection 
MEHP was suspended in DMSO to increase solubility, and stored at a concentration of 1 
mg/ml. This MEHP mixture was diluted in DMSO and added to each treatment culture bottle to 
produce a final concentration of 100 or 250 µg/ml. These concentrations were optimized from 
previous experiments (Chapter 3), accounting for viability and morphology, as well as 
reproducibility from other phthalate WEC experiments [10,11]. Control bottles received an 
equivalent volume of DMSO only, and the total volume added was no greater than 1 µl/ml culture 
medium. Conceptuses remained in culture for 24 h.  
Following the culture period, conceptuses for DNA and histone analysis were thoroughly 
rinsed in HBSS and briefly inspected, at which time malformations and delayed closure of the 
embryonic neural tube were noted. EMB with closed neural tubes were denoted as NTD-, while 
those with open neural tubes were denoted as NTD+ (Fig. 4.1). At the time of collection, no control 
samples had notable defects to the neural tube. Conceptuses providing tissues for DNA isolation 
were dissected into EMB and VYS, snap frozen, and stored at -76⁰C until use. Conceptuses for 
histone isolation were also dissected into EMB and VYS, but histone proteins were immediately 
extracted using the EpiQuik™ Total Histone Extraction Kit (Epigentek). Following extraction, 
proteins were stored at -20⁰C overnight until completion of histone methylation experiments the 
following day. 
Conceptuses for histiotrophic nutrition analysis were untreated for the first 24 h in culture, 
before beginning histiotrophic nutrition protocols outlined in [12,13]. After 24 h (GD 9), 
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fluorescently tagged FITC-albumin was added to the culture media at a nontoxic, total 
concentration of 100 µg/ml. At this time, 100 or 250 µg/ml MEHP treatment was added. Ethanol 
treatment was also performed as a positive control, as it is a known inhibitor of endocytosis and 
histiotrophic nutrition processes (unpublished data) [14]. These treatment conditions occurred in 
complete darkness for 3 h. At the conclusion, conceptuses were removed from culture and 
thoroughly rinsed in HBSS. They were then pooled in duplicate and transferred into a 150 μl drop 
containing 50 mM sodium phosphate buffer (pH=6.0) for dissection. The VYS was removed and 
collected into 0.1% Triton X-100, followed by the EMB. The extra-embryonic fluids (EEF) were 
thus remaining in the sodium phosphate buffer and also collected. 
Whole conceptuses for analysis for C1 component quantification or quantification of 
methyl donors were treated with 100 or 250 µg/ml MEHP for 24 h in culture. At the conclusion of 
the culture period, whole conceptuses were carefully rinsed and kept intact. Samples for C1 
component quantification were collected in reducing agent containing dithiothreitol and sodium 
hydroxide and incubated at room temperature for 15 min. Conceptuses for quantification of choline 
and betaine were collected into 100 μl acetonitrile, and conceptuses for quantification of folate and 
vitamin B12 were collected into 500 μl 6% trichloroacetic acid (TCA). 
 
Histiotrophic Nutrition Assay 
 Histiotrophic nutrition assays were conducted using a modified version of the protocol 
outlined in [12]. Though its contribution to total fluorescence is minimal, fluorescence in the EMB 
fraction of the conceptus was also measured. After tissue separation and collection, samples were 
sonicated. A 20 μl aliquot of each sample and of culture media were immediately collected and set 
aside for measurement of total fluorescence, following addition of 230 μl of Triton X-100 and 750 
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ml of 6% TCA with 1% SDS. 750 μl of 6% TCA was added to the remainder of each sample, 
followed by vortexing and precipitation at 4°C overnight. 
 The next morning, samples were centrifuged at 9,500 x g for 10 min. The supernatant of 
each sample was transferred to a new tube for quantification of soluble fraction fluorescence. One 
ml of 500 mM and 150 μl of 1N sodium hydroxide were added to each tube, before setting aside 
for fluorescence quantification. The insoluble fractions were precipitated in 150 μl of 1N NaOH 
at room temperature for 1 h, prior to addition of Tris buffer, sodium hydroxide, and 6% TCA in 
equivalent amounts to the soluble fractions. 
Soluble, insoluble, and total fluorescence were quantified by fitting sample fluorescence to 
a standard curve, ranging from 1-250 μg/ml FITC-albumin. Samples were plated onto opaque, 
black 96-well plates in triplicate replicates of 200 μl for each sample. Plates were read by 
spectrofluorometer, with excitation and emission wavelengths set at 495 and 520 nm, respectively. 
Normalization of results to sample protein concentrations was performed following bicinchoninic 
acid (BCA) assay. 
 
C1 Metabolism Component Quantification 
 Quantification of C1 components was performed as previously described in [5]. Liquid 
chromatography-tandem mass spectrometry was performed using a TSQ Quantum Ultra AM triple 
quadrupole mass spectrometer (Thermo Scientific, Rockford, IL) coupled to a Water 2695 
Separations Module (Waters, Milford, MA). These were fitted with a Luna C18(2) 5-μM 250 x 
4.6-mm column and 4 mm C18 guard column (Phenomenex, Torrence, CA). All data was recorded 
using Xcalibur software (Thermo). 
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 Briefly, isotopic standards for SAM, methionine, cysteine, and homocysteine were added 
to each sample in known quantities following the incubation in reducing agent. To precipitate the 
samples, 0.1% formic acid and 0.05% trifluoroacedtic acid were added to the samples before 
centrifugation and transfer of the supernatant to high-performance liquid chromatographic (HPLC) 
vials for analysis. The pellet was resolubilized in 0.25M sodium hydroxide, and total protein was 
quantified using BCA assay. A gradient method was programmed to conduct linear transitions 
between mobile phases containing water and 0.1% formic acid (mobile phase A) and acetonitrile 
and 0.1% formic acid (mobile phase B). All transitions, flow rate, and injection volume were 
optimized through direct tuning. Concentrations of each analyte were calculated by ratio of the 
measured analyte to the known quantity of the isotopic standard in each sample. All data was 
normalized to the total protein concentration of the conceptus to account for the differences in size 
and morphology due to MEHP treatment (Chapter 3). 
 
Quantification of Choline and Betaine 
 Quantification of choline and betaine was performed using a modified version of the 
protocol outlined in [15]. The same instrumentation used to measure C1 components was utilized, 
but outfitted with an Atlantis HILIC Silica 3-μm 4.6 x 30-mm column (Waters) and 4-mm guard 
column. Samples collected in acetonitrile were centrifuged and the supernatant was removed. The 
pellet was reconstituted in 0.25M sodium hydroxide and used to determine total protein 
concentration using BCA assay. Choline-d9 and betaine-d9 isotopic standards were added to 
supernatants at final concentrations of 0.4 μM, and the samples were transferred to HPLC vials 
prior to injection. The concentration of choline and betaine was a response factor, calculated as the 
ratio of the analyte to the known quantity of isotopic standard, and normalized to total protein 
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concentration. Culture medium was also sampled, and there were no differences in the amounts of 
choline and betaine between culture bottles. 
  
Quantification of Folate and Vitamin B12 
 Samples collected in 6% TCA were briefly sonicated, and centrifuged at 9,500 x g for 5 
minutes. The supernatant was transferred to a new tube, snap frozen, and shipped to the 
Gastrointestinal Laboratory at the Texas A&M University Department of Veterinary Small Animal 
Clinical Sciences. Immunoassays for folate and vitamin B12 were conducted using the IMMULITE 
2000 system (Siemens Healthcare). The pellet was re-suspended in 0.25M sodium hydroxide, and 
total protein was determined using BCA assay. Folate and vitamin B12 measures concentrations 
were reported after normalization to total conceptal protein. No differences in the amounts of folate 
and vitamin B12 were detected between culture bottles. 
 A linear gradient method flowing at 2.0 ml/min was programmed for mobile phases. 
Mobile phase A was comprised of water, 10 mM ammonium acetate, and 0.15% formic acid. 
Mobile phase B was 100% acetonitrile. The gradient began at 20% A:80% B for 1 min, ramped to 
60% A from 1 to 2 min, and then held until 2.3 min until returning to initial conditions at 2.4 min. 
Flow was split 4:1, sending 500 ul/min to the mass spectrometer set to ESI positive ion mode. The 
injection volume was 2 μl. The following settings were applied: 3500 spray voltage, 55 units sheath 
gas, 30 units auxillary gas, capillary 300 C and 35 V, and 1.5 mtorr collision pressure. The needle 
wash used was 9:1 methanol:water, and carryover was very minimal. m/z transitions were 
optimized for detection of analytes and isotopic standards as follows: choline 104-60+, choline-d9 
113-69+ (collision energy 16V, tubelens 62 V), betaine 118-59+ and betaine-d9 127-68 (collision 
energy 21V, tubelens 75 V). 
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Global Histone Methylation 
Total histone protein was quantified using bicinchoninic acid assay, and equivalent 
amounts of histone protein were used for methylation analysis. Histone methylation at the H3K4 
and H3K27 loci was probed using EpiQuik™ Global Pan-Methyl Histone Quantification Kits 
(Epigentek). Fluorescence associated with methyl markers at the loci was detected and used to 
quantify percent methylation. H3K4 histone methylation is typically associated with activation of 
genes, making chromatin more accessible, and H3K27 methylation is typically considered a 
repressive marker, encouraging the tight packaging of chromatin [4]. These pan-methyl kits were 
selected to probe the effects of altered nutrition on histone methylation, instead of specifically 
investigating the effects on tri-methylation at these loci. 
 
DNA Isolation 
Genomic DNA from EMB and VYS samples exposed for 24 h to MEHP (100 or 250 
µg/ml) or controls (DMSO) was isolated using phenol-chloroform extraction. Briefly, thawed 
samples were sonicated in Buffer ATL (Qiagen), and digested overnight at 50⁰C after addition of 
Proteinase K (Qiagen). The following morning, RNase A was added before repeated phenol-
chloroform isoamyl alcohol extractions in phase-lock gel tubes (5 PRIME). A choloroform-only 
wash was performed, followed by repeated ethanol precipitations. The DNA pellet was then dried 
before storage in Tris buffer (pH 8.0) until use.  
 
LUmiometric Methylation Assay (LUMA) 
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LUMA was utilized as explained in [16,17] and previously performed in [5]. Briefly, DNA 
isolated from EMB and VYS samples was subjected to restriction enzyme digestion for 4 hours at 
37⁰C. Samples were separately digested with either methylation-sensitive HpaII or methylation–
insensitive MspI restriction enzymes (Invitrogen), which both cleave genomic DNA at CCGG 
sites. EcoRI (Invitrogen) was also added to each digest to function as an internal control. Following 
digestion, Annealing buffer (Qiagen) was added to the products and these were analyzed using the 
PyroMark™ Q96 MD system (Qiagen). Samples were run in triplicate to account for variation. 
Ratios for MspI and HpaII relative to their internal EcoRI controls were used to quantify overall 
percent methylation, using the following equation: 1-[(HpaII/EcoRI)/(MspI/EcoRI)]x100. 
 
Statistical Analysis 
 Results presented are presented as mean ± SEM. Unpaired t-tests and ANOVA with 
Tukey’s post-hoc test were used to probe statistical significance. A confidence level of 95% was 
used throughout the study, and all tests were performed using SPSS. Statistical outliers were 
removed if data points fell at least 1.5 times the interquartile range outside of the first and third 
quartile values. 
 
Results 
Histiotrophic Nutrition Assay 
 Total clearance, defined as the cumulative clearance from the culture medium into the 
VYS, EEF, and EMB, was quantified to determine whether MEHP could reduce histiotrophic 
uptake of proteins (Fig. 4.2). Clearance is expressed as the volume of culture media cleared of 
FITC-albumin per min per mg of conceptal protein. Immediately upon inspection, the insoluble 
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fraction clearance was less than 10% of the soluble fraction clearance. This is indicative of 
inhibition of RME rather than inhibition of proteolytic processes. For this reason, ethanol was 
selected as an appropriate positive control because it is a known inhibitor of RME (unpublished 
data) [14]. Soluble control histiotrophic clearance (54.6 ± 4.3 ml media/mg protein/h; n=9) and 
total (soluble + insoluble) FITC-albumin clearance (59.8 ± 5.2; n=9) was significantly greater than 
the clearance of ethanol-exposed conceptuses for both the soluble (34.5 ± 3.9; n=9) and total (35.5 
± 3.3; n=9) fractions (p=0.001). No significant changes were observed due to any MEHP or ethanol 
treatment for the insoluble fractions (p>0.05). Exposure to MEHP at the 100 µg/ml dose 
significantly decreased clearance as measured by the soluble fraction (38.9 ± 2.7; n=8; p=0.018), 
though only slightly decreased FITC-albumin clearance of the total fraction (48.8 ± 2.7; n=8; 
p=0.28). Exposure to MEHP at the 250 µg/ml dose significantly reduced both soluble (31.3 ± 2.5; 
n=9) and total (33.1 ± 4.7; n=9) fraction clearance (p<0.001). These decreases in clearance for the 
high MEHP exposure group were even greater than those of the ethanol positive control. Overall, 
MEHP can effectively reduce histiotrophic nutrient uptake of the conceptus, and this is most likely 
due to inhibition of RME. 
 
Quantification of Methyl Donors and C1 Metabolism Components 
 C1 metabolism components and dietary methyl group donors were quantified to determine 
whether these decreases in HNPs translate to functional methyl group deficiencies (Table 4.1). 
SAM concentrations were variable across samples, and thus no statistically significant differences 
were observed (p>0.05). However, there was an obvious increase in SAM concentrations with 
increasing MEHP dose. Control SAM concentrations (820.9 ± 87.3 ng/mg protein; n=4) were 
lower than those from conceptuses exposed to 100 μg/ml MEHP in culture (1487.4 ± 358.6; n=5; 
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p>0.5), and this increased further for those exposed at the 250 μg/ml dose (2380.1 ± 659.5; n=5; 
p=0.129). 
 This same increasing trend was evident for cysteine and methionine. Though control 
conceptal cysteine measurements (1467.4 ± 192.0 ng/mg protein; n=5) are lower than those of the 
100 μg/ml group (2338.4 ± 378.0; n=5), this relationship was not statistically significant (p=0.125). 
Cysteine was further increased in the 250 μg/ml group (2506.9 ± 265.2; n=5; p=0.062). Methionine 
concentrations increased with increasing MEHP dose from controls (635.1 ± 44.0 ng/mg protein; 
n=4) to 956.5 ± 171.8 (n=5; p=0.16) for the 100 μg/ml group and to 1427.0 ± 235.6 (n=5; p=0.031). 
 Homocysteine does not follow the same pattern as the other C1 metabolic components. The 
control (70.1 ± 5.1 ng/mg protein; n=5) and 100 μg/ml (63.8 ± 3.4; n=4) groups do not significantly 
differ (p>0.9). However, the 250 μg/ml group has significantly elevated homocysteine 
concentrations (97.4 ± 8.5; n=4; p=0.031). 
 Folate does not significantly change due to MEHP treatment after 24 h. Control folate 
concentrations (0.66 ± 0.04 ng/mg protein; n=4) were similar to those exposed at the 100 μg/ml 
dose (0.51 ± 0.03; n=4; p=0.4). At the 250 μg/ml dose, however, folate concentrations are slightly 
greater than the 100 μg/ml concentrations (0.74 ± 0.08; n=5; p=0.07). Choline also follows this 
pattern. Choline concentrations in control conceptuses (2.15 ± 0.41 ng/mg protein; n=5) are similar 
to 100 μg/ml dosed conceptuses (1.35 ± 0.54; n=5; p=0.18), and is slightly elevated in the 250 
μg/ml group (3.04 ± 0.87; n=4; p=0.15 compared to controls). The 250 μg/ml exposed conceptuses 
had significantly greater choline concentrations that the 100 μg/ml group (p=0.004). 
 Vitamin B12 control concentrations (17.00 ± 0.09 pg/mg protein; n=3) are significantly 
elevated compared to the 100 μg/ml MEHP dose (12.25 ± 0.41; n=3; p<0.001). Similarly to folate 
and choline, the 250 μg/ml MEHP dose concentration (15.23 ± 0.47; n=5) is significantly elevated 
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compared to the 100 μg/ml dose (p=0.003), but unlike folate and choline, this still remains 
decreased compared to the control measure (p=0.046). Betaine also follows this pattern. Control 
betaine concentrations (4.23 ± 0.39 ng/mg protein; n=4) are significantly greater than conceptuses 
exposed to 100 μg/ml MEHP (2.13 ± 0.95; n=5; p=0.002). Betaine concentrations are similar in 
the 250 μg/ml conceptuses (2.95 ± 0.42; n=4) compared to the 100 μg/ml group (p=0.3), but still 
slightly reduced compared to controls (p=0.056). 
 
Global Histone Methylation 
Global histone pan-methylation was measured in both control and MEHP-exposed (100 
µg/ml) EMB and VYS, also stratified by NTD status (Fig. 4.3). Pan methylation is defined as the 
cumulative mono-, di-, and tri-methylation at a locus. Pan-methylation was examined at the H3K4 
and H3K27 loci after 24 h in culture to determine whether nutritional modifications may result in 
methylation changes. H3K4 methylation was significantly increased in MEHP-treated, NTD+ 
EMB (55.1 ± 4.5; n=4) compared to MEHP-treated NTD- EMB (41.3 ± 1.9; n=6; p=0.01), and 
was also elevated compared to the controls (42.3 ± 4.5; n=6; p=0.08), though this increase was not 
statistically significant (Fig. 4.3A). No significant H3K4 methylation changes were observed 
between control (23.7 ± 2.8; n=5), MEHP-treated, NTD-negative (29.1 ± 5.3; n=8), or MEHP-
treated, NTD-positive (30.4 ± 8.0; n=4) VYS (p>0.05).  
H3K27 pan methylation was also measured in the EMB and VYS (Fig. 4.3B). No 
statistically significant changes in H3K27 methylation were observed in the EMB or VYS 
(p>0.05). H3K27 methylation was unchanged between control (58.2 ± 0.8; n=6), MEHP-treated 
and NTD-negative (56.7 ± 0.7; n=7), and MEHP-treated and NTD-positive (57.9 ± 2.5; n=4) EMB. 
H3K27 methylation was slightly increased in the VYS by MEHP treatment (64.6 ± 1.2; n=8) 
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compared to controls (62.7 ± 0.5; n=5), though this change was not statistically significant 
(p=0.18). H3K27 methylation was further increased in the NTD-positive, MEHP-treated VYS 
(66.4 ± 1.7; n=4), though this change was also not statistically significant (p=0.1). 
 
LUminometric Methylation Assay (LUMA) 
Global DNA methylation was measured in both control and MEHP-exposed (100 µg/ml) 
EMB and VYS following stratification by NTD status (Fig. 4.4A). MEHP exposure in the absence 
of NTD significantly reduced (p=0.03) DNA methylation in the EMB (54.7 ± 1.8; n=10) after 24 
h when compared to controls (61.9 ± 2.2; n=5). DNA methylation was further reduced in MEHP-
treated EMB with NTD (43.3 ± 7.7; n=3) compared to both controls (p=0.02) and MEHP-treated 
NTD negative EMB (p=0.04). In the VYS, there methylation was much lower than EMB DNA 
methylation and had the inverse response to treatment and NTD, though these changes were not 
statistically significant. MEHP exposure (37.7 ± 4.4; n=10) produced a trend of increased global 
DNA methylation in the VYS compared to controls (32.4 ± 3.8; n=4; p=0.4) but this was not 
significant. MEHP-treated VYS from conceptuses with NTDs also showed a mild trend but was 
not significant (p=0.08).  
The effect of treatment concentration was further examined by treating conceptuses with 
250 μg/ml MEHP (Fig. 4.4B). Again, regardless of NTD status, 100 μg/ml MEHP treatment 
significantly reduced global DNA methylation in the EMB (55.4 ± 1.9; n=13; p=0.01) compared 
to controls (61.9 ± 2.2; n=5). High variability of global DNA methylation was observed in EMB 
treated with 250 μg/ml MEHP, so no statistically significant further decrease was observed 
(p=0.4). No statistically significant changes were observed in the VYS (p=0.1-0.4), though there 
was a general trend of increased methylation with increasing MEHP dose. These changes are 
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consistent with methylation changes previously observed due to ethanol treatment, an inhibitor of 
RME (unpublished data). 
 
Discussion 
 The relationship between prenatal nutrition and growth and development has been well 
studied, though the long-term consequences of nutritional deficiencies are highly variable. 
Previous work has demonstrated that exposure to MEHP during early organogenesis may result in 
stunted growth and delayed or halted neurulation (Chapter 3). Here, a nutritional deficiency is 
observed after exposure to MEHP, suggesting that embryonic exposures to toxicants may reduce 
nutrition and produce a canonical stunting of growth. The primary focus of this work was to 
examine these relationships during embryogenesis and early organogenesis, and does not make 
any conclusions about the long-term fetal and child consequences of this deficiency. A growing 
body of epidemiological studies have suggested that in utero deficiencies may result in the 
programming of a thrifty phenotype, resulting in predispositions to metabolic syndromes later in 
life [18]. Though this work suggests that growth is immediately stunted, it is possible that 
adaptation to these deficiencies may result in a thrifty phenotype. 
 This is further supported by measurements of C1 components. In a previous study, it was 
demonstrated that decreases in HNPs result in C1 deficiencies 6 h after initial exposure [5]. Here, 
however, C1 metabolic components are increased with increasing MEHP concentrations in culture 
after 24 h. Because HNP activity is reduced in a dose-dependent fashion after 3 h, these results 
were surprising. It is hypothesized that methyl donors and C1 components are actually decreased 
in the short run, but the conceptuses are able to adapt and compensate by 24 h post-initial exposure. 
Future studies investigating the ontogeny of nutritional environmental changes following 
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exposures should be performed to probe the short-term nutritional consequences of MEHP 
treatment and the potential compensatory mechanisms by which the conceptus may adapt. 
Many studies have utilized toxicological and pharmacological agents to modify RME [19], 
though relatively few studies have demonstrated a link between toxicological or pharmacological 
agents and disruption of HNPs during development [14,20-27]. These studies encompass a wide 
range of chemical agents, with diverse structures and functions, and yet many of these exposures 
have the same outcomes. In this study, both ethanol and MEHP have been characterized to disrupt 
the RME portion of HNPs, but it is unknown whether or not they are acting via the same 
mechanism. Comparative toxicant studies should be done to characterize which classes of 
persistent compounds may directly affect HNPs, and to compare and contrast similarities in 
structure and function to predict HNP-mediated toxicity of other environmental agents. 
Additionally, an ontogeny of HNP clearance profiles would provide information about the 
compartmental differences in nutrient availability. In this study, total HNP clearance was 
measured, representing the total amount of media clearance to the VYS, EEF, and to the EMB. 
However, very little of the media had been cleared to the EMB during the 3-h window of 
investigation. By examining clearance over a greater time frame in the different conceptal 
compartments, it would be possible to understand the specificity and extent of reduced nutrition.  
Megalin and cubilin, known as the multiligand endocytotic receptor complex (MERC), are 
major receptors involved in HNPs are which are localized to polarized epithelia such as the VYS 
[28-30]. Though rodent VYS are inverted, both rodent and human VYS both highly express 
megalin and cubilin [31]. These receptors are also found on neuroepithelia, and have been 
implicated in neurulation and neurodevelopment [32-35]. The MERC is responsible for the uptake 
of a vast array of nutrients, including various proteins and their cargoes, cholesterol, vitamins, 
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lipids, iron, and calcium [29,34,35]. It is also a major transporter of the developmental ligands 
Sonic Hedgehog (Shh) and retinoic acid, which are crucial for neurulation [33,36-39]. Vitamin B12 
and folate are also co-transported across epithelia via the MERC by carrier proteins, suggesting a 
link between methyl donor metabolism and the MERC [29,40]. Future studies are required to 
discern whether MEHP acts through the MERC, and whether this response may be time-
dependent. Work with transgenic Lrp2-deficient or Cubn-deficient models could provide insight 
into this mechanism, as well as an ontogeny of Lrp2 and Cubn expression following MEHP 
exposure.  
In addition to the MERC, the solute carrier (SLC) families of transporters are also crucial 
for the transport of hormones, ligands, and nutrients across membranes. Several SLC families are 
responsible for the transport of choline, betaine, folate, and amino acids required for C1 
metabolism, and there are tissue- and organelle-specific transporters to allow for specific action. 
In particular, several SLC families are responsible for neurotransmitter transport and catabolism 
and cholinergic activity in the brain [41-44]. Studies have demonstrated that choline transporters 
and uptake are susceptible to chemical modulation of expression in the brain, including in fetal 
brain [45,46]. The relationship between embryonic toxicant exposures and molecular impacts on 
other transporters such as SLCs should be further characterized.  
Previous survey of epigenetic literature has typically correlated increased methyl donor 
supplementation and availability with increased global methylation measures [1]. Pharmacological 
inhibition of HNPs was associated with decreased EMB and VYS SAM concentrations after 6 h 
and decreased global DNA methylation at both 6- and 24-h post initial treatment [5]. Here, 24 h 
treatment with increasing concentrations of MEHP increased C1 component concentrations but 
had varying effects on methyl donor concentrations. As a result, VYS DNA methylation was 
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increased as would be expected, but EMB DNA methylation was decreased. However, the 
concentrations of methyl donors and C1 metabolic components were measured in whole 
conceptuses inclusive of the VYS, EMB and all EEF. Further examination of compartmental C1 
components and methyl donors would provide more information about the bioavailability of these 
methylation substrates throughout the conceptus. It is probable that there are compensatory 
responses to nutrient deficits that may recycle and restore C1 function, due to its metabolic 
importance. An ontogeny of C1 component concentrations over this range of time would provide 
novel insight into the mechanisms by which decreased nutritional clearance may not alter C1 
component concentrations. 
During embryogenesis, histone methylation is reprogrammed. H3K4 methylation is absent 
in the zygote and increases through to organogenesis, while H3K27 methylation becomes 
progressively demethylated between the zygote and organogenesis stages [4]. In the VYS, both 
treatment with MEHP and presence of NTD are associated with increased H3K27 methylation.  It 
is possible that treatment with MEHP or presence of NTD prevent the demethylation processes 
required for normal methylation programming at the H3K27 locus. H3K4 global histone 
methylation was increased by both MEHP treatment and presence of NTD in both EMB and VYS, 
though most significantly in NTD+ EMB. Because H3K4 methylation is an activating epigenetic 
mark, it is possible that this is a mechanism of gene dysregulation that leads to teratogenesis.  
Pan methylation of H3K4 and H3K27 histone loci was assayed, rather than tri-methylation, 
in order to establish a nutritional framework. It was expected that decreased HNPs would result in 
decrease SAM biosynthesis and decreased methylation of histones and DNA. However, this was 
not the case at the time point examined. It is likely that the tight control of gene regulation during 
embryonic development is prioritized and more conserved. Though there were slight modifications 
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to histone methylation, it is unknown whether these changes will lead to altered epigenetic 
regulation. Future work should investigate tri-methylation at these loci, since these measures are 
most closely associated with epigenetic gene regulation. ChIP-seq could also be conducted to 
determine whether or not these methylation alterations would affect chromatin structure via 
histone binding. 
Like histone methylation, DNA methylation also undergoes substantial reprogramming 
during the first trimester of development. After fertilization, DNA is substantially demethylated 
and then remethylated later during embryogenesis and early organogenesis [2-4]. In this study, 
treatment with MEHP was initiated and continued during this de novo remethylation phase of 
development. It was expected that MEHP would decrease HNP activity and deplete methyl donor 
availability, and that this would lead to decreased SAM generation and resultant decreased 
methylation. This is concordant with findings of a previous study [5], but was not entirely the case 
here. MEHP did in fact reduce EMB DNA methylation, but DNA methylation was increased in 
MEHP-treated VYS. These findings are consistent with previous studies conducted in EMB and 
VYS treated with ethanol, another inhibitor of endocytosis. It is unknown why DNA methylation 
would increase in the VYS if HNP function is reduced, though it is possible that increased DNA 
methylation due to treatment in the terminally-differentiated VYS could be a mechanism to 
conserve other cellular resources for the developing EMB. Separate quantification of methyl 
donors and C1 metabolic components should be done in order to determine whether the nutritional 
consequences observed in the whole conceptus are consistent with each compartment of the 
conceptus. It is possible that nutrient concentrations are maintained in the VYS and potentially 
even the EEF, but that these are not properly taken up by the EMB. 
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It is also possible that this effect is due to lineage-specific effects of phthalate exposure, 
since VYS is primarily paternally-imprinted [47,48]. It has been previously demonstrated that 
impaired activity of the de novo DNA methyltransferase (Dnmt) enzyme, Dnmt3a, results in EMB 
with open neural tubes, loss of maternal imprints throughout the genome, and yet most of the 
paternal imprints and methylation at repetitive elements were maintained [49]. It is possible that 
the increase in NTD, loss of methylation in the EMB, and increase of methylation in the VYS that 
follow MEHP-treatment may be related to the function of Dnmt3a. In a previous study, an inhibitor 
of the proteolysis stage of HNPs was unable to modify Dnmt3a expression in the EMB or VYS 
[5]. However, it is possible that inhibitors of endocytosis may result in differential expression of 
Dnmts. It is also possible that the relationship between decreased HNP function and Dnmts does 
not exist on the expression level and that there is potential for post-translational modulation of 
Dnmt activity. More work is needed to characterize the specific activities of Dnmts after disruption 
of HNPs during development. 
The use of WEC in this study provided unique tools for the investigation of nutrient uptake. 
Though WEC conditions mimic many of the in utero conditions, the translation of this work to in 
vivo studies would allow further examination of the link between nutrition and epigenetic 
regulation with a more complex environment. The uterine glands secrete nutrients which are 
transported through the trophoblast to the coelomic fluid and ultimately undergo the HNPs via the 
VYS [50,51]. In vivo studies of these relationships would also provide insight into the effects of 
MEHP treatment on the function of the uterine glands, and intermediate transport steps before 
entering the conceptal HNPs. Because conceptuses must share these nutrients with litter mates in 
the same uterus, in vivo studies would also provide information about the potential for resource 
competition due to altered nutrition pathways. 
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In summary, this study has demonstrated the ability of MEHP to modify the conceptal 
nutrition environment and ultimately the epigenetic landscape of the developing embryo. 
Histiotrophic clearance of nutrients was decreased with increasing MEHP treatment 
concentrations after 3 h, though measured conceptal methyl donor concentrations were variable 
and relatively unchanged after 24 h. C1 metabolism components were increased with increasing 
MEHP concentration in culture after 24 h, including increased SAM. DNA methylation of the 
EMB was increased at 24 h, though increased in the VYS. Histone methylation at the H3K27 locus 
was decreased in MEHP-treated VYS, though H3K4 methylation was increased in EMB with 
NTDs. HNP sensitivity to toxicants during this window of development may be a mechanism by 
which developmental susceptibility is induced. Toxicants may disrupt HNPs in either the 
endocytosis or proteolysis stage, and these modulations of nutrient environment may manifest as 
different epigenetic patterns. Further characterization of the mechanisms by which toxicants may 
alter HNPs is necessary, and may provide predictive models of toxicant-nutrient disruption for 
future compounds. 
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Figure 4.1. Schematic representing the sampling strategy utilized in this study. Samples were 
characterized by both treatment with MEHP as well as by NTD status (-) or (+).  
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Figure 4.2. Histiotrophic nutrient uptake is hindered by MEHP treatment. Clearance is measured as μl 
media cleared into conceptus per mg protein per hour, and thus is the rate of uptake. Ethanol was used as a 
positive control, as it has been previously demonstrated to decreased endocytotic processes. *p<0.05, 
**p<0.01. 
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Figure 4.3. Global histone H3K4 and H3K27 methylation percentages in the EMB and VYS. MEHP-
treated (100 μg/ml) and NTD positive EMB have elevated H3K4 methylation compared to controls and 
MEHP-treated NTD negative EMB (A). No significant changes in H3K4 methylation were observed in the 
VYS.  No significant changes in H3K27 methylation were observed in EMB or VYS (B). *p<0.05 
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Figure 4.4. Global DNA methylation is modified by MEHP treatment and in conceptuses with NTDs. EMB 
exposed to MEHP at 100 μg/ml concentrations in culture had significantly lower global DNA methylation 
percentages than controls, regardless of NTD status (A). EMB that were MEHP treated and NTD+ had 
further reduced DNA methylation. In the VYS, MEHP treatment and NTD status did not significantly alter 
DNA methylation, though there was an increasing trend. DNA methylation decreases in the EMB and 
increases in the VYS with increasing MEHP dose (B). *p<0.05 
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Table 4.1. Measurements of dietary methyl donors and C1 metabolism components in whole conceptuses 
following 24 h in WEC. All measurements were normalized, and are reported as the concentration of each 
nutrient per mg total protein. Comparisons between treatments and controls: *p<0.05, **p<0.01, 
***p<0.001. Comparisons between low- and high-dose groups: $p<0.05, $$p<0.01. 
 
  Control MEHP (100 μg/ml) MEHP (250 μg/ml) 
Folate (ng/mg protein) 
0.66±0.04 
(n=4) 
0.51±0.03 
(n=4) 
0.74±0.08 
(n=5) 
Vitamin B12 (pg/mg protein) 
17.00±0.09 
(n=3) 
12.25±0.41*** 
(n=3) 
15.23±0.47*$$ 
(n=5) 
Choline (ng/mg protein) 
2.15±0.41 
(n=5) 
1.35±0.54 
(n=5) 
3.04±0.87$$ 
(n=4) 
Betaine (ng/mg protein) 
4.23±0.39 
(n=4) 
2.13±0.95** 
(n=5) 
2.95±0.42 
(n=4) 
SAM (ng/mg protein) 
820.93±87.27 
(n=4) 
1487.44±358.57 
(n=5) 
2380.10±659.50 
(n=5) 
Cysteine (ng/mg protein) 
1467.39±192.00 
(n=5) 
2338.37±377.96 
(n=5) 
2506.89±265.18 
(n=5) 
Homocysteine (ng/mg protein) 
70.10±5.07 
(n=5) 
63.75±3.36 
(n=4) 
97.37±8.50*$$ 
(n=4) 
Methionine (ng/mg protein) 
635.06±43.95 
(n=4) 
956.51±171.79 
(n=5) 
1426.98±235.62* 
(n=5) 
Total protein (mg/sample) 
2.68±0.09 
(n=5) 
2.84±0.09 
(n=5) 
2.40±0.11$ 
(n=5) 
 
 
 
  
124 
 
References 
 
1. Anderson, O.S., K.E. Sant, and D.C. Dolinoy, Nutrition and epigenetics: an interplay of dietary 
methyl donors, one-carbon metabolism and DNA methylation. The Journal of Nutritional 
Biochemistry, 2012. 23(8): p. 853-859. 
2. Reik, W., W. Dean, and J. Walter, Epigenetic Reprogramming in Mammalian Development. 
Science, 2001. 293(5532): p. 1089-1093. 
3. Faulk, C. and D.C. Dolinoy, Timing is everything: The when and how of environmentally induced 
changes in the epigenome of animals. Epigenetics, 2011. 6(7): p. 791-797. 
4. Reik, W., Stability and flexibility of epigenetic gene regulation in mammalian development. 
Nature, 2007. 447(7143): p. 425-432. 
5. Sant, K.E., et al., Inhibition of proteolysis in histiotrophic nutrition pathways alters DNA 
methylation and one-carbon metabolism in the organogenesis-stage rat conceptus. The Journal of 
Nutritional Biochemistry, 2013. 24(8): p. 1479-1487. 
6. Zeisel, S.H., Importance of methyl donors during reproduction. Am J Clin Nutr, 2009. 89(2): p. 
673S-7S. 
7. Imbard, A., J.F. Benoist, and H.J. Blom, Neural tube defects, folic acid and methylation. Int J 
Environ Res Public Health, 2013. 10(9): p. 4352-89. 
8. Osterhues, A., N.S. Ali, and K.B. Michels, The role of folic acid fortification in neural tube 
defects: a review. Crit Rev Food Sci Nutr, 2013. 53(11): p. 1180-90. 
9. Harris, C., Rodent Whole Embryo Culture, in Developmental Toxicology, C. Harris and J.M. 
Hansen, Editors. 2012, Humana Press. p. 215-237. 
10. Robinson, J.F., et al., Dose–response analysis of phthalate effects on gene expression in rat whole 
embryo culture. Toxicology and Applied Pharmacology, 2012. 264(1): p. 32-41. 
11. Janer, G., et al., Use of the rat postimplantation embryo culture to assess the embryotoxic potency 
within a chemical category and to identify toxic metabolites. Toxicology in Vitro, 2008. 22(7): p. 
1797-1805. 
12. Ambroso, J. and C. Harris, Assessment of Histiotrophic Nutrition Using Fluorescent Probes, in 
Developmental Toxicology, C. Harris and J.M. Hansen, Editors. 2012, Humana Press. p. 407-423. 
13. Ambroso, J.L., et al., Fluorometric analysis of endocytosis and lysosomal proteolysis in the rat 
visceral yolk sac during whole embryo culture. Teratology, 1997. 56(3): p. 201-209. 
14. Steventon, G.B. and K.E. Williams, Ethanol-induced inhibition of pinocytosis and proteolysis in 
rat yolk sac in vitro. Development, 1987. 99(2): p. 247-53. 
15. Holm, P.I., et al., Determination of choline, betaine, and dimethylglycine in plasma by a high-
throughput method based on normal-phase chromatography-tandem mass spectrometry. Clin 
Chem, 2003. 49(2): p. 286-94. 
16. Karimi, M., S. Johansson, and T. Ekström, Using LUMA: a Luminometric-Based Assay for 
Global DNA-Methylation. Epigenetics, 2006. 1(1): p. 45-48. 
17. Karimi, M., et al., LUMA (LUminometric Methylation Assay)—A high throughput method to the 
analysis of genomic DNA methylation. Experimental Cell Research, 2006. 312(11): p. 1989-1995. 
18. Hales, C.N. and D.J. Barker, The thrifty phenotype hypothesis. Br Med Bull, 2001. 60: p. 5-20. 
19. Ivanov, A.I., Pharmacological inhibition of endocytic pathways: is it specific enough to be 
useful? Methods Mol Biol, 2008. 440: p. 15-33. 
20. Claussen, U., et al., The embryotoxicity of cyclophosphamide in rabbits during the histiotrophic 
phase of nutrition. Teratog Carcinog Mutagen, 1985. 5(2): p. 89-100. 
21. Beck, F., Induced cell injury and cell death as a cause of congenital malformations in rats. 
Histochem J, 1981. 13(4): p. 667-79. 
22. Holson, J.F., et al., Mode of action: yolk sac poisoning and impeded histiotrophic nutrition--
HBOC-related congenital malformations. Crit Rev Toxicol, 2005. 35(8-9): p. 739-45. 
23. Ambroso, J. and C. Harris, In vitro embryotoxicity of the cysteine proteinase inhibitors 
benzyloxycarbonyl-phenylalanine-alanine-diazomethane (Z-Phe-Ala-CHN2) and 
125 
 
benzyloxycarbonyl-phenylalanine-phenylalanine-diazomethane (Z-Phe-Phe-CHN2). Teratology, 
1994. 50(3): p. 214-228. 
24. Ambroso, J.L. and C. Harris, Chloroquine accumulation and alterations of proteolysis and 
pinocytosis in the rat conceptus in vitro. Biochemical Pharmacology, 1994. 47(4): p. 679-688. 
25. Hunter, E.S., 3rd, et al., Altered visceral yolk sac function produced by a low-molecular-weight 
somatomedin inhibitor. Teratology, 1991. 43(4): p. 331-40. 
26. Brent, R.L., et al., Experimental yolk sac dysfunction as a model for studying nutritional 
disturbances in the embryo during early organogenesis. Teratology, 1990. 41(4): p. 405-13. 
27. Balkan, W., et al., Role of the mouse visceral yolk sac in nutrition: inhibition by a somatomedin 
inhibitor. J Exp Zool, 1989. 249(1): p. 36-40. 
28. Christensen, E. and P. Verroust, Megalin and cubilin, role in proximal tubule function and during 
development. Pediatric Nephrology, 2002. 17(12): p. 993-999. 
29. Moestrup, S.K. and P.J. Verroust, Megalin- and Cubilin-Mediated Endocytosis of Protein-Bound 
Vitamins, Lipids, and Hormones in Polarized Epithelia. Annual Review of Nutrition, 2001. 21(1): 
p. 407-428. 
30. Muller, D., A. Nykjaer, and T.E. Willnow, From holoprosencephaly to osteopathology: role of 
multifunctional endocytic receptors in absorptive epithelia. Ann Med, 2003. 35(5): p. 290-9. 
31. Burke, K.A., et al., Expression and immunolocalisation of the endocytic receptors megalin and 
cubilin in the human yolk sac and placenta across gestation. Placenta, 2013. 34(11): p. 1105-9. 
32. Willnow, T.E., et al., Defective forebrain development in mice lacking gp330/megalin. Proc Natl 
Acad Sci U S A, 1996. 93(16): p. 8460-4. 
33. Fisher, C.E. and S.E.M. Howie, The role of megalin (LRP-2/Gp330) during development. 
Developmental Biology, 2006. 296(2): p. 279-297. 
34. Zohn, I.E. and A.A. Sarkar, The visceral yolk sac endoderm provides for absorption of nutrients 
to the embryo during neurulation. Birth Defects Research Part A: Clinical and Molecular 
Teratology, 2010. 88(8): p. 593-600. 
35. Kozyraki, R. and F. Gofflot, Multiligand endocytosis and congenital defects: roles of cubilin, 
megalin and amnionless. Curr Pharm Des, 2007. 13(29): p. 3038-46. 
36. Duester, G., Retinoic acid synthesis and signaling during early organogenesis. Cell, 2008. 
134(6): p. 921-31. 
37. Maden, M., Retinoids and spinal cord development. J Neurobiol, 2006. 66(7): p. 726-38. 
38. Copp, A.J. and N.D. Greene, Neural tube defects--disorders of neurulation and related embryonic 
processes. Wiley Interdiscip Rev Dev Biol, 2013. 2(2): p. 213-27. 
39. Shimamura, K., et al., Longitudinal organization of the anterior neural plate and neural tube. 
Development, 1995. 121(12): p. 3923-33. 
40. Gelineau-van Waes, J., et al., Microarray analysis of E9.5 reduced folate carrier (RFC1; 
Slc19a1) knockout embryos reveals altered expression of genes in the cubilin-megalin 
multiligand endocytic receptor complex. BMC Genomics, 2008. 9(1): p. 156. 
41. Okuda, T., et al., Substrate-induced internalization of the high-affinity choline transporter. J 
Neurosci, 2011. 31(42): p. 14989-97. 
42. Haga, T., Molecular properties of the high-affinity choline transporter CHT1. J Biochem, 2014. 
43. Pramod, A.B., et al., SLC6 transporters: structure, function, regulation, disease association and 
therapeutics. Mol Aspects Med, 2013. 34(2-3): p. 197-219. 
44. Broer, S. and U. Gether, The solute carrier 6 family of transporters. Br J Pharmacol, 2012. 
167(2): p. 256-78. 
45. Mao, C., et al., The effect of prenatal nicotine on mRNA of central cholinergic markers and 
hematological parameters in rat fetuses. Int J Dev Neurosci, 2008. 26(5): p. 467-75. 
46. Silva, V.S., et al., Comparative effects of aluminum and ouabain on synaptosomal choline uptake, 
acetylcholine release and (Na+/K+)ATPase. Toxicology, 2007. 236(3): p. 158-177. 
47. Rastan, S. and B.M. Cattanach, Interaction between the Xce locus and imprinting of the paternal 
X chromosome in mouse yolk-sac endoderm. Nature, 1983. 303(5918): p. 635-7. 
126 
 
48. Davis, T.L., K.D. Tremblay, and M.S. Bartolomei, Imprinted expression and methylation of the 
mouse H19 gene are conserved in extraembryonic lineages. Dev Genet, 1998. 23(2): p. 111-8. 
49. Kaneda, M., et al., Essential role for de novo DNA methyltransferase Dnmt3a in paternal and 
maternal imprinting. Nature, 2004. 429(6994): p. 900-3. 
50. Burton, G.J., J. Hempstock, and E. Jauniaux, Nutrition of the human fetus during the first 
trimester--a review. Placenta, 2001. 22 Suppl A: p. S70-7. 
51. Burton, G.J., et al., Uterine glands provide histiotrophic nutrition for the human fetus during the 
first trimester of pregnancy. J Clin Endocrinol Metab, 2002. 87(6): p. 2954-9. 
 
 
127 
 
Chapter V 
Integrated Epigenomic and Transcriptomic Profiles of Early Organogenesis-Stage 
Mouse Conceptuses after Exposure to Mono-2-Ethylhexyl Phthalate: Effects in the 
Absence and Presence of Neural Tube Defects 
 
Introduction 
Despite recent intervention efforts, neural tube defects (NTDs) remain one of the most 
prevalent birth defects worldwide. Folate supplementation of foods has reduced but not eradicated 
the prevalence of NTDs, and the mechanism by which this occurs is controversial. Folate and other 
dietary methyl donors are responsible for supplying substrates necessary for cellular methylation 
processes, including epigenetic modifications [1]. An association between neural tube defects, 
central nervous system (CNS) defects, and various epigenetic modifications has been suggested, 
including disruption of methyl group donors [2-4]. 
Mono-2-ethylhexyl phthalate (MEHP) is the primary metabolite of di-2-ethylhexyl 
phthalate, a ubiquitously used plasticizing agent that has been widely found as an environmental 
contaminant. Phthalates are xenoestrogens, and are well-known and best characterized for their 
endocrine-disrupting function in reproduction. However, previous studies have demonstrated other 
mechanisms by which MEHP may alter embryogenesis and early organogenesis, including 
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decreased overall growth, disruption of redox signaling, decreased nutrient uptake, and alteration 
of epigenetic marks (Chapters 2 and 3). 
Previous work demonstrated that increasing dose of MEHP for 24 h between GD 8-9 in 
mouse whole embryo culture (mWEC) significantly increased the prevalence of NTDs in mouse 
conceptuses (Chapter 3). Here, we try to identify the pathways 1) that are most significantly 
impacted by MEHP treatment and 2) that are amplified in conceptuses with open neural tubes 
compared to those with normal neural tube closure in order to understand processes that may 
contribute to the development of NTDs. 
 
Materials & Methods 
Chemicals & Reagents 
HPLC-grade dimethyl sulfoxide (DMSO), Tyrode’s balanced salt solution (TBSS), and 
penicillin/streptomycin (10,000 units/ml penicillin, 10,000 μg/ml streptomycin sulfate) were 
obtained from Sigma/Aldrich (St. Louis, MO). Mono-2-ethylhexyl phthalate was obtained from 
AccuStandard (New Haven, CT). Hanks balanced salt solution (HBSS) was purchased from 
GIBCO/Life Technologies (Grand Island, NY). 
 
Mouse whole embryo culture 
Mouse whole embryo culture was performed following the conditions outlined in [5] and 
described previously (Chapters 3 and 4). Briefly, time-mated female CD-1 mice were obtained 
from Charles River (Portage, MI). The morning of the discovery of a vaginal plug was designated 
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as gestational day (GD) 0. Food and water were supplied ad libitum, and animals were kept on a 
12 h light:dark cycle. On the morning of GD 8, pregnant mice were euthanized with CO2, and the 
gravid uterus was removed. Conceptuses were explanted from the uterus, removed from their 
decidual masses, pooled, and randomized into 10 ml culture bottles containing 5 ml of 75% heat-
inactivated rat serum/25% TBSS, and supplemented with penicillin/streptomycin. Bottles were 
placed in a rotating incubator that supplied continuous gas to conceptuses during the culture period. 
The intial gas mizture was low-oxygen to mimic the uterine conditions, containing only 5% O2/5% 
CO2/90% N2. After 6 h in culture, the gas mixture was adjusted to contain 20% O2/5% CO2/75% 
N2 to mirror the increased oxygenation of the environment due to implementation of circulation. 
 
Exposure & sample collection 
MEHP was suspended and stored in dimethyl sulfoxide (DMSO) at a concentration of 1 
mg/ml. MEHP was added to culture bottles containing GD 8 conceptuses at a final concentration 
of 100 μg/ml in culture. DMSO was added to control bottles at an equal volume (<1 μl/ml), which 
is below the toxic concentration in culture. Conceptuses grew overnight in culture before sampling 
24 h later, on GD 9. At the conclusion of the culture period, conceptuses were removed and 
thoroughly washed in HBSS. EMB and VYS were manually separated using watchmakers’ 
forceps. EMB and VYS were classified by their treatment status as either control or MEHP-treated. 
At this time, a brief morphological assessment was performed. If the neural tube of an EMB was 
open, these EMB and their corresponding VYS were designated as NTD positive (Fig. 5.1).  
RNA isolation was performed immediately upon sampling using the RNeasy Mini Kit 
(Qiagen), and isolated RNA was stored at -80°C until use. DNA was performed using a phenol-
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chloroform extraction method. Briefly, EMB or VYS tissue were each individually collected into 
540 μl Buffer ATL lysis buffer (Qiagen) and sonicated. Proteinase K (Qiagen) was added, and 
samples were incubated overnight at 50°C. RNase A was added to each sample before repeated 
phenol-chloroform isoamyl alcohol extractions in phase-lock gel tubes (5 PRIME). One 
chloroform only extraction was performed prior to repeated ethanol precipitations. Pellets were 
dried and genomic DNA was suspended in Tris buffer (pH 8.0). To ensure purity for future 
applications, DNA clean-up was performed using the DNA Clean & Concentrator-25 Kit (Zymo 
Research). DNA was stored at -20°C until use. 
 
Affymetrix microarray analysis of expression 
RNA for Affymetrix microarray processing were submitted to the University of Michigan 
Microarray Core Facility, and analyzed as described previously (Chapter 3). Briefly, Affymetrix 
Mouse MG-430 PM strip arrays were processed using the IVT Express Kit (Affymetrix), and RNA 
purity and integrity were confirmed using the RNA 6000 Nano Kit for the Agilent 2100 
Bioanalyzer. Other quality controls including PM chip density, RNA degradation, and standard 
error analyses were performed on the raw data. Background correction, normalization, and 
quantification of log2 expression was performed within-array using RMA, and quantile 
normalization was used across-arrays. Principle component analysis revealed distinctions between 
samples, confirming EMB and VYS tissue differences (Fig. 5.2).  
First, differences in expression between control (n=4) and MEHP-treated tissues (n=6), 
regardless of NTD status, were examined in both EMB and VYS using the Limma package in R 
2.4.1. Potential outliers were downweighted using the lmFit function, and raw p-values were 
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calculated by t-test. These p-values were adjusted and ranked using an empirical Bayesian method 
(eBayes function in Limma package). LRpath software was utilized to identify significantly altered 
(enriched) and conserved (depleted) concepts, as annotated by the Kyoto Encyclopedia of Genes 
and Genomes (KEGG) database  [6]. Differences in expression between NTD negative (n=6) and 
positive (n=4) EMB and VYS, regardless of treatment, were also examined using the same 
methodologies. Validation of candidate genes Dnmt3b, Mat2a, Lrp2, and SLC25a32 was 
performed by qPCR. Proprietary primers and complimentary SYBR green master mix (Qiagen) 
were utilized. All samples were run in triplicate at the University of Michigan Microarray Core 
facility using the PRISM 7900HT Sequence Detection System (Applied Biosystems). 
 
NimbleGen DNA promoter methylation tiling array 
 Genomic DNA from each sample was divided into two aliquots and sheared to 200-1000 
bp fragment sizes using sonication (Episonic). Fragment sizes were confirmed using gel 
electrophoresis, and one aliquot from each sample was set aside as control DNA for each sample. 
Methyl-CpG binding domain-based capture (MBD-cap) was utilized to enrich the methylated 
fractions of each sample, using the protocols outlined by the Methylated DNA Enrichment Kit 
(Epimark). Whole genome amplification of the methylation-enriched samples was performed by 
using the GenomePlex Complete Whole Genome Amplification Kit (Sigma). These methylation-
rich samples were labeled with Cy5 cyanine dye and the control fractions were labeled with Cy3 
cyanine dye, using the NimbleGen Dual-Color DNA Labeling Kit (Roche). Both labeled fractions 
were pooled for each sample, and hybridized to NimbleGen Mouse DNA Methylation 3x720K 
CpG Island Plus RefSeq Promoter Arrays (Roche). After the 20 h hybridization period, arrays were 
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washed and then scanned in the Glover laboratory in the University of Michigan Department of 
Human Genetics using the NimbleGen MS 200 Microarray Scanner (Roche).  
Microarray images were obtained and analyzed using the NimbleGen DEVA Software v2.3 
(Roche). Raw Cy5 and Cy3 signal intensities for each aligned and analyzed array were exported 
for analysis. Within-array normalization of the raw data was performed using LOESS on each 
array using the Limma package in R 2.4.1. These were then converted to log2 ratios (Cy5/Cy3) for 
each sample, mean-centered, and quantile normalization was used for across-array normalization. 
Like the expression array data, promoter methylation was analyzed for changes between control 
(n=3) and MEHP-treated (n=6) tissues, regardless of NTD status, and changes in NTD negative 
(n=6) and positive (n=3) tissues, regardless of treatment. Data was analyzed using the Limma 
package in R, using the lmFit function and eBayes. LRpath software was used to identify 
significantly enriched and depleted pathways.   
 
Results 
Expression profiles of functional pathways 
 Overall functional pathways for which gene expression was affected by MEHP treatment 
or in NTDs are shown in Fig. 5.3. Significantly affected pathways, as identified by LRpath, were 
organized and grouped according to KEGG BRITE pathway hierarchies [7]. In the VYS, MEHP 
treatment mostly impacted metabolic pathways, though key regulatory pathways involved in 
genetic information processing, cellular process, and organismal systems were also impacted (Fig. 
5.3C). In the EMB, MEHP treatment had more diverse effects (Fig. 5.3A). Pathways involved in 
the etiology of human diseases were impacted, along with substantial changes to metabolic and 
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systemic pathways. A smaller percentage of pathways involving the processing of environmental 
information as well as governing cellular processes also were affected. 
 In EMB with NTDs, the majority of affected pathways were involved in metabolic 
processes, though several pathways involved in environmental information processing were also 
impacted (Fig. 5.3B). In the VYS of conceptuses with NTDs, changes in metabolic pathways 
accounted for approximately 50% of affected pathways, and pathways involved in human disease 
accounted for most of the remaining fraction (Fig. 5.3D). Secondary functional pathway clusters 
observed in each of these groups are shown in Table 5.1. It is interesting to note that several of 
these hierarchical pathways involved in the etiology of human disease appear as those affecting 
immune and infection response. Most of the affected genes in these pathways govern inflammatory 
processes, such as cytokine function. 
 
Promoter methylation profiles of functional pathways  
 Overall functional pathways for which promoter methylation was affected by MEHP 
treatment or in NTDs in EMB and VYS are shown in Fig. 5.4. KEGG BRITE pathway hierarchies 
were interrogated after analysis in LRpath, as performed for expression. In the EMB, MEHP 
treatment induced methylation changes primarily in metabolic pathways, though changes in 
organismal systems and environmental information processing pathways were also observed (Fig. 
5.4A). In the VYS, methylation of genes involved in organismal systems was most significantly 
affected, though environmental information processing, metabolism and human disease pathways 
were also represented (Fig. 5.4C).  
In EMB and VYS from conceptuses with NTDs, methylation of genes in pathways 
involved in the etiology of human disease represent the largest percentages of affected pathways. 
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Changes to promoter methylation in EMB with NTDs occurred in pathways of diverse functions 
(Fig. 5.4B). Though human disease pathways were most impacted in NTDs in the VYS, 
environmental and genetic information processing pathways were also affected (Fig. 5.4D). 
Secondary functional pathway clusters observed in each of these groups are also shown in Table 
5.1. 
 
Expression pathways altered by MEHP treatment 
 Analysis of significantly affected gene expression pathways was performed using LRpath 
and interrogating the KEGG pathway database. Pathways significantly enriched by MEHP-
treatment in VYS and EMB are shown in Table 5.2. In the VYS, few pathways were significantly 
enriched. These pathways were primarily metabolic, though cytokine-cytokine receptor interaction 
was also enriched. Metabolism of xenobiotics by cytochrome P450 was the most enriched pathway 
induced by MEHP-treatment in the VYS. Cyp1a1 was one of the most significantly altered genes 
(p=1.427E-07), as expression was increased more than 3-fold in VYS due to MEHP-treatment. 
 In the EMB, pathways involved in xenobiotic metabolism were also enriched. Numerous 
pathways involved in the metabolism and biosynthesis of lipids were also affected, including 
linoleic acid and arachidonic acid metabolism. Regulation of autophagy was also enriched by 
MEHP-treatment after 24 h, which is consistent with findings from 6 h MEHP-treatment data 
(Chapter 3). Numerous interferons and insulin II (Ins2) in this pathway were downregulated by 
MEHP-treatment in the EMB, and several PI3K subunits were upregulated. The autophagy/beclin 
1 regulator 1 (Ambra1) gene, a known contributor to autophagic processes in the early CNS, was 
increased in EMB treated with MEHP. A large number of the pathways significantly impacted by 
MEHP-treatment in the EMB surround the function of the immune system, namely pathways 
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involved in the inflammatory response. Such pathways include cytokine interactions, and those 
involved in the progression of autoimmune and inflammatory disorders.  
 
Expression pathways altered in NTDs 
 Pathway analysis was similarly performed for genes differentially expressed in VYS and 
EMB from conceptuses with NTDs compared to controls (Table 5.3). In EMB, NTDs were 
associated with altered signaling in pathways primarily involved in amino acid metabolism and 
biosynthesis, including valine, leucine, isoleucine, arginine, proline, glycine, serine, and threonine. 
Again, Ambra1 was increased in expression. In the VYS, NTDs were associated with changes to 
a diverse array of pathways, including those involved in amino acid and other nutrient metabolism, 
inflammatory response, and the development of Type I diabetes and maturity onset diabetes of the 
young. Similar to the MEHP-treated EMB, Ins2 expression was altered in VYS with NTDs. Genes 
involved in the anti-inflammtory and antioxidant responses of cells were heavily impacted. 
Expression of thioredoxin reductase 1 (Txnrd1) was the most significantly change observed 
(p=1.106E-05), with a nearly 40% decrease in gene expression.  
 
Methylation pathways altered by MEHP treatment 
 Analysis of pathways containing genes with significantly altered promoter methylation was 
similarly performed for EMB and VYS treated with MEHP (Table 5.4). In the EMB, inositol 
phosphate metabolism and phosphatidylinositol signaling system pathways were most 
significantly altered, including the hypermethylation of several Pi3k catalytic and regulatory 
subunits. Other metabolic pathways were affected, such as propanoate metabolism, though 
hypermethylation of lactate dehydrogenase gene promoters account for several of these changes. 
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In the VYS, the Jak-STAT signaling pathway was most significantly altered by MEHP-treatment, 
as were two related pathways, B cell receptor signaling and natural killer cell cytotoxicity. These 
pathways are directly related to autophagic and apoptotic potential of cells, and have several genes 
in common.  
 
Methylation pathways altered in NTDs 
 Pathway analysis was also performed in significantly altered genes based upon the NTD 
status of the tissue (Table 5.5). In EMB with NTDs, several pathways involved with cell fate and 
proliferation were significantly enriched, including the mTOR and Jak-STAT signaling pathways, 
and numerous pathways involved in cancers. Cyp11a1 was the most impacted gene, significantly 
hypermethylated in its promoter. Very few pathways were enriched in VYS with NTDs compared 
to normal VYS. Only methylation of pancreatic cancer, primary immunodeficiency, and 
recombination pathways was enriched.  
 
Overall profiles for expression and methylation changes 
Log2 fold change ratios for expression and promoter methylation were matched for each 
gene within each tissue and treatment or NTD status. Genes for which both expression and 
promoter methylation data were not available were excluded. Data sets were merged, and the 
distributions were plotted (Fig. 5.5). Because of the assumption that most points would be centered 
around a log2 fold change of zero, a diamond shape would be expected as a normal distribution. 
When comparing EMB with and without NTDs (Fig. 5.5B), this diamond shape was evident. This 
was also similar for VYS from conceptuses with and without NTDs (Fig. 5.5D), though there was 
a slightly greater degree of variability of promoter methylation. Log2 fold change ratios for EMB 
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and VYS based upon exposure to MEHP showed a greater degree of variability in expression. In 
the VYS (Fig. 5.5C), the distribution was fairly normal with a slightly higher degree of variability 
in expression ratios due to treatment. In both the VYS and the EMB (Fig. 5.5A), hypomethylation 
was more variable than hypermethylation due to MEHP treatment, though the data is mean-
centered. In EMB treated with MEHP, the range of log2 expression ratios is great. Though 
variability is high, expression changes due to MEHP treatment are skewed toward increased 
expression. Overall, MEHP treatment more significantly affects expression and promoter 
methylation profiles than NTD status, and these effects are more exaggerated in the EMB. 
 
Canonical changes in expression and methylation 
 After analysis, genes that were either hypomethylated and over-expressed or 
hypermethylated and under-expressed due to MEHP treatment or NTD status in the EMB and VYS 
were identified. Only genes for which treatment or NTD status produced significant p-values were 
included. Log2 fold change values of less than 0.5 in either direction were excluded, and genes 
were only included in the canonical sets if change in methylation and in expression were in 
opposing directions. The number of genes meeting these criteria ranged from 53-575 genes, with 
the most canonical changes in MEHP-treated EMB and the fewest in NTD+ EMB. Of these 
changes, several genes were consistently altered in both tissues by both MEHP treatment and in 
NTDs.  
 The gene D-3-phosphoglycerate dehydrogenase (Phgdh) was hypomethylated and had 
increased expression in MEHP-treated EMB and VYS, as well as in EMB and VYS with NTDs. 
Studies have demonstrated a correlation between decreased Phgdh expression and brain 
malformations, and these malformations were followed by lethality in knockout models [8-12]. 
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Increased expression of Phgdh has been implicated in numerous cancers [13-19]. Phgdh is an 
oxidoreductase involved in energy metabolism and additionally is crucial for the biosynthesis of 
serine, which is elevated in many cancers. The mechanism by which increased serine induces 
oncogenesis is unknown, but increased cellular serine increases proliferation of cells and can 
increase the one-carbon pool [19]. Because conceptal tissues are undergoing extensive epigenetic 
remodeling that is dependent upon the one-carbon pool, it is no surprise that the increased demand 
solicits increased Phgdh expression. Likewise, because growth of the conceptus requires 
proliferation, Phgdh is essential. The hypomethylation of the Phgdh promoter and increased 
expression in EMB and VYS due to MEHP treatment and also in NTDs suggests that Phgdh 
overexpression may play an important role in dysmorphogenesis. 
 Also of interest was the hypermethylation and underexpression of somatostatin in EMB 
treated with MEHP and in EMB with NTDs. Somatostatin has been previously shown to be 
hypermethylated and underexpressed in cancers [20-23]. Somatostatin is an important endocrine 
signaling molecule, inhibiting the release of hormones such as insulin, glucagon, and thyroid-
stimulating hormone. Thus, it is possible that exposure to MEHP during early organogenesis may 
alter the metabolic programming of the EMB. 
 
Similarities in observed expression and promoter methylation changes 
Comparisons were made to identify genes that are commonly altered across tissues, 
treatments, and NTD states. To identify genes for which expression changes are common, all genes 
for which at least one probe was significantly changed at the p<0.05 level were included in the 
data set and collapsed. Figure 5.6 shows the percent of the total number of genes significantly 
changed in each categorization. In EMB with NTDs, 7.6% of total genes were significantly altered, 
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and 12.1% were significantly changed in VYS from conceptuses with NTDs. MEHP-treatment 
more significantly altered expression, affecting 48.1% of genes in the EMB and 32.9% in the VYS. 
21.6% of genes were commonly changed in the MEHP-treated tissues. In EMB with NTDs, 7.6% 
of genes are significantly changed, and 12.1% in the VYS are impacted by NTD state. 1.6% of 
total genes were commonly altered in both EMB and VYS from conceptuses with NTDs. In all, 
0.5% of total genes were affected by treatment and NTD state in both the EMB and VYS. 
Because of the large number of probes on the promoter methylation arrays, a confidence 
level of 99.9% (p<0.001) was used to identify commonly affected gene promoters (Fig. 5.7). In 
the EMB, 5.8% of total genes had altered promoter methylation due to MEHP-treatment, and 2.8% 
were significantly changed in NTDs. In the VYS, 1.1% of gene promoters had aberrant 
methylation due to MEHP-treatment, and 3.3% were altered in VYS with NTDs. Only 0.1% of 
gene promoters were commonly affected by treatment in both the EMB and VYS, and only 0.2% 
were common to both the EMB and VYS from conceptuses with NTDs. No gene promoters had 
altered methylation for all tissues, treatments, and NTD states.  
 
Expression changes in candidate pathways 
 The solute carrier (SLC) families of genes represent membrane transporters integral to 
cellular processes across tissues and organelles. Though numerous SLC genes were significantly 
increased or decreased in expression, a heatmap was constructed on all SLC genes in order to 
visualize overall effects of treatment and in NTDs for EMB and VYS (Fig. 5.8). Array expression 
values were median-centered, and arrays were hierarchically clustered by Euchlidean distance 
using Cluster 3.0 software [24]. Results were visualized using Java TreeView [25]. Arrays were 
statistically clustered by treatment, rather than by NTD status. Overall, no trends were obvious in 
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the VYS (Fig. 5.8B). However, there was notably decreased expression of SLC genes in MEHP-
treated EMB (Fig. 5.8A). The same pattern was observed when examining genes in glutathione 
(GSH) metabolism and thioredoxin-response (Fig. 5.9). Again, hierarchical clustering of arrays 
reveals that treatment, rather than NTD status, was a better predictor of gene expression in these 
pathways.  Though no trends were obvious in the VYS (Fig. 5.9B), these antioxidant metabolic 
pathways appear to be downregulated in EMB due to MEHP-treatment (Fig. 5.9A). 
 
Discussion 
In this study, we have examined transcriptomic and epigenomic changes produced by 
MEHP-treatment during early organogenesis. Comparatively, we also identified changes 
associated with the incomplete closure of the neural tube. This case-control methodology allowed 
for novel investigation of the underlying mechanisms surrounding MEHP-induced teratogenesis. 
Though NTD status was associated with altered signaling and metabolism in numerous pathways, 
MEHP-treatment had more extensive and broader impacts on expression and promoter 
methylation. Studies have previously demonstrated altered lipid and steroid metabolism in rat 
WEC, which was concordant with findings observed in this study [26]. However, additional 
patterns were observed and further amplified by stratification by NTD status. Following pathway 
analyses, several conditions were identified as key contributors to NTDs or MEHP-induced 
toxicity. 
Redox environment plays a crucial role in the determination of cell fate in the developing 
EMB, driving cells towards proliferation, differentiation, or apoptosis fates [27]. In a previous 
study, it was demonstrated that MEHP-treatment in WEC induced embryonic susceptibility to 
oxidation at key time points in development (Chapter 3). Here, an overall decrease in the 
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expression of genes in glutathione metabolism and biosynthesis was observed in EMB that had 
been treated with MEHP. Txnrd1 expression was the most significantly altered gene in NTD 
positive VYS, decreasing by more than 40%. Inhibition of autophagy pathways is associated with 
altered mitochondrial membrane potential, which may have impacts on oxidative phosphorylation 
and energy metabolism processes [28]. Because apoptosis and redox potentials are closely related, 
more work is necessary to elucidate a relationship between autophagy and redox balance during 
development.  
Canonical changes were observed in EMB and VYS due to MEHP-treatment. Numerous 
lipid metabolism and amino acid metabolism pathways were disrupted by MEHP-treatment, as 
was steroid hormone biosynthesis. It is also not surprising that MEHP-treatment induced 
xenobiotic response pathways, nor that treatment induced changes in inflammatory processes. 
Many of these processes are governed by the activity of peroxisome proliferator-activated 
receptors (PPARs) [29]. Phthalate exposures have been widely associated with activation of PPAR 
signaling, especially in reproduction and development [22-25]. 
The manifestations of MEHP-treatment and of NTDs in pathways involved in cell fate 
should be underscored. Several studies have associated PPAR activation with repressed interferon 
(IFN) production and signaling [30,31]. In these tissues, IFNs and Ins2 were under-expressed and 
Pi3K was overexpressed. Because IFNs shunt towards an apoptotic cell fate and Pi3K towards 
autophagy, it is possible that prolonged exposure to MEHP are instead shunted towards autophagic 
responses in order to preserve viability and proliferation of these cells.  
Autophagy and apoptosis are crucial to development and tissue patterning, including that 
of the neural tube [32-35]. Autophagy, defined as the lysosomal proteolysis of sequestered 
cytosolic substrates and organelles, degrades non-essential cellular contents and provides these as 
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building block for basal cellular functions such as basal energy metabolism [36]. In this study, 
Ambra1, a gene commonly expressed in neuroepithelium at this stage of mouse development, was 
significantly overexpressed by MEHP-treatment and in NTD-positive EMB [37]. Ambra1 
overexpression has been demonstrated to induce autophagy and decrease proliferation rate [37]. 
In this study, an increased number of NTDs was observed, mostly those of incomplete neural tube 
closure. In other studies, decreased Ambra1 expression was associated with exencephaly and 
uncontrolled proliferation and outgrowth of early central nervous system cells [37]. Thus, it is 
possible that the truncation of neural tube growth and closure may be due to improper 
overexpression of Ambra1, or that even the Ambra1-indicated induction of autophagy was not 
enough to maintain cellular homeostasis. 
In a previous study, MEHP-treatment in WEC reduced overall conceptal nutrition during 
early organogenesis (Chapter 4). Here, amino acid metabolism and other energy metabolism 
pathways were altered by MEHP treatment, and SLC family genes were relatively underexpressed. 
In cell culture models, increased Ambra1 expression was observed in serum-starved, or nutrient-
deficient cells [38]. Because NTDs are more commonly observed in malnourished EMB, it is 
possible that Ambra1 overexpression in deficient EMB are a major contributor to malformations. 
Future studies should investigate the mechanisms by which nutrient-starvation may induce 
autophagic teratogenesis. 
In recent years, elucidating a mechanism by which endocrine disruptors such as phthalates 
may increase risk for obesity has been a research priority. Decreased IFN expression and decreased 
insulin expression have been associated with obesity phenotypes [39]. In this study, pathways 
involved in the etiology of diabetes were significantly affected in the VYS, the primary metabolic 
barrier for the early-organogenesis stage of development, and insulin-2 expression was decreased. 
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Likewise, MEHP-treatment was previously demonstrated to increase conceptal oxidative stress,  
which has been associated with increased risk for obesity and diabetes through autophagy 
mechanisms (Chapter 3) [40]. Because MEHP decreases conceptal nutrition and alters conceptal 
redox potentials, it is possible that nutrient starvation and redox control of autophagy (NSRCA) 
may serve as a mechanism contributing to the development of a “thrifty phenotype” [41].  
Epigenetic reprogramming of the genome provides a unique window during which 
exposures and adverse environmental factors may induce changes to gene expression that could 
last throughout the lifecourse. In this study, epigenomic changes due to MEHP-treatment or in 
NTD-positive conceptuses were probed. Numerous metabolic genes and transporters were found 
to be hyper- or hypomethylated due to treatment or observed in NTDs, such as lactate 
dehydrogenase or Cyp11a1. More work is necessary to identify potential mechanisms by which 
early exposures and induced autophagy may alter metabolic programming and induce metabolic 
changes throughout the lifecourse. 
In conclusion, this study demonstrated that metabolic pathways may be disrupted in the 
developing conceptus. It is likely that NSRCA is being induced due to MEHP-treatment, and that 
these processes may contribute to the development of NTDs. It is possible that amino acid and 
micronutrient starvation may “shunt” towards autophagy rather than apoptosis, and that these 
processes may result in metabolic and morphological disruption of development and potentially 
changes that remain throughout the lifecourse. 
  
144 
 
 
Figure 5.1. Schematic illustrating the sampling techniques employed. At the conclusion of the culture 
period, conceptuses remained separated into treatment groups but were then stratified by NTD status. 
Tissues from conceptuses with NTDs were designated as NTD-positive, and those that had no 
morphological defects were NTD-negative.  
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Figure 5.2. Principle component analysis (PCA) plot of RNA from collected tissues. Samples were 
clustered by overall similarity, revealing expected large differences between the two tissues (EMB and 
VYS). Variability was greater in EMB samples, and treatment appeared more explanatory than NTD status. 
In the VYS, there was less overall variability, though distinction between treatment groups was still evident. 
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Figure 5.3. Functional pathways of gene expression changes due to MEHP treatment or in NTDs. In the 
EMB, MEHP treatment (A) primarily affected pathways involved in metabolism, organismal systems, and 
human disease, as well as some pathways involved in environmental information processes and cellular 
processes. In EMB with NTDs (B), expression in pathways involved in metabolism were most affected, as 
well as environmental information processing. In the VYS, MEHP treatment (C) largely affected metabolic 
pathways, though genetic information processes, cellular processes and organismal systems were also 
impacted. In VYS from conceptuses with NTDs (D), metabolism was also largely affected, as was human 
disease. 
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Figure 5.4. Functional pathways of promoter methylation changes due to MEHP treatment or in NTDs. In 
the EMB, MEHP treatment (A) primarily affected pathways involved in metabolism, organismal systems, 
and environmental information processing. In EMB with NTDs (B), there was diversity in the functional 
pathways affected, though human disease accounted for the largest percentage. In the VYS, MEHP 
treatment (C) also had diversity in affected pathways, though organismal systems encompassed the largest 
percentage of pathways, though environmental information processing, human disease, and metabolic 
pathways were also impacted. In VYS from conceptuses with NTDs (D), human disease accounted for half 
of the affected pathways. 
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Figure 5.5. Overall fold-change transcriptomic and epigenomic profiles. Data sets were merged and log2 
fold-change ratios were plotted. Profiles were fairly normally-distributed (diamond-shaped) comparing 
changes in NTD-positive to NTD-negative EMB (B) and VYS (D). Though normally distributed expression 
and methylation was slightly more variable in MEHP-treated VYS (C). Expression was highly variable, 
and methylation was skewed toward hypomethylation in MEHP-treated EMB (A). Overall, this suggests 
that more dysregulation occurs in MEHP-treated EMB than in VYS tissue or by NTD status. 
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Figure 5.6. Venn diagram of expression changes in EMB and VYS. Numbers shown are the percent of 
significantly altered genes in each group compared to the total gene count (p=0.05). The four overlapping 
regions represent the percent of total genes that the overlapping groups have in common. The central circle 
represents the percentage of genes that were significantly changed and common to all analyses. 
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Figure 5.7. Venn diagram of promoter methylation changes in EMB and VYS. Numbers shown are the 
percent of significantly altered genes in each group compared to the total gene count (p=0.001). The four 
overlapping regions represent the percent of significantly altered genes that the overlapping groups have in 
common. The central circle represents the percentage of genes that were significantly changed and common 
to all analyses. 
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Figure 5.8. Heat map of expression profiles for SLC genes in the EMB and VYS. Expression values were-
mean centered and hierarchically clustered by array. Though no obvious trends were detected for VYS (B), 
MEHP treatment appeared to decrease overall expression of SLC genes in the EMB (A). 
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Figure 5.9. Heat map of expression profiles for glutathione and thioredoxin metabolic genes in the EMB 
and VYS. Expression values were-mean centered and hierarchically clustered by array. Though no obvious 
trends were detected for VYS (B), MEHP treatment appeared to decrease overall expression of glutathione 
metabolism genes in the EMB (A).   
153 
 
Table 5.1. Secondary functional pathways included in the functional pathways analyses. 
Secondary functional pathways affected by treatment 
and/or NTD status of EMB and VYS 
EXPRESSION METHYLATION 
Metabolism 
Amino acid metabolism 
Energy metabolism 
Glycan biosynthesis and metabolism 
Lipid metabolism 
Metabolism of cofactors and vitamins 
Metabolism of other amino acids 
Xenobiotics biodegradation and metabolism 
Amino acid metabolism 
Carbohydrate metabolism 
Energy metabolism 
Glycan biosynthesis and metabolism 
Metabolism of other amino acids 
Xenobiotics biodegradation and metabolism 
  
Genetic Information Processing 
Translation Folding, sorting and degradation 
Replication and repair 
Transcription 
Translation 
  
Environmental Information Processing 
Signal transduction 
Signaling molecules and interaction 
Signal transduction 
Signaling molecules and interaction 
  
Cellular Processes 
Transport and catabolism Cellular community 
Transport and catabolism 
  
Organismal Systems 
Digestive system 
Endocrine system 
Immune system 
Sensory system 
Digestive system 
Endocrine system 
Immune system 
  
Human Disease 
Endocrine and metabolic diseases 
Immune diseases 
Infectious diseases: Bacterial 
Infectious diseases: Parasitic 
Cancers: Overview 
Cancers: Specific types 
Immune diseases 
Infectious diseases: Parasitic 
Infectious diseases: Viral 
Neurodegenerative diseases 
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Table 5.2. A summary of significantly altered expression pathways in GD9 conceptal tissues following 24h 
exposure to 100μg/ml culture concentrations of MEHP.  
Pathways significantly enriched in EMB tissue P-value 
Neuroactive ligand-receptor interaction 8.21E-12 
Cytokine-cytokine receptor interaction 8.60E-07 
Arachidonic acid metabolism 1.63E-06 
Linoleic acid metabolism 7.59E-05 
Complement and coagulation cascades 3.09E-04 
Staphylococcus aureus infection 7.19E-04 
Metabolism of xenobiotics by cytochrome P450 8.75E-04 
Olfactory transduction 1.14E-03 
Jak-STAT signaling pathway 1.31E-03 
Taste transduction 2.49E-03 
Gastric acid secretion 6.50E-03 
Steroid hormone biosynthesis 6.60E-03 
Asthma 7.32E-03 
Rheumatoid arthritis 1.08E-02 
Hematopoietic cell lineage 1.12E-02 
Drug metabolism - cytochrome P450 1.22E-02 
Primary immunodeficiency 1.59E-02 
Nicotinate and nicotinamide metabolism 1.66E-02 
Regulation of autophagy 2.36E-02 
Autoimmune thyroid disease 2.54E-02 
Systemic lupus erythematosus 2.77E-02 
Malaria 4.08E-02 
Renin-angiotensin system 4.43E-02 
African trypanosomiasis 4.97E-02 
Pathways significantly enriched in VYS tissue P-value 
Metabolism of xenobiotics by cytochrome P450 1.17E-05 
Steroid hormone biosynthesis 3.49E-05 
Tryptophan metabolism 2.93E-04 
Retinol metabolism 4.28E-03 
Cytokine-cytokine receptor interaction 1.74E-02 
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Table 5.3. A summary of significantly altered expression pathways in GD9 conceptal tissues from 
conceptuses with open neural tubes.  
Pathways significantly enriched in EMB tissue P-value 
Aminoacyl-tRNA biosynthesis 7.14E-09 
Valine, leucine and isoleucine biosynthesis 6.17E-05 
Arginine and proline metabolism 2.26E-03 
Complement and coagulation cascades 4.74E-03 
Glycine, serine and threonine metabolism 5.63E-03 
Pathways significantly enriched in VYS tissue P-value 
Allograft rejection 3.11E-05 
Lysosome 2.81E-04 
Autoimmune thyroid disease 7.08E-04 
Primary bile acid biosynthesis 1.08E-03 
Asthma 3.81E-03 
Other glycan degradation 7.67E-03 
Sulfur metabolism 1.08E-02 
Type I diabetes mellitus 1.37E-02 
Complement and coagulation cascades 1.38E-02 
beta-Alanine metabolism 1.50E-02 
Tryptophan metabolism 1.70E-02 
Glycine, serine and threonine metabolism 2.34E-02 
Glycosaminoglycan biosynthesis - keratan sulfate 3.12E-02 
N-Glycan biosynthesis 3.16E-02 
Graft-versus-host disease 3.31E-02 
TGF-beta signaling pathway 3.47E-02 
Histidine metabolism 3.89E-02 
Maturity onset diabetes of the young 4.32E-02 
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Table 5.4. A summary of significantly altered promoter methylation pathways in GD9 conceptal tissues 
following 24h exposure to 100μg/ml culture concentrations of MEHP.  
Pathways significantly enriched in EMB tissue P-value 
Inositol phosphate metabolism 6.71E-05 
Phosphatidylinositol signaling system 1.91E-03 
Propanoate metabolism 4.03E-02 
Vitamin digestion and absorption 4.59E-02 
Pathways significantly enriched in VYS tissue P-value 
Jak-STAT signaling pathway 1.59E-03 
Other glycan degradation 3.56E-03 
B cell receptor signaling pathway 4.22E-03 
Natural killer cell mediated cytotoxicity 5.08E-03 
RIG-I-like receptor signaling pathway 3.32E-02 
Cell adhesion molecules (CAMs) 3.48E-02 
Hepatitis C 4.72E-02 
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Table 5.5. A summary of significantly altered promoter methylation pathways in GD9 conceptal tissues 
from conceptuses with open neural tubes.  
Pathways significantly enriched in EMB tissue P-value 
Bladder cancer 2.42E-04 
Focal adhesion 5.01E-04 
Pathways in cancer 3.43E-03 
Selenocompound metabolism 1.07E-02 
mTOR signaling pathway 1.27E-02 
ECM-receptor interaction 1.72E-02 
Pancreatic cancer 1.86E-02 
Amoebiasis 2.35E-02 
Prostate cancer 3.50E-02 
RNA polymerase 3.74E-02 
Jak-STAT signaling pathway 3.88E-02 
Pathways significantly enriched in VYS tissue P-value 
Pancreatic cancer 5.68E-03 
Homologous recombination 6.59E-03 
Primary immunodeficiency 1.09E-02 
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Chapter VI 
Conclusion 
 
I. Summary of Results 
The early organogenesis stage of development has not been widely studied. Most 
developmental toxicology studies focus primarily on the pre-implantation stage with in vitro 
fertilization or later in the fetal stage of development after the placenta is fully functional. The 
early organogenesis window of development is highly susceptible to external cues, partly because 
the metabolic demands of the embryo during this phase are so great. Rapid proliferation, 
programmed and specific differentiation, and spatially-coordinated cell migration and death 
require precision for normal growth and development. Cellular environmental factors including 
nutrition, redox potential, and external signaling all play crucial roles in the guidance of these cell 
fates. In this study, mono-2-ethylhexyl phthalate (MEHP) was used as an environmental toxicant 
that may potentially disrupt these processes. In a proof-of-principle study, inhibition of 
histiotrophic nutrition pathways (HNPs) via treatment with the proteolysis inhibitor leupeptin 
altered one-carbon (C1) metabolism and epigenetic programming in the embryo (EMB) and 
visceral yolk sac (VYS) [1]. On this principle, it was hypothesized that oxidation of protein thiols 
induced by MEHP treatment would disrupt the HNPs, altering C1 metabolism and epigenetic gene 
regulation, and this would lead to general dysregulation of gene expression and increase risk for 
neural tube defects (NTDs). 
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 MEHP significantly decreased overall growth and morphological development. Overall 
size, as measured by EMB crown-rump length, was decreased by 7-42% depending on the 
concentration of MEHP treatment; head size was reduced by 7-33% as measured by head length 
(Chapter 3). From an overall sample of conceptuses from over 60 litters, the background control 
incidence of NTDs was less than 5%. Incidence of NTDs significantly increased with increasing 
concentration of MEHP in culture, with over a 33% incidence at the lowest concentration (100 
μg/ml). MEHP concentrations of 100 and 250 μg/ml in culture significantly reduced histiotrophic 
nutrition over 3 h in culture on GD 9 (Chapter 4). Because amino acids and cofactors from the 
maternal serum (exocoelomic fluids) are the primary building blocks for growth and metabolism, 
it is no surprise that decreased uptake results in decreased overall growth with increasing dose of 
MEHP. 
 After 24 h, the concentrations of methyl donors was relatively unchanged in MEHP-treated 
conceptuses (Chapter 4). However, components of the C1 metabolism cycle were increased with 
increasing concentration of MEHP. This was further confounded by global epigenetic methylation 
data. Global DNA methylation was decreased in the EMB and increased in the VYS by MEHP 
treatment. When stratified by NTD status, regardless of treatment, global DNA methylation was 
decreased in EMB with NTD and increased in VYS with NTD (Chapter 4). Global histone H3K4 
and H3K27 methylation was variable. H3K27 methylation was increased in MEHP-treated VYS, 
and H3K4 methylation was increased in EMB with NTDs. These findings did not fit the original 
model’s expectations, as decreases in HNP function were expected to be coupled with decreased 
methyl donors and C1 metabolism component concentrations and decreased epigenetic 
methylation. 
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 Over the course of 24 h from GD 8 to GD 9, total glutathione concentrations (reduced 
(GSH) + 2 oxidized (GSSG) glutathione) declined (Chapter 3). Total cysteine concentrations 
(reduced (cys) + 2 oxidized (cySS) cysteine) were depleted by increasing dose of MEHP in culture 
over the first 6 h on GD 8. Redox potentials based upon the glutathione (GSH/GSSG) and cysteine 
(cys/cySS) redox couples were decreased in a dose-dependent manner at 12 and 3 h, respectively. 
Transcriptomic analysis at 6 h revealed that MEHP treatment induces susceptibility to xenobiotics 
and oxidative stress, and decreases oxidative phosphorylation and energy and amino acid 
metabolism. These characteristics are indicative of nutrient starvation, as well as cell survival and 
apoptosis pathways [2,3]. These changes were further amplified by 24 h, and genes in pathways 
involved in metabolism and biosynthesis of amino acids as well as autophagy were differentially 
expressed. Transporters in SLC families were decreased in expression, while the multiligand 
endocytotic receptor complex (MERC) was increased in expression due to MEHP-treatment in the 
EMB. Tissue was also an important consideration during this investigation. While all of these 
changes were amplified in the EMB, almost no significant changes in redox potentials and 
expression in these pathways were observed. Very few early-organogenesis stage studies 
investigate mechanisms of toxicity in the VYS, but the conclusions made in this study would not 
have been evident without the utilization of the VYS. The stratification of the tissues not only by 
treatment but also by NTD status was also novel and important in these studies. It appeared as 
though MEHP treatment had a much greater impact on these processes than the presence of an 
NTD overall, but this approach allowed us to observe some of the potential mechanisms by which 
penetrance of NTDs is affected. 
Over the course of this body of work, it became apparent that the original model was 
innaccurate (Fig. 6.1). Only upon completion of all experiments could we appreciate the spectrum 
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of changes observed throughout these chapters, and could not have come to these conclusions 
using a reductionist approach to study. The utilization of systems biology approaches throughout 
this work, coupled with reductionist screening methodologies, encouraged a changing of 
paradigm. The original model proposed that MEHP treatment during embryonic development 
would induce oxidative stress, and that this would in turn decrease nutrition, decrease epigenetic 
marks, alter gene expression, and ultimately lead to NTDs (Chapter 1). However, it appears as 
though MEHP treatment decreases histiotrophic nutrition, and that this major environmental 
manipulation results in the altered redox states, increased C1 pool, and altered global epigenetic 
methylation and dysregulated gene expression measures. It is likely that nutrient starvation may 
be central to all of these observations. Autophagy, or macroautophagy, is the sequestration and 
subsequent lysosomal degradation of cytoplasmic proteins and substrates to supply building blocks 
for basal survival cellular processes such as gluconeogenesis and protein synthesis [4]. Autophagy 
initially requires formation of a sequestered-substrate-containing vesicle, followed by lysosomal 
fusion and degradation of the vesicle-bound substrates. This process may also engulf entire 
organelles, including mitcohondria, that pose additional energy requirements in a time of nutrient 
starvation. In many ways, autophagy resembles the latter portion of HNPs, with lysosomal fusion 
of nutrient-containing vesicles. However, HNPs are believed to be an automatic process, governed 
by the binding of ligands to receptors for receptor-mediated endocytosis (RME), and lysosomally 
degraded when substrates are available. Autophagy is believed to be a sensory process, occurring 
due to nutrient starvation or generation of reactive oxygen species (ROS). 
Though autophagy was not directly measured in this study, the numerous processes that 
contribute to the intiation of autophagy were characterized [4]. These processes, herein called 
nutrient starvation and redox control of autophagy (NSRCA), were probed to quantify redox 
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potentials and characterize the depleted nutritional status of the conceptal tissues. NSRCA is the 
synthesis of several existing hypotheses surrounding the induction of autophagy. First, redox state 
and ROS generation have been repeatedly associated with autophagy activity [5]. These oxidative 
stress measures have been demonstrated to have direct and indirect impacts on autophagy 
mechanisms, via oxidation of thiol residues in active sites of crucial signaling molecules, and also 
indirectly via redox potentials as indicators of deviation from cellular homeostasis [5-8]. Other 
studies have focused on the role of nutrient starvation as a controlling mechanism for the induction 
of autophagy, namely amino acid starvation via activation of the general amino acid control 
(GAAC) pathway [9-14]. Few studies, however, have acknowledged the correlation between these 
two pathways. 
In this chapter, I will address the significance of all results and provide evidence for why 
NSRCA is proposed to be the overarching mode of action in the etiology of MEHP-induced NTDs. 
I will additionally enumerate the ways in which future work could build upon this research, and 
implications of this work in public health. 
 
II. Environmental Modulations of Nutrition and Induction of Nutrient Starvation 
The study of nutrition during the embryonic and early organogenesis stages of development 
has been very limited. During the pre-implantation stage, the increased surface area: volume ratio 
of the total conceptus does not require more transport than diffusion of nutrients and ligands across 
a thin layer of cells. The “nutrition” of the pre-implanation conceptus is merely assumed based 
upon the contents of the culture broth. Once the placenta has become active during the fetal stage 
of development, active circulation both within the conceptus and supplied by the maternal 
circulation allows for maximal supply of nutrients and ligands throughout the growing fetus, and 
165 
 
maternal nutrition and serum concentrations of nutrients are often good biomarkers for fetal 
nutrition. The post-implantation embryo, however, must provide nutrients and ligands to rapidly 
growing tissues though no systemic transport is yet available. 
Many developmental nutrition studies merely use periodically obtained maternal serum 
nutrient status to estimate the embryonic and fetal nutrition. This may be appropriate for the fetus, 
since maternal serum is directly transported across the placenta to the fetus. However, as 
demonstrated in this study, this is not always the case for the embryo. Though the nutrient supply 
in the maternal serum could be a basic predictor of embryonic nutrition, conditions such as 
toxicants, oxidation, stress hormones, and other factors may all be able to reduce the actual supply 
of nutrients crossing the VYS to the EMB. Though other biomarkers, such as nutrient status in 
amniotic fluid, would be a better choice, these methods are highly invasive and potentially 
dangerous. Therefore, maternal serum remains the best option. More work to understand the 
dynamics of pharmacological and toxicological modulation of HNPs is necessary, and should 
strive to develop mathematical models to predict the nutritional flux following maternal exposures. 
From a public health perspective, methods to reduce maternal exposures to such toxicants would 
be the most cost-effective way to circumvent this problem. However, identification of compounds 
and chemical properties that reduce HNP activity need to be further characterized in order to 
prioritize the risk of pharmacological, occupational, and environmental exposures. 
Decreased HNP function would limit the total supply of nutrients to the growing conceptus. 
However, it is important to consider the mode of HNP disruption. Inhibition of endocytosis 
decreases the overall uptake of new and essential nutrients. Inhibition of proteolysis, on the other 
hand, leaves the variety of nutrients vesicle bound and unavailable for cellular processes. If 
endocytosis alone is inhibited, cells may still rely on autophagy for a supply of substrates for 
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crucial cellular processes (Figure 6.2). If proteolysis is inhibited, minimized lysosome function 
may not be able to maintain even autophagy functions. This might be a contributing factor to the 
difference in global DNA methylation patterns observed by leupeptin (Chapter 2) and MEHP 
inhibition of HNPs (Chapter 4). MEHP, likely inhibiting endocytosis only, decreased global DNA 
methylation in the EMB but increased methylation in the VYS (Chapter 4). In this case, NSRCA 
in the VYS may be able to preserve some of the amino acid (and potentially methionine) pools, 
though this might not translate to the EMB. In the case of leupeptin, a proteolysis inhibitor, 
autophagy would also be inhibited, and DNA methylation decreased in both the EMB and VYS as 
a result. This hypothesis is further supported by the anti-malarial chloroquine. Chloroquine is 
widely used in studies as an inhibitor of autophagy, and studies have demonstrated the anti-
proteolytic potential of chloroquine and its abilitiy to inhibit HNPs [15-19]. However, no studies 
have investigated the effects of chloroquine on epigenetic measures or constructed a nutritional 
ontogeny after treatment. 
The reduced supply of several amino acids has been implicated in intrauterine growth 
restriction (IUGR), though all of these studies have focused on the fetal stages of development 
[20-23]. In this experiment, methionine and cysteine were measured after 24 h in culture, and were 
substantially increased in a dose-dependent manner (Chapter 4). However, HNPs were inhibited 
in this same manner at a 3 h time point. Either HNP activity must be restored between 3-12 hours, 
or some other mechanism is contributing to the amino acid pool. Future work should measure C1 
at more time points and over shorter intervals of time in order to characterize whether transporter 
adaptation is occurring or whether proteolysis is the major supplier of these nutrients in the cellular 
pool. It is possible that both of these processes were occurring, but that we missed the window of 
development. It is also likely that NSRCA may augment the C1 pool after the induction of 
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autophagy. Because autophagy will degrade non-essential cellular proteins and substrates in favor 
of essential ones, it is likely that replenishment of the C1 pool would be favored in order to secure 
future epigenetic marks, post-translational modifications, and enzymatic and metabolic function 
in the mitochondria for future energy production. 
Because total cysteine and total glutathione exhibit an overall decrease over time, increased 
HNP activity is unlikely to be a major contributor. The degradation of proteins from other 
processes and structures to resupply the amino acid pool of substrates is a likely candidate, which 
is likely to act through proteolytic function and autophagy. Throughout the lifecourse, several 
amino acids are considered “essential”, meaning that they must be obtained through the diet 
because they cannot be synthesized metabolically from other substrates. The expression of genes 
directly involved in the metabolism of several essential amino acids, likely due to depletion of 
these essential amino acids, was significantly altered in NTDs at 24 h, including tryptophan, 
histidine, valine, leucine, threonine, and isoleucine. During pregnancy, several other amino acids 
are considered “conditionally essential”, meaning that they can be synthesized but this cannot meet 
the increased gestational demand. Three other conditionally essential amino acids were also 
affected in EMB with NTDs, namely arginine, glycine, and proline [24]. Deficiencies and altered 
metabolism in these pathways could be largely responsible for the decreased overall size of the 
EMB due to MEHP treatment. Furthermore, glycine, serine, and threonine metabolism were 
significantly altered at 24 h only in EMB and VYS from conceptuses with NTDs (Chapter 5). The 
abundance of these amino acids, especially serine and glycine, has been implicated in autophagy 
of a myriad of cell and tissue types, including neurological cells in neurodevelopment and 
neurodegeneration [25,26]. mTOR, a key signaling molecule in numerous processes including cell 
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fate and autophagy, is a serine/threonine kinase. In the absence of these amino acids, it is possible 
that mTOR signaling and function is impaired, which leads to the induction of autophagy. 
In this work, transcriptomic and epigenomic data were used to characterize changes in 
amino acid metabolism. However, no measurement of actual activity of enzymes within these 
pathways was performed. Future work should focus upon the metabolic activities of these, and 
related, pathways governing NSRCA. Previous studies in whole embryo culture (WEC) 
investigated proteomic changes following treatment with other HNP disruptors, namely leupeptin 
and ethanol (unpublished data). In these studies, proteins involved in the uptake, degradation, 
translation, and metabolism of bulk proteins and nutrients were altered. Additionally, several 
proteins involved in key metabolic pathways, such as the rate-limiting C1 metabolism enzyme 
Mat2a, were found to have oxidative post-translational modifications due to treatment. Thus, 
NSRCA may be further governed on the translational or post-translational levels. 
 
III. MEHP-Induced Oxidation: Direct or Indirect? 
HNPs are evolutionarily adaptive, as they limit the oxygenation and resultant generation 
of teratogenic ROS during the first, and most sensitive, trimester [27,28]. In this study, the 
immediate oxidative effects due to increasing MEHP treatment was minimal. Instead, MEHP dose-
dependent oxidation occurred at times when other sources of oxidation were ample. For example, 
a dose-dependent oxidation of cellular redox state was induced in EMB at the 12 h time point 
(Chapter 3). This is a time in development when metabolic demands are very high: the heart starts 
beating, conceptal circulation begins, the embryo rotates, and differentiation and patterning of 
tissues is widely occurring. Additionally, the oxygenation of culture is increased prior to this time 
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point in order to mimic the increased oxygenation due to activation of conceptal circulation. Thus, 
the environment itself is likely contributing to some of this oxidation.  
But why does it occur in a dose-dependent manner only at this time point? Because MEHP 
decreases HNP function, it is likely depleting the building blocks for endogenous antioxidant 
function, such as cysteine, glutamate, and glycine required for GSH biosynthesis. This decreased 
reducing buffer capacity and decreased endogenous antioxidant response, coupled with increased 
oxygenation and likely ROS formation in the conceptus, could produce an MEHP-related 
oxidation response that is not directly a result of MEHP-induced acute toxicity. An ontogeny of 
ROS production, as well as amino acid bioavailability, would provide more information about 
whether or not this oxidation is in fact due to delayed MEHP-related ROS generation or whether 
it is due to decreased antioxidant biosynthetic capacity. 
Total glutathione was decreased as time of treatment with MEHP increased, as would be 
expected due to decreased HNP function (Chapter 3). There were occasional periods over the first 
3 hours of temporarily increased total concentrations, which may be indicative of increased GSH 
biosynthesis. Further inspection was done using LRpath by probing the TRANSFAC® 
transcription factor binding sites database [29]. Nrf2 transcription factor binding was identified as 
maintained after 24 h indicating that Nrf2 binding and induction of the endogenous antioxidant 
response is still occurring. This would be consistent with increased demand for GSH biosynthesis. 
Over this time period, glutathione redox potentials are stable, indicating that the continued GSH 
biosynthesis may be able to preserve the cellular redox potentials. However, the total glutathione 
continues to decrease after this and dose-dependent oxidation of the EMB still occurred with 
MEHP exposure. This would not be expected with steady Nrf2 induction of glutathione 
biosynthesis. Thus, another process may be governing these relationships. Previous studies have 
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demonstrated impairment of Nrf2 translocation to the nucleus in the presence of cellular oxidation 
[30]. Future work should investigate the relationship between ROS generation following nutrient 
starvation and the binding and translocation dynamics of the Nrf2-Keap1 complex. Additionally, 
the protein p62, a protein involved in the formation of aggregates for proteolysis in autophagy, is 
also involved in the regulation of Nrf2 [31,32]. Though the consequences of p62 accumulation on 
the progression of autophagy are complex and diverse, p62 stabilizes the continuous activation of 
Nrf2, because p62 has a much greater binding affinity to the Keap1 active domain [31]. Thus, this 
could be another mechanism by which Nrf2 induction is being more highly conserved. 
Numerous genes involved in the regulation of autophagy are regulated specifically by ROS 
and oxidative stress. Atg4 is a cysteine-protease, and is sulfenated, sulfinated, or sulfonated in 
oxidizing conditions at either the Cys-77 or Cys-81 residue [33,34]. This oxidative modification 
inactivates Atg4, and activates the lipidation of Atg8—which in turn activates autophagy [34]. The 
sulfenation of Atg4 is reversible via enzymatic reduction, such as by glutathione and thioredoxin 
[35]. This sensitivity and reversibility of Atg4 to oxidative modifications could be a redox-sensor 
and important initiator of oxidative stress-induced autophagy. The MTORC1 complex is another 
important sensor molecule. The dephosphorylation of MTORC1 results in a pro-autophagy 
signaling cascade, and is dependent upon cellular environmental conditions, such as redox 
environment, amino acid starvation, and glucose starvation [35].  
 Though the link between starvation and autophagy, and the link between ROS and 
autophagy have been repeatedly demonstrated, it is likely that starvation and ROS generation are 
highly correlated via NSRCA. In this study, MEHP induced embryonic oxidation in a dose-
dependent manner—but only at time points when other sources of oxidation were already present, 
such as the increased oxygenation of the culture environment (Chapter 3). It has been previously 
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demonstrated that nutrient starvation increases cellular superoxide concentrations in the mediation 
of autophagy, and that this is likely to act at a point upstream of the Atg internal portions of the 
autophagy pathway [36]. In this study, several PI3K subunits were significantly upregulated, and 
mimicked these findings. Thus, cellular oxidation and ROS are able to act within the autophagy 
pathways, and also upstream of PI3K. 
 
IV. Autophagy in Neurodevelopment: A Major Factor? 
Decreased histiotrophic nutrient uptake in the conceptus, for the aforementioned reasons, 
may impair normal cell signaling, and instigate survival mechanisms to avoid aberrant cell death 
and likely defects in the developing conceptus. Autophagy is a likely mechanism for cellular 
preservation, because the degradation of existing cellular substrates will serve as the metabolic 
precursors for energy. NSRCA processes were significantly altered in these MEHP-treated 
conceptuses and those with NTDs.  
In autophagy, cellular proteins and even organelles are degraded to provide substrates for 
the most essential of cellular processes. Often, despite the growing need for energy production, 
mitochondria are the first to go because of the high energy demands in maintaining the proton 
gradient and membrane potential. Cells undergoing autophagy rely primarily on glycolysis at the 
expense of lower ATP generation rather than oxidative phosphorylation due to the intial ATP and 
biochemical investment. Expression of genes involved in oxidative phosphorylation and other 
pathways that interact with the TCA cycle were significantly affected by MEHP treatment and in 
the conceptuses with NTDs. Thus, mitochondrial function may be either compromised or 
suppressed throughout this study. 
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Central nervous system (CNS) tissues have high metabolic demands in order to control and 
coordinate the physiological systems and neural processes of the body. For this reason, the 
developing brain is particularly susceptible to oxidative damage, and exposures coupled with 
nutrient starvation may result in autophagy [37]. Initially, autophagy is a preservation mechanism 
for the developing CNS, providing substrates for basal cellular processes. However, with no new 
influx of nutrients, autophagy cannot be maintained and ultimately aberrant and potentially 
excessive cell death may occur [38-41]. The balance between autophagy and apoptosis in 
embryonic morphology is an emerging topic of research, and it is possible that developmental 
exposures to chemicals may play a role in the disruption of this balance in teratogenesis. In the 
CNS, coordinated autophagy and apoptosis help to guide closure of the neural tube, and also the 
proliferation of neural cells [41]. The gene Ambra1 has been implicated to be central to the 
direction of cell fate in the developing neural tube, as it is widely expressed in the neuroepithelium 
during neural tube closure and expressed widely throughout the CNS during organogenesis [39]. 
Ambra1 is an activator of Beclin-1 mediated autophagy in the CNS. Its overexpression results in 
the initiation of autophagy; its underexpression results in rapid, uncontrolled cellular proliferation, 
exencephaly of the midbrain and hindbrain regions, and ultimately embryonic death (Table 6.1) 
[39]. In this study, Ambra1 expression was significantly increased in the EMB both due to MEHP-
treatment and in EMB with NTDs. This is a strong indicator that autophagy has been initiated in 
the EMB, specifically in the neural tube, but that this energetic shunt was still not enough to 
support normal morphology in development. 
 
V. Epigenetic Consequences & the Developmental Origins of Health and Disease 
173 
 
The overall hypothesis proposed in the introduction was not observed in this study. If 
absolute nutrient starvation were truly occurring, we would expect to see decreased global histone 
and DNA methylation due to the decreased availability of methyl group substrates following 
MEHP treatment. However, this was not the case. Though decreased global DNA methylation was 
observed in the EMB, DNA methylation was actually increased in the VYS. Almost all histone 
methylation was maintained or even increased, with the exception of H3K27 methylation in the 
MEHP-treated EMB. Because histiotrophic nutrition was decreased, some other mechanisms must 
be contributing to the methyl pool. Given all of the aforementioned supporting data, NSRCA is a 
likely candidate. Due to the importance of epigenetic gene regulation during development, the 
maintenance of those processes might be considered a cellular priority. It is possible that the 
resultant degradation products from autophagy could be shunted towards epigenetic marks, since 
proper placement of these marks may conditionally govern survival. This is further amplified 
because the NTD status was more influential on H3K4 and DNA methylation than MEHP-
treatment. It is possible that the inability to retain or restore these epigenetic marks in NSRCA may 
play a role in the etiology of NTDs. 
The VYS is a “selfish” tissue. It serves as the metabolic barrier during the first trimester of 
development, regulating what passes from the maternal interface to the embryonic interface. From 
an evolutionary standpoint, it is important to note that many genes involved in the uptake of 
nutrients and investment into increased growth and likely larger birth size are expressed from the 
paternal-allelic origin [42]. This would increase the overall ecological fitness of the progeny, 
resulting in successive generations of progeny carrying those paternal genes. During development, 
the VYS is primarily maternally-imprinted, facilitating the “selfish” conceptal uptake of nutrients 
from the mother [43].  One cluster of these imprinted genes on chromosome 7 are demonstrative 
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of this relationship, and to no surprise, it contains several genes central to insulin signaling and 
nutrient uptake. Insulin II (Ins2) is a paternally-expressed gene in the VYS, located directly 
upstream of the Igf2 gene, which is also maternally-imprinted in the VYS [44,45]. This cluster of 
genes on chromosome 7 are particularly enriched for processes involved in growth, especially the 
insulin signaling pathway and increased uptake of glucose substrates. These genes are suggested 
to be biallelically expressed during this window development, but are soon-after reduced solely to 
paternal expression in the VYS. These genes, including Ins2, Igf2, and H19 are regulated by 
imprinting in the same region of chromosome 7 [44]. One such region, known as the H19 DMR, 
is located several thousand bp upstream of the H19 transcription start site. This locus is primarily 
maternally expressed and paternally imprinted. Methylation of the regions flanking the H19 DMR 
were highly hypomethylated in MEHP-treated VYS and in NTD-positive VYS, and was slightly 
hypomethylated in MEHP-treated and NTD-positive EMB. This suggests that there may be a loss 
of paternal imprinting of these regions following MEHP treatment and in conceptuses with NTDs, 
namely in the VYS. Surprisingly, there was no significant change in the expression of Igf2 or H19 
in the VYS. 
Studies have demonstrated that Ins2 is the only insulin gene expressed in the head and 
developing central nervous system during this phase of development, but is expressed biallelically 
[43]. In this study, Ins2 expression was decreased in the EMB due to MEHP treatment and in EMB 
with NTDs, and was also decreased in VYS from conceptuses with NTDs. This would be expected, 
considering the importance of insulin signaling for the uptake of glucose and nutrients via 
epithelia. However, this decreased expression is contradictory to the hypomethylation of the 
regulatory H19 DMR, and suggests that other regulatory factors are influential in Ins2 expression. 
Alterations to pathways involved in Type I Diabetes and maturity onset diabetes of the young were 
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observed in VYSs with NTDs. Conceptuses with NTDs on average were much smaller in size and 
exhibited numerous signs of gene dysregulation. It is possible that a “tipping point” was reached 
in these conceptuses, which makes them no longer able to regulate insulin signaling. Phthalate 
exposure, namely DEHP and thus MEHP exposure), during development has been widely 
associated with increased risk for obesity and potentially diabetes [46-49]. Unlike in the VYS, Ins2 
is expressed biallelically in the developing pancreas [44]. Studies have demonstrated the 
importance of autophagy in the function of the β-cells of the pancreatic islets, and that impaired 
autophagy may result in pancreatic cell death and contribute to increased risk for obesity and 
diabetes [50-52]. The importance of Nrf2 mediation of oxidative stress and autophagy in the 
pancreatic islets has also been proposed [53]. Therefore, it is possible that NSRCA is responsible 
for the reprogramming or decay of pancreatic cells, which alters these signaling pathways and may 
predispose these progeny to diabetes and obesity later in life. Future work should investigate the 
long term expression and epigenetic regulation of expression profiles of insulin and insulin II in 
the pancreas to characterize whether embryonic alterations in these pathways may predispose 
progeny to metabolic diseases later in the life course. 
Other aging and degenerative diseases have identified autophagy as a potential mechanism. 
Numerous studies have implicated NSRCA processes and autophagy in neurodegenerative 
disorders [54-59]. Though only morphological defects of the CNS were measured in this study, it 
is possible that the altered nutrition, cellular signaling profiles, and epigenetic modifications 
accrued during this study may contribute to other functional or cognitive defects postnatally and 
throughout the lifecourse, including neurodegenerative disease. Because neurogenesis is initiated 
during this developmental period, it is possible that delayed or halted neural tube closure may alter 
the chemical and spatial patterning of the brain. From the growing body of evidence implicating 
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the role of autophagy in aberrant neurodevelopment, one may hypothesize that adaptation to 
nutrient starvation early in development may result in altered signaling and capacity throughout 
the life course, and may predispose individuals to neurodegenerative diseases such as Parkinson’s 
and Alzheimer’s diseases. Autophagy has been associated with histone deacetylase (HDAC) 
inhibition has been implicated in neurodegeneration and cancer [60,61]. However, HDAC6 
activity is often impaired in cells with protein aggregation and dysfunctional autophagy [61,62]. 
Therefore, more work is necessary to understand the role of HDACs and histone epigenetics in the 
progression of developmental autophagy and potential for altered programming that may result in 
adult-onset disease. 
 
VI. Now What?: Public Health Recommendations 
Several studies have demonstrated that pharmacological remediation of impaired 
autophagy can in fact prevent NSRCA-induced neural tube defects [63]. Development of more 
pregnancy-safe pharmacological agents to target NSRCA via restoring HNPs and reducing 
oxidative stress is a potential option for intervention. However, the use of preventative 
pharmaceuticals during pregnancy is controversial. Minimization of chemical exposures during 
pregnancy and consumption of a balanced diet would be the best preventative plan. However, the 
chemicals that may inhibit HNPs and induce NSRCA pathways are relatively uncharacterized. 
More studies should focus on classes of toxicants that may impose the effects seen in this study, 
with specific regard to whether or not they are inhibitors of HNPs. HNP function appears to be the 
primary mechanism for induction of NSRCA during early organogenesis, so understanding which 
chemicals modify HNPs and whether or not they inhibit the endocytosis or proteolysis stages of 
HNPs would provide guidance for risk assessment. 
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Controversy surrounds the timeline of the embryo-fetal transition in humans. In humans, 
the time at which the placenta becomes an active and functional metabolic barrier and delivery 
system for nutrients is somewhat controversial. Though it was previously believed that the placenta 
was formed and functional before the 8th week of pregnancy, more studies have suggested that it 
is more likely to occur during weeks 10-13 of gestation [27,64-66]. Regardless of whether or not 
this occurs as early as week 8 or as late as week 13, this is still a very susceptible window of 
development. Histiotrophic function still serves as the primary delivery system for nutrition, and 
altered function may induce NSRCA. The work performed in this dissertation was performed in 
mouse and rat conceptuses, which have an inverted VYS relative to the human anatomy. While 
the rodent VYS completely surrounds the EMB, the human yolk sac is an umbilical vesicle in the 
amniotic cavity [67]. The human amnion surrounds the entire embryo, and also serves as a barrier 
for post-implanation and pre-placental development. However, similar to in rodents, the human 
yolk sac collects the nutrients required for growth and then they are distributed to the EMB. Thus, 
the yolk sac would control the progression of NSRCA processes in humans as well as in rodents.  
These studies were all performed in whole embryo culture, which is an excellent model for 
embryonic development. However, it is unknown whether or not these compounds would have the 
same effects in vivo as they do in vitro. Preliminary unpublished data has suggested that DEHP 
treatment in vivo in mice, regardless of antioxidant supplementation with the pharmacological Nrf2 
inducer dithiole-3-thione (D3T), may impact conceptal redox status at temporary windows of 
embryonic development. However, no characterization of HNP function has been performed to 
assess embryonic nutritional status to date. Currently, maternal nutritional statuses are utilized for 
these purposes, but this study suggests that this may not be an accurate biomarker. Methods should 
be developed in order to help characterize in vivo nutritional relationships. 
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VII. Study Strengths & Limitations 
This study has several limitations that give rise to opportunities for future studies. One 
limitation of this study was the selection of MEHP and DEHP concentrations for culture. 
Quantitative measures of environmental MEHP concentrations reaching the VYS and EMB tissues 
have yet to be obtained. At the time this study was initiated, only one mouse WEC study 
investigating MEHP treatment had been performed, and correlated in vivo morphological effects 
with WEC benchmark concentrations (BMC) [68]. MEHP was found to be the most potent DEHP 
metabolite in this study, with a BMC of approximately 0.3 mM in WEC [68]. Our lowest 
concentration investigated in this study was 100 μg/ml, or approximately 0.359 mM. Soon after 
the initiation of the work in this thesis, another study was conducted using the same range of culture 
concentrations as used in this study (Chapter 3) [69]. However, the effects observed in this study, 
namely NTDs, were found in about one third of conceptuses at this lowest concentration. Future 
studies should investigate these effects at lower, more environmentally relevant concentrations. 
However, in vivo studies measuring the concentrations of MEHP and other toxicants measured in 
these tissues would be crucial to construct these environmentally-relevant dose ranges. 
 DEHP has been implicated in numerous cancers and adverse reproductive outcomes. It is 
believed that this toxicity is largely due to the endocrine-disruptor activities of phthalates, 
mediated by the peroxisome proliferator–activated receptors (PPARs) and steroidogenic acute 
regulatory protein (StAR) [70-74]. These effects have often been found to be sex-specific, acting 
through different mechanisms. Because of the endocrine-disrupting potential of DEHP treatment, 
bimodal responses due to sex differences often contribute to variability in the physiological effects 
of phthalate exposures. Because the primordial germ cells have not yet begun migration or tissue 
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patterning of the reproductive systems during the investigated window of development, these sex-
specific physiological differences were not expected to contribute to early organogenesis 
teratogenicity in this study [75]. However, it is possible that sex of the offspring may contribute to 
differences in the penetrance of NTDs in conceptuses, or play a role in the metabolic consequences 
of exposures. Future work should address sex-specific differences in morphological, metabolic, 
and mechanistic responses. 
 Additional studies would also provide more opportunity to study control (untreated) 
conceptuses with NTDs. Because this study also investigated the mechanisms that may contribute 
to NTDs, having untreated conceptuses with NTDs would provide insight into the mechanisms 
that may contribute to penetrance. In this study, NSRCA was identified as a potential mechanism 
that contributes to the etiology of NTDs. However, the relationship between autophagy and NTDs 
in untreated, non-mutant EMB has yet to be characterized. Likewise, several endpoints in this 
study utilized tissues that were not qualified as NTD negative or positive, including the 
measurement of redox profiles. Future work should stratify all tissues, including those used in the 
histiotrophic nutrition studies. 
 This study also has many strengths and novel facets. First, we have identified a model 
pathway by which MEHP may induce NTDs and other morphological deficits. However, this 
model is not limited to MEHP, nor to phthalates. The model proposed in this study could be 
investigated following a myriad of developmental exposures to various chemicals. Numerous 
antiviral, antimalarial, and antiepileptic drugs have chemical components that are known or 
suggested inhibitors of HNPs, and thus this model could be used to investigate whether these 
pharmacological agents are detrimental during pregnancies. Likewise, numerous dietary and 
environmental exposures may also fit the proposed model, yet very few studies have been 
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conducted to date. This study suggests future investigation of common exposures to determine 
whether or not they may increase risk for NTDs or other adverse outcomes that may result from 
these mechanisms. 
 The stratification of the samples by NTD status as well as treatment status was novel for 
teratology studies. This design allowed for us to not only investigate the teratogenic potential of 
MEHP, but also to determine what mechanisms may play a role in the etiology of NTDs following 
exposures. Without the use of this study design, it is likely that the conclusion about the proposed 
NSRCA response would not have been reached. Recent studies suggest that autophagy may play 
an important role in the normal closure of the neural tube, and disruption of autophagy following 
complete depletion of resources may lead to apoptosis and ultimately NTDs [40,41]. 
   
 
VIII. Conclusion 
In conclusion, I suggest that the best model for the role of MEHP in the etiology of NTDs 
is via NSRCA pathways leading to autophagy (Figure 6.3). It is proposed that MEHP treatment 
reduces histiotrophic nutrition, and this nutrient deficiency then results in decreased antioxidant 
capacity and altered redox signaling, as well as altered epigenetic programming. These changes, 
in turn, lead to altered gene expression and potentially post-translational modifications that may 
result in autophagy and ultimately NTDs. These findings and this model have implications across 
species during the first trimester of development, and may alter gestational outcomes including 
atypical organogenesis or even spontaneous abortion. Though additional work is needed to 
elucidate the specific mechanisms by which NSRCA occurs, this serves as a sequence of 
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physiological and genetic endpoints that may coordinate embryonic exposures and teratogenesis, 
such as the induction of MEHP in NTDs.  
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Figure 6.1. Original schematic representing the hypothesized pathway by which MEHP treatment may 
increase risk for NTDs. 
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Figure 6.2. Decreased HNP activity shifts proteolytic activity from nutrient-containing vesicles to cellular 
proteins and organelles. Under normal conditions, nutrients are taken up via endocytosis and bound in 
vesicles. Lysosomes then degrade the vesicles to release nutrients and substrates for cellular processes. 
When HNPs are reduced, the cell must rely on degradation of current cellular proteins and structures, often 
mitochondria, to provide substrates for the most crucial cellular survival processes.  
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Figure 6.3. Schematic representing the proposed pathway by which MEHP treatment may increase risk for 
NTDs. Under normal conditions, nutrient uptake is unimpeded, and substrates are readily available for 
cellular processes (left). When HNPs are inhibited, NSRCA causes dysregulation and may increase risk for 
defects (right). However, the initiation of autophagy may recycle substrates for essential cellular processes, 
enabling survival and normal development if full compensation occurs. 
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Table 6.1. Ambra1 expression is a control of cell fate and morphological outcomes in the developing CNS. 
 
  
Ambra1 expression? Response Morphological Outcome 
Normal Homeostasis Normal growth & development 
Overexpressed Autophagy Normal development (nutrient recovery) 
Overexpressed Autophagy NTDs, Embryonic lethal (nutrient starvation) 
Underexpressed Rapid proliferation Exencephaly, Embryonic lethal 
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